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Protein S-acylation is the post-translational modification of proteins with longchain fatty acids at cysteine residues via a thioester linkage. The most commonly
attached lipid is 16-carbon palmitate, thus the process is often called palmitoylation.
Unlike other lipid modifications, protein S-acylation is reversible. Consequently, cells
use acylation/deacylation cycles to regulate protein localization, stability, and activity. A
family of integral membrane enzymes called DHHC proteins because of a conserved
Asp-His-His-Cys motif, catalyze protein S-acylation within cells. DHHC proteins have
been associated with human diseases including cancers, Huntington’s disease, and mental
retardation. However little is known about their function or regulation. This work
focuses on developing a better mechanistic understanding of mammalian DHHC proteins.
To facilitate biochemical characterization, a protocol was developed to express
and purify recombinant DHHC proteins from insect cells using recombinant baculovirus.
Protein S-acyltransferase (PAT) activity was measured by in vitro assays using
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radiolabeled palmitoyl-coenzyme A and purified protein substrates. Assay conditions
were optimized to maximize PAT activity.
In vitro, both protein substrate and DHHC protein incorporated palmitate. This
latter process is termed enzyme autoacylation and lead to the hypothesis that DHHC
proteins use a two-step ping-pong mechanism with an acyl-enzyme transfer intermediate.
A fluorescent peptide, high performance liquid chromatography-based PAT assay was
developed for classic steady-state kinetic experiments. Single turnover assays supported
the hypothesis with radiolabeled fatty acid transferring from acyl-DHHC to protein
substrate. Unexpectedly, these investigations also revealed that DHHC proteins display
different acyl-CoA chain length preferences. A mechanism for this difference is
proposed and tested.
Inhibitors of DHHC proteins will be useful tools for studying protein S-acylation
within cells and as potential pharmaceutical agents. Others in the field have identified
classes of compounds that reduce cellular S-acylation. Four representative compounds
and the known palmitoylation inhibitor 2-bromopalmitate (2BP) were tested for
inhibition of DHHC-mediated S-acylation with four DHHC proteins and their cognate
substrates in vitro. Two compounds, 2BP and 2-(2-Hydroxy-5-nitro-benzylidene)benzo[b]thiophen-3-one (compound V), inhibited autoacylation and acyl-transfer of all
DHHCs tested. These compounds were further characterized for reversibility and timedependence. Given their modest potency and lack of specificity, new screens for
inhibitors of DHHC proteins are needed.
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Chapter 1
Introduction
Cells typically use one of three mechanisms to anchor proteins at membranes:
insertion with transmembrane domains, interaction with other membrane components, or
covalent modification with lipids. This last process, called protein lipidation, occurs
through multiple mechanisms and involves a variety of lipids including fatty acids,
isoprenoids, and cholesterol (Table 1.1). Lipid modifications can be divided into two
broad categories: those that occur in the cytoplasm or on the cytoplasmic face of
membranes, and those that occur in the lumen of the secretory pathway (1). Lipid
modifications on secreted proteins include glycosylphosphatidyl-inositol (GPI) anchors
and fatty acylation including O-acylation and N-palmitoylation; however they are beyond
the scope of this discussion and one is referred to reviews elsewhere (2-7). Lipid
modifications occurring in the cytoplasm include protein S-acylation, N-myristoylation,
and prenylation. While S-acylation is the main focus of these studies, it often occurs
adjacent to N-myristoylation and prenylation sites; therefore, they will also be briefly
discussed.

Protein S-acylation
Protein S-acylation is the post-translational modification of proteins with longchain fatty acids at cysteine residues via a thioester linkage. The most common fatty acid
donor is 16-carbon palmitoyl-coenzyme A (palmCoA), so the process is often called
protein palmitoylation. However, a second type of palmitoylation, N-palmitoylation,
1

exists so the term S-acylation will be used. N-palmitoylation occurs on secreted proteins
and this modification is mediated by a separate group of enzymes, membrane-bound Oacylation transferases (MBOATS), which are structurally distinct from protein Sacyltransferases (PATs, (8). The only known N-palmitoylated protein that is not secreted
is Gαs, which is N-palmitoylated on Gly2 by an unknown mechanism and S-palmitoylated
on Cys3 (9).
Protein modification with fatty acids was the first covalent lipid modification
described in eukaryotic cells (10). In 1971, two groups reported that highly purified brain
myelin proteolipid protein contained covalently attached fatty acids (11, 12). Stoffyn and
Folch-Pi further characterized the lipids as attached via an ester linkage (either oxy- or
thio-ester) and a mixture of palmitate, stearate, and oleate (11). These properties are
consistent with our current understanding of protein S-acylation. However, their work
was largely forgotten and in 1979 S-acylation was rediscovered for viral membrane
glycoproteins (13) and soon thereafter as a widespread modification of eukaryotic
proteins (14). Today, thanks in particular to advances in chemical biology and mass
spectrometry, palmitoyl-proteomes have been analyzed for a number of cell lines.
Revealing both novel and known S-acylated proteins, these techniques detect hundreds of
modified proteins and in some cases, identify the site(s) of modification (15-20).
Although protein S-acylation was discovered first, the molecular identity of the
enzymes responsible remained unknown until the last ten years. Traditional biochemical
approaches at determining the molecular identity of PATs were unsuccessful. Gutierrez
and Magee detected a membrane localized PAT activity from mouse fibroblasts that co-
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fractionated with Golgi markers and S-acylated N-ras, then called p21N-ras (21).
Similarly, Berthiaume and Resh partially purified PAT activity from bovine brain that in
vitro acylated N-myristoylated Fyn and behaved as a membrane-bound enzyme (22). Liu
and coworkers also partially purified a palmitoyltransferase activity from rat liver that in
vitro acylated H-ras using palmCoA as a substrate (23). However, subsequent
sequencing and immunoblotting determined that Liu and coworkers had purified
peroxisomal 3-oxoacyl-CoA thiolase A (24), an enzyme involved in β-oxidation of fatty
acids, and unlikely a bona fide PAT. The ability of thiolase A to catalyze S-acylation was
dependent on imidazole in the PAT assay, which was present in the buffer of the Histagged Ras substrate. Since then, a number of thiolases have been shown to catalyze
acylation in the presence of imidazole (25). Dunphy and coworkers from our group also
partially purified detergent-solubilized PAT activity from bovine brain membranes. This
activity was not contaminated with thiolase, was enriched in plasma membranes, and was
capable of acylating G-protein α-subunits (26). However, none of these groups could
obtain highly purified preparations of detergent-solubilized PAT to permit molecular
identification. Labile activity, poor recovery from conventional chromatographic steps,
and sensitivity to freeze/thaw cycles limited further purification (10, 22). Of note, the Nras PAT in Golgi membranes and the Gα-subunit PAT in plasma membranes suggested
multiple enzymes with different subcellular localizations, which is consistent with our
present understanding of DHHC proteins (27).
Prior to the determination that DHHC proteins account for the majority of PAT
activity in cells (16), some questioned whether S-acylation was enzyme catalyzed.
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Nonenzymatic S-acylation, also called autoacylation, can occur by incubating a thiolcontaining peptide or protein with long-chain acyl-CoAs in the context of a hydrophobic
surface. Known S-acylated proteins that demonstrate autoacylation in vitro include Gprotein α subunits (28), myelin proteolipid proteins lipophilin (29) and P0 (30), rhodopsin
(31), and Bet3 (32). Supporting this nonenzymatic mechanism, in vitro acylation of these
proteins displayed similar properties to acylation observed in vivo, including fatty acid
attachment at similar cysteine residues, enhancement of acylation on N-myristoylated
versus non-myristoylated proteins, and reactions occurring at physiological pH and
temperature. While Gαs was shown to nonenzymatically S-acylate in vitro (33),
subsequent work showed that this occurred at Cys160 and not the physiological Cys3 site
(34). For lipophilin, rhodopsin, and Gα subunits, the authors determined that
autoacylation kinetics fit the Michaelis-Menten equation, saturating at high palmCoA
concentrations, and reported Km values of 50, 40, and 450 µM palmCoA, respectively
(28, 29, 31). However, these Km values more likely reflected the concentration of
detergent micelles in the assay (50, 50, and 400 µM, respectively) and thus call into
question the relevance of these observations for the following reasons. In vitro in
aqueous buffer palmCoA forms micelles around 4 µM (CMC = 3-4 µM at 10 mM KCl,
no detergent; (35)) and the in vivo predictions of free long-chain acyl-CoA
concentrations are around 0.2 µM after factoring in sequestration by acyl-CoA binding
protein (ACBP) and fatty acid binding protein (FABP) (36). The abundant cytosolic
protein ACBP binds long-chain acyl-CoAs with high nanomolar affinity and greatly
increases the half-times for spontaneous S-acylation of proteins to tens of hours (37)
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whereas in cells, acylation half-times are a few minutes (6 min H-ras, 1 min N-ras (38)).
In contrast, partially purified Gα PAT activity (26) remains active in the presence of
physiological concentrations of ACBP and acyl-CoA and likely represents the
predominant mechanism of S-acylation in vivo (39). Nonenzymatic autoacylation
requires the cysteine residue and palmCoA present at an aqueous-hydrophobic interface
(40, 41); thus the saturation observed in the kinetics may be more a measure of the
amount of this reactive surface than of the binding interaction between palmCoA and
protein substrate. It is possible that nonenzymatic acylation of some proteins is
physiologically relevant (e.g. Bet3 (32)), although DHHC proteins account for most
cellular S-acylation (16). When assaying in vitro DHHC-catalyzed acylation of
substrates, and especially for proteins similar to Gα subunits or at high acyl-CoA
concentrations, nonenzymatic substrate autoacylation must be controlled for.

Dual Lipidation
Although protein S-acylation can occur on otherwise completely cytoplasmic
proteins, it often occurs in the context of other membrane association signals and in some
cases, even on integral membrane proteins. To date, no well-defined amino acid
recognition sequences are known for protein S-acylation sites except the presence of a
free cysteine sulfhydryl. Nevertheless, software programs for the prediction of Sacylation sites have been developed and work with varying success (42-47). However,
validation by biochemical experimental methods is recommended. These programs are in
part based on the fact that protein S-acylation sites are frequently adjacent to other
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membrane anchoring signals. The two-hit model, which has other names including the
two-signal hypothesis and the kinetic trapping model, attempts to explain this occurrence
of adjacent membrane anchoring signals. This model states that one membrane
anchoring signal, such as N-myristoylation, prenylation, or a polybasic sequence, allows
a protein to sample different cellular membranes because of a reasonably fast off rate
from the membrane. Supporting this part of the model, peptides that were either Nmyristoylated (48) or prenylated (49, 50) lacked sufficient binding energy to stably
anchor them to the membrane. The model goes on to state that when a protein acquires a
second hit, the dually anchored protein is trapped at the membrane due to a very slow off
rate (1, 49, 51). Reversible protein S-acylation is often the ‘second hit’ allowing cycles
of acylation/deacylation to dynamic regulation membrane association (38). While
several ‘first hit’ anchoring signals exist, I want to highlight two: N-myristoylation and
prenylation. In addition, I will describe the kinetic mechanism for the enzymes that
mediate these lipid modifications so that they can be compared with the proposed
catalytic mechanism for DHHC proteins.

Myristoylation
Protein N-myristoylation is the covalent attachment of 14-carbon myristate to Nterminal glycine residues via an amide linkage (Table 1.1). In 1982, myristoylation was
originally described as an unusual blocking group on N-terminal residues that was
resistant to Edman degradation and that required high acetonitrile concentrations to elute
from HPLC columns (52, 53). Following removal of the initiator methionine residue by
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methionine aminopeptidase, myristoyl-CoA:protein N-myristoyltransferase (NMT)
catalyzes the irreversible attachment of myristate. S. cerevisiae (54) and Drosophila (55)
each contain one NMT gene, which is essential for survival, whereas vertebrates have two
NMT genes, NMT1 and NMT2. NMT is a soluble, monomeric enzyme recognizing a
substrate consensus sequence of Gly2-X-X-X-Ser/Thr6- at the extreme N-terminus.
Relevant examples include a subset of G-protein α subunits (i, o, z, t, and g) and the Src
family of tyrosine kinases (Lck, Fyn, Src, Lyn, etc) (56). These and most known
examples of myristoylation occur co-translationally, however, a growing number of posttranslational myristoylation events have been described. In apoptotic cells, activated
caspases cleave proteins exposing internal “cryptic” myristoylation consensus sequences
(57). Examples include BID (58), β-actin (59), gelsolin (60), and p21-activated kinase 2
(PAK2) (61). In the case of BID, myristoylated caspase-truncated BID was more
effective than non-myristoylated at releasing cytochrome c from mitochondria (58).
Although NMT uses acyl-CoAs and protein substrates similar to DHHC proteins,
its kinetic mechanism is likely different. Initially a ping-pong mechanism was suggested
for yeast NMT because incubation of purified NMT with [14C]-myristoyl-CoA and
hydroxylamine treatment demonstrated a covalent ester-linked acyl-enzyme (62, 63).
However, subsequent Lineweaver-Bruke analysis (64, 65) and crystal structures with and
without bound substrates (66-68) support a sequential ordered Bi Bi mechanism.
Myristoyl-CoA binds first followed by protein substrate for a direct nucleophilic
addition-elimination reaction, which is followed by the release of CoA and subsequent
release of the N-myristoylated protein. Crystal structures also revealed that specificity
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for 14-carbon acyl-CoAs is achieved by measuring the fatty acid length between an
oxyanion hole binding the carbonyl and the floor of the hydrophobic pocket. In addition,
a hydrophobic groove induces bends in myristate that further restrict acyl-chain
saturation and branching (69).

Prenylation
Protein prenylation is the covalent attachment of an isoprenoid lipid to C-terminal
cysteine residues via a thioether linkage (Table 1.1). Three prenyltransferases are known:
farnesyltransferase (FTase) and geranylgeranyltransferase type I (GGTase-I), together
termed the CaaX prenyltransferases, and protein GGTase-II (or RabGGTase). FTase
transfers the 15-carbon farnesyl-group using farnesyl diphosphate (FPP) as a lipid source
whereas GGTases utilitize geranylgeranyl diphosphate. FTase and GGTase-I have a
consensus recognition sequences of -CaaX where C is the modified cysteine residue, ‘a’
are typically small aliphatic residues, and X is the terminal residue that helps specify
which enzyme recognizes the site. After lipidation, most prenylated proteins undergo
removal of the aaX tripeptide by the protease Rce1 and are then carboymethylated on the
prenylated cysteine residue by isoprenylcysteine carboxyl methyltransferase (Icmt).
Farnesylation was first identified in 1978 on a fungal mating factor (70). In 1989,
oncogenic Ras proteins were first described as farnesylated (71) and the next year, FTase
was identified by multiple groups as the enzyme responsible for this modification (72,
73). FTase is a heterodimer composed of two subunits encoded by RAM1 and RAM2, an
essential gene in yeast (74, 75).
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The kinetic mechanism of FTase is well characterized with all rate constants
known, in part because it is a stable, soluble enzyme and crystallographic studies have
produced structures of all major steps along the reaction pathway (76). FTase uses a
sequential ordered Bi Bi reaction mechanism. FPP binds first followed by the CaaX
substrate to form a ternary complex. A required Zn2+ ion helps orient and stabilize the
cysteine thiolate ion for a direct SN2 reaction with the C1 carbon on the farnesyl group.
This results in formation of a nascent thioether bond to the protein and loss of the
oxyether bond to the pyrophosphate leaving group, which is stabilized by a Mg2+ ion.
Pyrophosphate readily leaves the complex first, whereas release of the prenylated protein,
the rate-limiting step, requires displacement by a new farnesyl diphosphate molecule (7678).

DHHC proteins are protein S-acyltransferases
DHHC proteins were determined to be the enzymes responsible for cellular Sacylation through the phenomenal power of yeast genetics. In 1999, a genetic screen in
the yeast Saccharomyces cerevisiae using a palmitoylation-dependent RAS2 allele
revealed the first PAT, effector of ras function, Erf2, and a second protein, Erf4 (79).
Subsequent studies showed Erf2 function required binding partner Efr4, and they formed
an endoplasmic reticulum-associated complex (80). In 2002, the Erf2/Erf4 complex was
purified and shown to catalyze the transfer of radiolabeled palmitate from CoA to a Ras2like substrate, demonstrating it was a bona fide PAT (81). Concurrently, a second yeast
protein, Akr1, was also demonstrated to have PAT activity for the substrate Yck2 (82).
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Analyzing amino acid sequences of these first two PATs lead to the discovery of a larger
family of proteins called DHHC proteins with a conserved Asp-His-His-Cys cysteine-rich
domain (DHHC-CRD) (83).
DHHC proteins make up a family of enzymes conserved in eukaryotes.
Searching translated genome databases reveals 7 DHHC proteins in S. cerevisiae, 5 in
Schizosaccharomyces pombe, 16 in Caenorhabditis elegans, 22 in Drosophila
melanogaster (84), 23 in Arabidopsis thaliana (85), and 24 in Homo sapiens (86). In
mammalian genomes, DHHC genes are designated ZDHHC1- ZDHHC2- ZDHHC3 and
so on, with the exception that there is no ZDHHC10. The “Z” reflects the fact that these
proteins were originally predicted to be zinc-finger proteins involved in protein-protein or
protein-DNA interactions (87); however, neither the metal nor DNA binding ability of
these proteins has been characterized.
DHHC proteins have several conserved elements, with the function of some
elements known. DHHC proteins are named for a highly conserved Asp-His-His-Cys
motif within a larger cysteine-rich domain of approximately 51 amino acid residues
(Figure 1.1) (83). Hydropathy analysis of most DHHC proteins predicts four
transmembrane domains (TMDs) with the DHHC motif on the cytoplasmic loop between
TMD2 and TMD3 (27, 88). Yeast Ark1 and Akr2 and mammalian DHHC17 (HIP14)
and DHHC13 (HIP14L) are part of a subset of DHHCs predicted to have N-terminal
ankyrin repeats within the cytoplasm and two additional TMDs. Indeed, this topology
was experimentally confirmed for Akr1 (88). Additionally, homology and phylogenetic
analysis revealed a conserved DPG (aspartate-proline-glycine) motif N-terminal to the
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DHHC sequence but within the same cytoplasmic loop and a TTxE (threonine-threoninevariable-glutamate) motif after the last TMD (Figure 1.1) (83). The function of these
motifs is unknown.
The C-terminal cytoplasmic tails of DHHC protein vary greatly in sequence and
length and have been assigned multiple functions. C-terminal to the TTxE motif, a 16
amino acid palmitoyltransferase conserved C-terminal (PaCCT) motif was described that
is conserved in 70% of PATs from eukaryotic organisms (Figure 1.1). A conserved
aromatic residue within this motif was essential for yeast DHHC proteins Swf1 and Pfa3
to S-acylate their protein substrates in vivo (89). Using mass spectrometry techniques to
compare human S-acylated proteins in lipid raft versus non-raft membranes, Yang and
coworkers identified DHHC5, DHHC6, and DHHC8 to be S-acylated on a novel three
cysteine motif, CCX7-13C(S/T) (20). For DHHC6, this motif is about 50 residues
downstream of the PaCCT motif. Interestingly, for DHHC5 and DHHC8 this tricysteine
motif overlaps their PaCCT motifs. The functions of these motifs are largely unknown,
however one possibility is that acylation-deacylation cycles of the tricysteine motif could
regulate PaCCT motif accessibility and thus function. In vivo most long-chain acylCoAs are bound by ACBP (36, 90) and partially purified PAT activity can used ACBPbound palmCoA (39). The PaCCT motif may be involved in recruiting ACBP:acyl-CoA
complex to the DHHC protein and/or causing the release of acyl-CoA. It is unknown
whether DHHC proteins can utilize ACBP-bound acyl-CoAs and the interaction between
the two is an unexplored area in the field. The tricysteine and PaCCT motifs are present
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on DHHCs with different subcellular localizations, arguing against them being
localization signals.
DHHC proteins are localized to multiple membranes throughout the cell. Ohno
and coworkers published the localization of ectopically expressed, epitope-tagged human
and yeast DHHC proteins as well as the tissue expression patterns of human ZDHHC
mRNAs (27). The majority of DHHC proteins displayed endoplasmic reticulum (ER)
and/or Golgi localization. The exceptions were human DHHC-5, -20, and -21 and yeast
Pfa5, which were localized to the plasma membrane (PM), and yeast Pfa3, which located
to the yeast vacuole membrane (27, 91). However, a number of these results do not agree
with work from others that looked at endogenous proteins or less highly expressed
proteins. For example, Ohno et al described DHHC2 as having very restrictive tissue
distribution and localizing to the ER and Golgi. In contrast, another group looking at
DHHC2 found it was ubiquitously expressed in all tissues (92), and multiple groups have
found DHHC2 localized to the PM and recycling endosomes (93-96). Interestingly,
DHHC2 cycles between endosomes and the PM in PC12 cells and the PM localization is
dependent on it C-terminal cytoplasmic tail (94). In neurons, DHHC2 also displays
regulated localization, translocating from dendritic shaft vesicles to post-synaptic
densities at the PM of dendritic spines and this translocation is enhanced in response to
activity blockade (93). How the localization of most other DHHC proteins is determined
or regulated remains unknown.
DHHC proteins may have other functions in addition to catalyzing protein Sacylation. Yeast Swf1, with its DHHC cysteine mutated to alanine, was still able to
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mediate its functions of organizing the actin cytoskeleton and localizing Cdc42 (97).
Similar, the Drosophila DHHC protein GABPI (CG17257) has a highly conserved
DHHC-CRD with the important exception that the DHHC cysteine is a serine (84), which
in all DHHC proteins tested blocks S-acyltransferase activity (83). GABPI shows high
expression in neural tissue and uses its luminal loops, that are on the opposite side of the
bilayer from the DHHS domain, to bind a Golgi localized glycosyltransferase (98). The
mammalian orthologs of GABPI (DHHC-23, -11, and -1) have retained the canonical
DHHC sequence whereas most insect orthologs have lost it (84, 98), suggesting this
alternative DHHC function may be unique to insects.
DHHC proteins have been implicated in the transport of divalent metal ions.
DHHC13 shares 69% sequence similarity with DHHC17 and is also referred to as HIP14like protein or HIP14L. These two DHHC proteins have been associated with
magnesium homeostasis. Low magnesium concentrations have been shown to increase
endogenous DHHC-13 and -17 mRNA and protein levels. When expressed in Xenopus
oocytes, both DHHC-13 and -17 mediated Mg2+ uptake that was dependent on the DHHC
cysteine and sensitive to inhibition by 2-BP. The authors conclude that DHHC-13 and 17 are Mg2+ transport proteins and DHHC autoacylation regulates transport (99). Using
similar techniques, this group also published that DHHC3 (GODZ) is a Ca2+ transport
protein (100). While DHHC proteins may have dual functions as both acyltransferases
and metal ion transporters, a more likely explanation is that DHHC-dependent acylation
activates metal transporters or transport pathways within the cell. DHHC proteins have
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not been directly tested for metal ion transport capabilities, however they are predicted to
be zinc-binding proteins (87).

Functions and regulation of protein S-acylation
Protein S-acylation can cause a variety of effects on the protein that is modified.
From a technical standpoint, addition of a long-chain fatty acid to a protein increases its
hydrophobicity, however this can have different functional consequences depending on
the protein being modified.
Serving as a membrane anchor, S-acylation can influence protein localization and
trafficking. A biologically important example of this is found on the proto-oncogene Hras, which is part of the ras family of genes that are mutated in 30% of all human cancers.
After prenylation and processing, H-ras is either mono- or dually acylated at cysteines
181 and 184. Monoacylation at Cys181 is required and sufficient for efficient trafficking
to the plasma membrane. In contrast, monoacylation at Cys184 results in trafficking to
the Golgi but not beyond (101, 102). A second example is the ATP-binding cassette
transporter (ABC)A1 that is acylated on four cysteine residues, likely by DHHC8.
Mutation of any one of these sites prevents ABCA1 trafficking to the plasma membrane
(103).
The membrane microdomain distribution of a protein can also be influence by Sacylation. A-Kinase anchoring protein 79 (AKAP79) is S-acylated on two N-terminal
cysteine residues and is involved in the clustering of proteins for efficient cyclic AMP
signaling. Mutation of AKAP79’s acylation sites excludes it from lipid rafts and thus
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prevents it from regulating adenylyl cyclase type 8 (AC8) activity (104). Acylation of
the death receptor Fas on a cytoplasmic cysteine residue adjacent its single TMD targets
it to cytoskeleton-linked lipid rafts. The Fas receptor ligand, FasL, is similarly acylated
and localizes to rafts. Acylation of both receptor and ligand is necessary for Fas-FasL
complex assembly in rafts and signaling to downstream caspases (105, 106). Acylation
was shown to promote raft affinity for 35% of raft-associated transmembrane proteins
(107). However, not all S-acylated transmembrane proteins associate with rafts, one
example being transferrin receptor 1 (108). Other examples include the anthrax toxin
receptors, TEM8 and CMG2. S-acylation of these transmembrane proteins prevents their
association with lipid rafts, which in turn prevents premature ubiquitination by Cbl3, a
necessary step in toxin internalization (109).
Protein S-acylation can regulate protein-protein interaction and facilitate complex
formation. Two examples of this already mentioned are AKAP79-AC8 and Fas-FasL.
A third example is Gαo, which when lacking an acyl-group exists as a mixture of
monomers and oligomers (dimers, trimers, tetramers, and pentamers) that disaggregate
into monomers after GTPγS stimulation. Acylated Gαo however, exist only as oligomers
and is resistant to GTPγS-dependent disassembly (110). In the case of huntingtin (htt), Sacylation by DHHC17 (HIP14) reduces its ability to aggregate and form inclusion (111).
Finally, regulation of enzyme activity has been credited as a function of protein Sacylation. Acylation of G-protein-coupled receptor kinase GRK6 has dual roles in
increasing its activity. Acylation promotes membrane association of GRK6, bringing it
closer to its membrane-bound substrates and acylation also increases the kinase catalytic
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activity of GRK6 (112). Within the epithelial Na+ channel (ENaC), which has several
transmembrane domains, S-acylation regulates channel gating (113).
Given the multiple functions of protein S-acylation and the fact that its thioester
bond is reversible, it is likely that DHHC-mediated S-acylation is regulated in cells. To
date the only process known to regulation DHHC protein activity is interaction with
binding partners. Both yeast Erf2 and its human ortholog DHHC9 require interaction
with accessory proteins Erf4 and GCP16, respectively, for transfer and autoacylation
activities (81, 114) (Also see appendix). Perhaps serving a similar role, huntingin (htt)
was shown to bind DHHC17 (HIP14) and stimulate both DHHC autoacylation and
acylation of multiple substrates (115).
An alternative mechanism of regulating protein S-acylation is to control the
access of DHHC proteins to cysteine thiols on protein substrates. Phosphodiesterase 10A
(PDE10A) is phosphorylated in Thr16 and this prevents acylation of Cys11, which is
otherwise acylated by DHHC7 and/or DHHC19 (116). Recently, the reciprocal
modification of cysteine residues 3 and 5 in postsynaptic density protein 95 (PSD-95) has
been described (117). Protein S-nitrosylation at these sites reduced S-acylation and vice
versa. An alterative way to control DHHC access to substrate thiols is to regulate DHHC
protein localization. This is the case for DHHC2, which following activity blockade in
neurons, translocates between intracellular vesicles and postsynaptic densities where it
mediates acylation of PSD-95 (93, 94). To date, there are no known posttranslational
modifications of DHHC proteins that regulate acyltransferase activity.
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Biological importance of DHHC proteins in disease
As our understanding of DHHC proteins increases, a growing number of human
diseases are being associated with DHHC proteins and protein S-acylation. ZDHHC
genes that have been associated with disease are summarized in Table 1.1. A table
summarizing DHHC proteins and their known protein substrates has recently been
published (86). Several of these mammalian S-acylated proteins also have disease
connections. Finally, the S-acylation of a large number of viral and parasitic proteins has
been reported and in many cases, protein S-acylation is necessary for efficient infection
(118-120). A few diseases connections to DHHC proteins are highlighted below; one is
referred to recent reviews for more examples (86).
As previously mentioned, the causative protein of Huntington disease (HD),
huntingtin (htt) is an S-acylated protein. DHHC17, also called huntingtin interacting
protein 14 (HIP14), has been implicated as the PAT for htt. Polyglutamine tract
expansion of htt, which proportionally increases susceptibility to HD, reduces interaction
with DHHC17 and consequently reduces htt acylation. Nonacylated htt forms inclusions
faster and is more toxic than acylated htt (111, 121). DHHC17 is also a potential
oncogene having the ability to induce colony formation and anchorage-independent
growth in cell lines, and tumors in mice (122).
Several DHHC proteins have been associated with human cancer. ZDHHC2 was
originally identified as a gene on 8p21.3-22 that displayed reduced expression associated
with metastasis (REAM), suggesting that ZDHHC2 might be a tumor suppressor.
Reduced expression was observed in more than half of the human colorectal cancers
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examined and somatic mutations of ZDHHC2 were found in colorectal cancer (M356I,
Figure 1.1), hepatocellular carcinoma (S306F), and a nonsmall lung cancer (R269stop)
(92). Interestingly, two of these mutations (M356I and S306F) are found within a region
of the C-terminal tail of DHHC2 (N299 to the C-terminus) that controls its dynamic
translocation between recycling endosomes and the plasma membrane (94).

Concluding Remarks
In my thesis work, I have focused on developing a better mechanistic
understanding of how DHHC proteins catalyze protein S-acylation. Information on a
protein’s catalytic mechanism can provide insight into the function of residues within an
active site and clarify structure-function relationships. Kinetic rate constants predict how
enzyme activity will respond to cellular changes in substrate availability and provide
insight into rate-limiting steps within pathways. Kinetic parameters can be used to
quantify enzyme preferences among competing substrates or to quantify different
enzymes preferences for the same substrate. Knowledge of substrate addition and
product release can be beneficial in the development of enzyme inhibitors. Inhibitor
sensitivities and mechanisms can reveal information about an enzyme’s active site and
catalytic mechanism. By initiating these types of studies on DHHC proteins, I sought to
reveal new information about this biologically important family of enzymes.
In the following chapters I discuss the biochemical and enzymatic
characterization of DHHC proteins and potential DHHC inhibitors. When these
investigations began, partial purification and limited PAT activity assessment had only
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been described for a few DHHC proteins (81, 82, 114, 123). In Chapter 2, I described the
improvement of methods and assays to purified and characterize DHHC proteins. These
procedures were used to determine that DHHC proteins use a two-step ping-pong
catalytic mechanism. Additionally in Chapter 3 is the first reported evidence that DHHC
proteins display acyl-CoA specificity. Assays that I developed were also used to
characterize known and potential inhibitors of DHHC proteins. In the final chapter I
discuss the implication of these studies and potential future studies based on these results.
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Enzyme (substrate)
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Attachment Site

Table 1.1. Lipid modifications found on proteins.
1Although C16:0 palmitate is the most common lipid attached through protein S-acylation, other acyl chain lengths
ranging from C14 to C22 with various degrees of unsaturation have been observed on proteins isolated from cells.
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Modifying Group

Farnesylation

N-Myristoylation

S-Acylation
(S-palmitoylation)1

Modification

Table 1.2. Proteins modified by S-acylation with acyl length other than 16-carbon
palmitate
Fatty Acid1
Proteins
14:0
band 3 (AE1), rhodopsin
15:0

rhodopsin

16:1

band 3 (AE1), rhodopsin, unidentified proteins

18:0
18:1

P-selectin, HEF (influenza C virus), E1 (Semliki
Forest virus), band 3 (AE1), rhodopsin
band 3 (AE1), rhodopsin

18:2

rhodopsin

20:4
20:5

G-protein α-subunits i, q, and z; rhodopsin,
unidentified platelet proteins
unidentified platelet proteins

22:6

rhodopsin

References
(31, 124)
(31)
(31, 124, 125)
(31, 124, 126, 127)
(31, 124)
(31)
(31, 128, 129)
(129)
(31)

Notes: 1Number of carbons in acyl chain and number of desaturations.
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Table 1.3. DHHC proteins associated with disease
DHHC1
Disease
2 (REAM) Cancer: colorectal, hepatocellular, and lung

Ref.
(92)

3 (GODZ) Squamous cell cervical carcinoma

(130)

5

Drip loss (in pigs)

(131)

7 (SERZ-β) Invasive breast cancer, oestrogen receptor-positive

(132)

8

Radiation susceptibility

(133)

8

Schizophrenia2

8

Smooth pursuit eye movement (SPEM) abnormality

8

DiGeorge syndrome (22q11.2 deletion syndrome)

9

X-linked mental retardation associated with Marfanoid habitus

(139)

9

Microsatellite stable and instable colorectal cancer

(140)

9

Splay leg (in pigs)

(141)

(134, 135)

9 (CGI-89) Colorectal cancer

(136)
(137, 138)

(142)

11

Bladder cancer progression

(143)

11

Cancer: non-small lung

(144)

13 (HIP14L) Alopecia, osteoporosis, systemic amyloidosis
14
14
14
15

(145)

Post-transplant lymphoproliferative disorders
Diffuse large B-cell lymphomas
Cancer: gastric

(146)

Acute biphenotypic leukemia
Acute myeloid leukemia
X-linked mental retardation

(148)

17 (HIP14) Huntington’s Disease

(147)

(149)
(150)

17

Diabetes

(151)

17

Cancer: colon, stomach, breast, lung, and liver

(152)

19

Enterotoxigenic E. coli F4ab/ac susceptibility (in pigs)

(153)

20

Cancer: ovarian, breast, and prostate

(154)

21

Hair loss

(155)

Notes: 1Alternative names for DHHC proteins are given in parenthesis.2Multiple reports
have been published both supporting and refuting the association between ZDHHC8 and
schizophrenia.
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Figure 1.1. DHHC consensus motif and predicted topology of human DHHC2.
A, Consensus sequence for the DHHC cysteine-rich domain (CRD) and surrounding
DPG and TTxE motifs. B, DHHC2 (367 amino acids) is predicted to have four
transmembrane domains as indicated here. Highlighted are the DPG (purple), DHHC
(red), and TTxE (cyan) motifs and the seven conserved cysteine residues of the
DHHC-CRD (yellow). In addition, DHHC2 has a PaCCT motif (orange). The
C-terminal tail of DHHC2 (gray, residues 299-367) is involved in regulating DHHC2
localization in cells. Somatic mutations (green) have been found in lung (R269stop),
heptaocellular (S306F), and colorectal (M356I) tumors.
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Chapter 2

Development of Assays to Monitor
DHHC-mediated Protein S-acylation
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Abstract
To facilitate our understanding of DHHC-mediated protein S-acylation, new and
well-characterized experimental assays were needed. DHHC proteins are integral
membrane enzymes and thus require detergent for membrane extraction and purification.
However, detergents as well as other assay components can affect enzyme behavior. The
conditions for an assay of protein S-acylation was modified from published protocols to
optimize enzyme activity. The assay is referred to as the standard PAT assay, which
measures the transfer of radiolabeled palmitate from palmitoyl-CoA to protein substrate.
Improving this assay has revealed important aspects of DHHC function and enabled more
detailed studies into the mechanism of DHHC proteins.
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Introduction
Developing purification protocols and robust and well-characterized assays for
enzyme function are critical first steps to mechanistically studying an enzyme. Using the
reductionist’s approach to studying enzymes allows one to minimize the myriad of other
simultaneous cellular processes and focus on the reaction of interest. Reconstitution of
enzyme function with purified components allows measurement of activity with minimal
side reactions and is a staple of the biochemist’s toolbox. Here, I developed and
improved assays for the reconstitution of DHHC PAT activity with purified components.
Earlier groups attempting to purify and identify PATs developed an assay for
tracking PAT activity. These groups applied detergent extracts from liver or brain
membranes to conventional chromatography columns. Column fractions were incubated
with radiolabeled palmCoA and a protein substrate capable of being S-acylated.
Reactions were stopped, resolved by SDS-PAGE, and analyzed by both fluorography,
indicating which bands incorporated radiolabel palmitate, and scintillation counting,
which provided a quantitative measure of PAT activity.
Once DHHC proteins were identified as catalyzing protein S-acylation,
recombinant protein technologies could be used to enrich PAT activity. Affinity-tagged
mammalian DHHC proteins were expressed with the Baculovirus system in Sf9 cells and
purified over sequential nickel and FLAG affinity resins. When I joined the lab, the
resulting purified DHHC proteins were tested with the same PAT assay used to monitor
activity extracted from tissue even though this assay had not been optimized for DHHC
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PAT activity. By carefully evaluating DHHC activity under various reaction conditions,
I made several improvements to our standard radiolabel-based PAT assay.

Results and Discussion
Purification of DHHC proteins and PAT assay reagents—My studies have
focused primarily on DHHC2 and DHHC3, requiring protocols to express and purify
both enzymes, as well as their protein substrates. Early studies with a His6-ExpressDHHC2 (pML850) construct showed that the enzyme was undergoing C-terminal
proteolysis, with enzyme autoacylation displaying two bands on films. Furthermore, one
of the enzyme bands comigrated with the substrate myrGαi1. Thus a construct was
generated with affinity tags at both termini and the calmodulin binding peptide, His6Express-CBP-DHHC2-FLAG-His6 (pML943), to both limit proteolysis and increase the
molecular weight. I first attempted to purify pML943 using sequential nickel and
calmodulin resins. Unfortunately buffers used to elute from calmodulin resin are
incompatible with binding to nickel resin and vice versa. This oversight was not unique
(156) and a review now warns about using a His6-CBP tandem affinity tag (157).
However, sequential chromatography using nickel and FLAG-peptide affinity columns
resulted in relatively pure protein that immunoreacted with Express (Chapter 4, Figure
4.2) and Flag antibodies (not shown), suggesting that full-length protein was purified.
Mouse DHHC3-FLAG-His6 was purified in a similar way. Detailed methods for
purification of DHHC2 and DHHC3 are found in chapters 4 and 3, respectively.
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I used two N-myristoylated proteins as protein substrates for DHHC2 and
DHHC3, N-myristoylated Gαi1 (myrGαi1) and N-myristoylated lymphocyte specific
kinase, N-terminal residues 1-226 (myrLckNT). These were generated in E. coli
coexpressing N-myristoyltransferase and were purified as described in Chapters 3 and 4.
The lipid substrate in the PAT assay is [3H]palmCoA, I observed a spurious band in
films of PAT assays that appeared at a position near DHHC2. This was identified as
residual acyl-CoA ligase from the palmCoA preparations. To remove this contaminant, a
chloroform-methanol extraction step was added to the palmCoA purification protocol.
Radiolabel-based PAT assay optimization—A protocol for assaying PAT activity
from cell lines and tissues had previously been published by our group (Table 2.1, left
side) (114), however reaction conditions had not been tested for their effect on DHHC
activity. Detergents needed for the purification of integral membrane proteins can have
unwanted effects on enzyme activity and behavior (158, 159). Initially our lab used
Triton X-100 for enriching and assaying an unknown PAT activity (26). Because DHHC
proteins were extracted from membranes and purified with nonionic n-dodecyl-β-Dmaltoside (DDM), we sought to test DHHC PAT activity in the presence of DDM. As
shown in Figure 2.1A, DHHC2 acylates myrGαi1 to a much higher extent when DDM
detergent is used versus Triton X-100. This is consistent with other reports of integral
membrane proteins showing highest activity in DDM when tested against a panel of
detergents (160). Dose-response curves were performed at various DDM concentrations
(Figure 2.1B). The highest activity was seen at 0.01% DDM, which is similar to DDM’s
critical micelle concentration (CMC) of 0.009% in water (ThermoScientific). Lower
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DDM concentrations likely resulted in loss of micelles and DHHC aggregation, whereas
high DDM concentrations likely resulted in more empty micelles, which could still bind
substrates and sequestered them from micelles containing DHHC proteins.
Because DHHC proteins are predicted to be zinc-binding proteins, the buffer
component EDTA was tested, however no effect was observed even at the highest
concentration (Figure 2.1C). Interestingly when zinc ions were included in the assay,
DHHC2 incorporated less palmitate into myrLckNT relative to either water or magnesium
ion controls (Figure 2.1D). It is known that the N-terminal SH3 domain of Lck has a Kd
for zinc of less than 100 nM and that zinc binding induces Lck homodimerization (161),
but it is unknown whether zinc binding or dimerization alter Lck’s ability to be acylated.
Additionally, zinc also likely affected DHHC2 because enzyme autoacylation was
observed on film in samples containing magnesium but not zinc (data not shown).
Investigations with the yeast PAT Erf2/Efr4 suggest that zinc concentrations as low as 20
µM are inhibitory (Robert Deschenes, personal communication). Whether DHHC
proteins bind zinc as predicted remains unknown and warrants further investigation.
Thiol-based reducing agents—Protein S-ayclation occurs through a thioester
linkage that is reversible. While this property is beneficial to cells, using
acylation/deacylation cycles to regulate protein behavior, it presents challenges to the
researcher. The thioester bond is susceptible to cleavage by reducing agents and their
concentration needs to be kept to a minimum. Conversely, formation of a thioester bond
requires free cysteine residues that are prone to oxidation. Thus early PAT assays
included low levels of dithiothreitol (DTT) in all buffers to maintain this balance (Table
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2.1, left side). This practice was questioned when initial attempts to purify autoacylated
enzyme for single turnover pulse-chase assays were unsuccessful. DHHC protein was
pre-incubated with low concentrations of [3H]palmCoA, forming a radiolabeled acylDHHC. High concentrations of unlabeled palmCoA were added with or without a
protein substrate and aliquots removed during a time course. It was predicted that [3H]palmitate would only transfer off the DHHC when protein substrate was present.
However, even in the absence of a protein substrate, DHHC proteins lost their
radiolabeled palmitate on a rapid time scale (data not shown [PAT ID#525]). This
suggested that DHHC proteins were rapidly acylating and deacylating during a standard
PAT assay and thus hydrolyzing and depleting palmCoA pools.
The hypothesis that DHHC proteins were hydrolyzing palmCoA in the presence
of thiol-based reducing agents was tested. DHHC3 was incubated with standard buffers
containing 1 mM DTT for either 0.2 or 30 min. The reaction was stopped and analyzed
by thin layer chromatography (TLC) for production of free [3H]-palmitate and by SDSPAGE gels and fluorography for enzyme autoacylation (Figure 2.2A). As shown, after
30 min DHHC3 produced more free [3H]-palmitate than a catalytically inactive DHHS2
or buffer control. Also consistent with the hydrolysis model, DHHC3 at 30 min was
radiolabeled less than at the earlier time point suggesting its palmitate was being released.
To determine whether the hydrolysis of palmCoA was reducing-agent dependent, time
courses for free [3H]-palmitate production were performed with or without DTT or βmercaptoethanol (β-ME) and monitored by TLC. For both DHHC2 and DHHC3,
reactions with reducing agent produced more [3H]-palmitate than those without (data not
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shown [PAT ID#533, 547, 629]). DHHC enzyme autoacylation was also studied in the
presence of reducing agents. As shown in Figure 2.2B, less acyl-DHHC3 was formed
when DTT or β-ME were included in the assay. Additionally, the amount of autacylated
DHHC3 rapidly decreased with time in the continued presence of reducing agent and
palmCoA. A similar but less pronounced pattern was also seen with DHHC2 (Figure
2.2C). This rapid decrease in acyl-DHHC and the production of free [3H]-palmitate
suggest that DHHC proteins were autoacylating and then deacylating in a reducing agentdependent process. Deacylation could occur by either an acyl-DHHC transferring its
palmitate to a free thiol present on the reducing agent or by the reducing agent cleaving
the acyl-enzyme thioester bond. Given the ratio of reducing equivalents to palmCoA of
2000 to 1, there is ample reducing agent present to greatly deplete the palmCoA pool.
This is suggested by DHHC3 deacylating to a low steady state level (Figure 2.2B). The
time frame required to reach this steady state level (under 10 min) was similar to the
linear reaction range observed in substrate acylation time courses (not shown). One
possibility is that the linear reaction ranges of substrate acylation were shortened because
palmCoA pools were being rapidly depleted. Indeed, when reducing agent was omitted
from a time course PAT assay with DHHC2 and myrLckNT, the linear range was
extended to at least 30 min [PAT ID#553]. Measuring acylation within the linear
reaction range was critical for the inhibitor and kinetics studies in subsequent chapters.
The effect of DTT on substrate S-acylation was also measured (Figure 2.2D). As
predicted, DHHC2 transferred less palmitate to myrLckNT in the presence of DTT.
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Given the negative effect of thiol-based reducing agents on DHHC PAT activity, I
sought to determine if reducing agents could be omitted. Reducing agents were
originally included in PAT assays to maintain free thiols available for acylation. High
pH accelerates non-enzymatic acylation and was used to evaluate the availability of thiols
on myrLckNT in the presence of reducing agents. Figure 2.2E shows that treatment with
reducing agents resulted in more myrLckNT being acylated at high pH. This suggests that
reducing agents are needed for maintaining free thiols on protein substrates.
Replacing thiol-based reducing agents with TCEP—The non-thiol based reducing
agent tris(2-carboxyethyl)phosphine (TCEP) was evaluated and determined to be less
detrimental for PAT assays than DTT. TCEP is a phosphine-based reducant that unlike
DTT is non-volatile, odorless, resistant to air oxidation, and compatible with immobilized
nickel affinity capture resins (Thermo Scientific) (162). TCEP was tested in a DHHC2
autoacylation PAT and shown to increase incorporation of palmitate into DHHC2 but not
the DHHS2 control (Figure 2.2 C). Analyzing reactions from the same assay by TLC
also showed that inclusion of TCEP produced considerably less free [3H]-palmitate than
inclusion of DTT (data not shown [PAT ID#629]). This suggests TCEP does not cause
the DHHC-catalyzed acyl-CoA hydrolysis that was observed with DTT and β-ME.
TCEP was also tested and shown to maintain free thiol availability on a protein substrate
at similar levels to DTT (Figure 2.2E). Including TCEP in a PAT assay with DHHC2
and myrLckNT resulted in a 4-fold increase in palmitoyl-myrLckNT versus a reaction
lacking reducing agent (Figure 2.2F). This indicated that TCEP could maintain free
substrate thiols while not negatively affecting DHHC2 PAT activity. A titration of TCEP
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into an assay with DHHC3 and myrGαi1 was carried out to determine the optimal TCEP
concentration. Figure 2.2G indicates that for this enzyme-substrate pair, concentrations
of TCEP greater than 1 mM were inhibitory to palmitate labeling of myrGαi1. For this
enzyme-substrate pair inclusion of TCEP into this assay did not increase substrate
acylation over a reaction lacking reducing agent, which is unlike the DHHC2-myrLckNT
pair in Figure 2.2F.
Together these results support the replacement of DTT with TCEP in PAT assays.
Given that reducant is included to maintain substrate thiols (Figure 2.2E) and that high
TCEP concentrations are inhibitory (Figure 2.2G), it is recommended that 1 mM TCEP
only be included in the substrate buffer as shown in Table 2.1. This allows reduction of
substrate thiols as well as dilution of the TCEP when the remaining assay components are
added. Although unlikely, one possibility that was not investigated is that TCEP may
break physiologically relevant disulfide bonds and the newly exposed thiols become sites
of acylation. This could be tested by determining if TCEP causes acylation of a substrate
that has the in vivo modified cysteine residues mutated (e.g. myrLckNT C3S C5S or
myrGαi1 C3S). Finally, the difference in response to TCEP between DHHC2 and
DHHC3 may suggest that DHHC proteins respond differently to reducing agents.
Effect of various compounds on DHHC-mediated PAT activity—Several other
compounds were tested in the radiolabel-based PAT assay as summarized in Table 2.2
and are briefly discussed here. During the purification of DHHC proteins several
protease inhibitors are used to limit protein degradation. These compounds were tested
for their effect on DHHC activity and most were found to have no effect. Because
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inhibitor compounds tend not be soluble in water at high concentrations and are instead
dissolved in organic solvents, these solvents were tested. Of these, ethanol showed
strong inhibition of PAT activity consistent with work by others in cells showing that
ethanol inhibits palmitoylation of G-protein α-subunits (163). Dimethylsulfoxide
(DMSO) displayed the least inhibition of the solvents tested and was used as the vehicle
for additives to the assay. Multiple reports have described the use of cerulenin,
tunicamycin, and analogs of each to inhibit protein acylation within cells (164-167).
Neither cerulenin nor tunicamycin inhibited DHHC2 PAT activity when tested,
suggesting that in cells these compounds may have other targets such as acyl-CoA ligase
or enzyme involved in fatty acid synthesis. Given the high conservation of cysteine
residues within the DHHC cysteine rich domain and thus their likely importance to
enzyme function, it was not surprising that the cysteine-specific alkylating reagent Nethylmaleimide (NEM) strongly inhibited DHHC activity. Interestingly, the histidinespecific alkylating reagent diethylpyrocarbonate (DEPC) also inhibited DHHC activity.
This may point to the histidine residues of the DHHC motif playing an important role in
acyltransfer.
Finally, two compounds currently in clinical trials were tested for ability to alter
DHHC PAT activity. Tecovirimat (ST-246) prevents the function of p37 (F13L), a
palmitoylated protein necessary for poxvirus infections and has shown promise as an
orally active drug (168, 169). When tested in our assay it showed no effect on PAT
activity. Farnesyl thiosalicylic acid (FTS, Salirasib), which was originally identified as
inhibiting carboxymethylation of CaaX motifs (170, 171), showed dose-dependent
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inhibition of both DHHC2 and DHHC9. One-possibility is that the long hydrophobic
farnesyl-side chain of this inhibitor competes with the acyl-chain of palmCoA for binding
to the DHHC. How DHHC proteins recognize and differentiate lipid substrates is
unclear.

Concluding remarks and future experiments
DHHC acyltransferase activity could be further improved by investigating other
conditions. We used detergent to extract and purify DHHC proteins within detergent
micelles, however in cells, DHHC proteins are found within a phospholipid bilayer.
Thus, reconstitution of DHHC proteins into liposomes may better represent physiological
conditions. For other integral membrane enzymes, profound effects on kinetics and
specificity have been described following reconstitution into lipid vesicles. For example,
the yeast polytopic integral membrane Ste14p, which acts on Ras, displays a ~15-fold
enhancement upon reconstitution into E.coli liposomes (160). Another integral
membrane enzyme MGAT (monoacylglycerol acyltransferase) displays 11-fold
stimulation by reconstitution into phosphatidic acid containing micelles, but inhibition by
oleate and sphingosine containing vesicles (172). One caveat of reconstitution into the
liposomes is orientation of the DHHC protein within the lipid bilayer. It is likely that
some DHHC proteins would incorporate with their active site to the lumen of the
liposome and thus, inaccessible for interaction with either substrate during a PAT assay.
When determining enzyme activity, these effectively inactive DHHC proteins could skew
calculations of turnover and specific activity.
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An alternative method of lipid reconstitution that gets around the orientation
problem of liposomes is the use of high-density lipoprotein particles, also called
Nanodiscs. Nanodiscs consist of a lipid bilayer approximately 7 nm in diameter
surrounded by a self-assembling membrane scaffolding protein (MSP) ‘belt’ derived
from human apolipoprotein A-1 (apo A1). Various lipids, including cholesterol, can be
used to form the bilayer and MSP mutants of varying length can alter the bilayer diameter
(173). Nanodisc components and a membrane protein of interest purified in detergent are
mixed and as the detergent is removed, membranes proteins incorporate into the
Nanodisc lipid bilayer. One advantage of this system is that both sides of the bilayer are
solvent accessible, and thus, protein orientation within the bilayer is not an issue. The
contribution of the surrounding lipid environment to DHHC activity is a largely
unexplored area.
For my studies DHHC proteins were epitope tagged at the N-terminus (DHHC2
pML850), the C-terminus (DHHC3), or both (DHHC2 pML943) with multiple different
tags. The yeast DHHC protein Erf2 displayed ~30% lower autoacylation and ~50%
reduced transfer activity when FLAG-tagged at the C-terminus versus the N-terminus
(83). Erf2-FLAG reduced activity could result from loss of interaction with its binding
partner Erf4, however this was not tested. Nevertheless, given this precedent, the
placement of affinity purification tags on DHHC proteins should be investigated.
As we learned more about DHHC proteins, differences are being found among
family members. These include differences in acyl-CoA specificities (Figures 3.3-5),
TCEP-induced activity enhancement (Figures 2.2F and G), binding partner requirements,
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and protein substrate preferences. Thus, the idea that one set of assay conditions be
optimal for all DHHC proteins seems unlikely and DHHC-specific protocol
modifications may be needed. For other enzymes families that have been well
characterized, assay conditions differ from one isoform to another. For example, within
the PKC family of protein kinases, differences are noted in calcium, magnesium,
diacylglycerol, and phospholipid requirements for maximal activity (174).
Given the data presented here regarding the use of thiol-based reducing agents in
PAT assays, care should be taken in analyzing previously published results. One
example is the inhibitor studies presented in Chapter 4 of this work. These studies were
carried out before we knew about the detrimental effects of DTT on DHHC-mediated
PAT activity. It is possible that those compounds that failed to inhibit DHHC proteins as
expected did so because of the presence of DTT within reaction buffers. If inhibitors
reacted with thiols within the DHHC protein, it is feasible the DTT could have removed
these inhibitors and restored enzyme activity. To determine if DTT affected inhibitor
action, DHHC9 was analyzed with the inhibitors in the absence of reducing agent. No
change was observed in the inhibition profile (data not shown [PAT ID#561]).
A second example where DTT may have affected enzyme activity is the work
presented by Mitchell and coworkers with the yeast DHHC protein Erf2 (175). They
developed a continuous assay to monitor palmCoA use by coupling the release of CoA to
the reduction of NAD+ to NADH by α-ketoglutarate dehydrogenase and monitoring the
change in NADH fluorescence. Using this assay they measured the rates of palmCoA
hydrolysis by wildtype and several mutants of Erf2. The buffers for this assay were
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reported to contain 1 mM DTT. If Erf2-catalyzed hydrolysis of palmCoA is DTTdependent as shown here for other DHHC proteins, then their reported hydrolysis rates
were likely dependent on reducing agent abundance and higher than rates had DTT been
omitted or TCEP used. While this would not change the major findings of the paper, it
complicates comparison of palmCoA hydrolysis rate to those determined by others.
Having robust, well-characterized assays of enzyme activity is one of the first
steps in biochemically investigating an enzyme. Here I described the optimization and
characterization of a number of properties for the radiolabel-based PAT assay. This
characterization was necessary for subsequent inhibitor studies, which needed to be
performed within the linear reaction range. Likewise, the single turnover assays used to
determine the kinetic mechanism of DHHC proteins required purification of the acylDHHC transfer intermediate that was not possible until DTT was omitted from buffers.
Together, these optimization experiments have improved the main assay used to study
DHHC function and have opened the door for new investigations.
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Table 2.1 Standard radiolabel-based PAT assay
Fall 2005 (114)
10 µL Enzyme in TEDT Buffer
50 mM Tris pH 7.4
125 mM NaCl
1 mM EDTA
10% glycerol
0.1% Triton X-100
1 mM DTT

Current Conditions
10 µL Enzyme in Enzyme Dilution Buffer
50 mM MES pH 6.4
100 mM NaCl
1 mM EDTA
10% glycerol
0.1% DDM

10 µL Substrate in HED
20 mM HEPES pH 8.0
1 mM EDTA
1 mM DTT

10 µL Substrate in MET
50 mM MES pH 6.4
1 mM EDTA
1 mM TCEP

30 µL Reaction Hot Mix
167 mM MES 6.4
1 mM DTT
1.7 µM [3H]-palmitoyl-CoA

30 µL Reaction Hot Mix
50 mM MES pH 6.4
1.7 µM [3H]-palmitoyl-CoA

Reaction at 30°C and stop with
5X Sample Buffer + 5 mM DTT final
Heated 100°C for 60 sec

Reaction at 25°C and stop with
5X Sample Buffer + 2 mM TCEP final
Heated 55°C for 60 sec
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Table 2.2 Effect of various compounds on PAT activity5
PAT Compound
ID#

Conc.

Percent
Inhibition

DHHC
(pML)

Sub.

729

Zinc (Zn2+)

2 – 20 mM2

100

2 (943) myrLckNT

729

Magnesium (Mg2+)

2 – 20 mM2

0

2 (943) myrLckNT

179

3X FLAG ® peptide

3 – 333 ng/µL1

0

2 (943)

263

Roche Complete® EDTA-free
inhibitor tablets

0

2 (943) myrLckNT

263

Pepstatin A

1 tablet per 32
mL1
5 µg/mL1

0

2 (943) myrLckNT

123
123
123

N-α-Tosyl-L-lysinylchloromethylketone (TLCK)
N-tosyl-L-phenylalaninylchloromethylketone (TPCK)
Phenylmethanesulfonylfluoride
(PMSF) in 2-Propanol

myrGαi1

0.5 – 10 mM2

0 to 26

2 (850)

myrGαi1

0.5 – 4 mM2

0

2 (850)

myrGαi1

0.2 – 1 mM2

−226

2 (850)

myrGαi1

123

2-Propanol

2%2

−116

2 (850)

myrGαi1

181

Ethanol (EtOH)

10%1

87

2 (943)

myrGαi1

123

Methanol

2%2

0

2 (850)

myrGαi1

1

289

Dimethyl sulfoxide (DMSO)

175
181

Tunicamycin

175

Cerulenin

117
119

Palmitic Acid (PA)

63
63

0 – 50%
0 – 50%1
1 – 100 µM2
5 – 500 µM1

Inhibits at >20% 2 (943) myrGαi1
Inhibits at >10% 2 (943) myrLckNT
0

2 (943)

myrGαi1

1 – 1000 µM2

0

2 (943)

myrGαi1

50 –
5000 µM1

0 to 14

2 (850)

myrGαi1

Diethylpyrocarbonate (DEPC)

5 mM1

59

2 (850)

myrGαi1

N-Ethylmaleimide (NEM)

5 mM1

88

2 (850)

myrGαi1

myrGαi1
myrLckNT
5 – 1580 µM1
0 – 100
Farnesyl Thiosalicylic Acid
2 (943) myrLckNT
427
4
1
100
H-ras
(FTS, Salirasib)
1580 µM
9 (418)
1
Notes: Concentration during pre-incubation with DHHC before addition of substrates.
2
Final concentration in assay, no pre-incubation.
3
Prevents function of p37 (F13L), a palmitoylated protein required by poxvirus (168, 169).
4
Inhibits carboxymethylation of CaaX motifs (171).
5
The concentrations of reaction components varied. Typical ranges were DHHC protein, 2 to 20
nM; protein substrates myrGαi1, myrLckNT, or H-ras 0.5 to 2 µM; and [3H]palmCoA, 0.5 to 1.3
µM. Reactions were incubated at 25°C for 4 to 12 min.6These compounds stimulated DHHC
activity.
6
These compounds stimulated DHHC activity.
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Tecovirimat (ST-246)3

0.5 – 500 µM2
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0

2 (943)
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Figure 2.1. Detergent and buffer effects on in vitro DHHC PAT activity. A, DHHC2 (pML850) was
assay with myrGαi1 in the presence of either 0.02% Triton X-100 or 0.02% n-dodecyl-β-maltoside (DDM)
[PAT ID#107; n=1]. B, DHHC3 (1000 fmol) autoacylating in various amounts of DDM detergent for 2 min
on ice in 1 μM [3H]palmCoA [PAT ID#531; n=2]. C, E, and F, DHHC3 (500 fmol) autoacylating in EDTA,
glycerol, or NaCl at the inducated concentrations for 4 min at 25°C in 1 μM [3H]palmCoA [PAT ID#601;
n=1]. D, DHHC2 (5 nM, pML943) was assayed for the ability to acylate myrLckNT (1 μM) in the presence
of either ZnCl2 or MgCl2 for 6 min at 25°C in 1.2 μM [3H]palmCoA. The final concentration of metal ions
in the 50 μL reaction is listed [PAT ID#729; n=1].
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FIGURE 2.2 Reducing agents affect in vitro DHHC autoacylation and PAT activity.

42

- + +
+ - +

1 mM TCEP

FIGURE 2.2. Reducing agents affect DHHC autoacylation and PAT activity in vitro.
A, DHHC3, DHHS2 (1 pmol), or enzyme buffer were incubated with 1.1 µM
[3H]palmCoA on ice for the indicated times. Reactions were stopped with SDS and an
aliquot was spotted on thin layer chromatography plates that were then developed in 50%
butanol/20% acetic acid/30% water for 5.5 hr. The plate was dried, sprayed twice with
En3Hance solution, and exposed to film at -70°C. The remaining reaction was resolved
by SDS-PAGE gels and processed as described in Chapter 4 [PAT ID#529]. B, DHHC3
was autoacylated with [3H]palmCoA in buffer containing no reducing agent (), 1 mM
dithiothreitol (DTT, ), or 2 mM β-mercaptoethanol (β-ME, )). Aliquots representing
500 fmol DHHC were removed at various times and analyzed by SDS-PAGE and liquid
scintillation counting [PAT ID#547; n=2]. C, DHHC2 (filled symbols) or DHHS2 (open
symbols, 500 fmol each) was incubated with 1 µM [3H]palmCoA in buffer containing no
reducing agent (), 1 mM DTT (), or 1 mM tris(2-carboxyethyl)phosphine (TCEP, )
for the indicated time on ice. DHHS2 was analyzed only at the 12 sec and 60 min time
points. Reactions were processed as in B [PAT ID#629; n=2]. D, PAT assay of DHHC2
or DHHS2 (20 nM) with myrLckNT for 12 min in 0.9 µM [3H]palmCoA with or without 1
mM DTT [PAT ID#541]. E, Non-enzymatic acylation of myrLckNT (100 pmol) in 1.7
µM [3H]palmCoA with no reducing agent (), 1 mM DTT (), or 1 mM TCEP () for
35 min at the indicated pH [PAT ID#633]. F, DHHC2 (5 nM) and/or myrLckNT (1 uM)
were incubated with 1 µM [3H]palmCoA for 8 min at 25°C either with or without 1mM
TCEP [PAT ID#631]. G, DHHC3 (10 nM) was incubated with 2 µM myrGαi1 and 1 µM
[3H]palmCoA for 6 min at 25°C in buffer containing the indicated concentration of TCEP
[PAT ID#779].
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Chapter 3

DHHC Protein S-Acyltransferases Use A Similar Ping-Pong
Kinetic Mechanism But Display Different Acyl-CoA Specificities

This chapter was reviewed for publication by the Journal of Biological Chemistry. Dr.
Maurine Linder and I are coauthors. The manuscript is accepted pending revision and
resubmission is anticipated in fall 2011.
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Abstract
DHHC proteins catalyze the reversible S-acylation of proteins at cysteine
residues—a modification important for regulating protein localization, stability, and
activity. However, little is known about the kinetic mechanism of DHHC proteins. A
high performance liquid chromatography (HPLC), fluorescent peptide-based assay for
protein S-acylation (PAT) activity was developed to characterize mammalian DHHC3.
Time courses and substrate saturation curves allowed the determination of Vmax and Km
values for both the peptide N-myristoylated-GCG and palmitoyl-coenzyme A. DHHC
proteins acylate themselves upon incubation with palmitoyl-CoA, which is hypothesized
to reflect a transient acyl-enzyme transfer intermediate. Single turnover assays with
DHHC2 and DHHC3 demonstrated that a radiolabeled acyl group on the enzyme
transferred to the protein substrate, consistent with a two-step ping-pong mechanism.
Enzyme autoacylation and acyltransfer to substrate displayed the same acyl-CoA
specificities, further supporting a two-step mechanism. Interestingly, DHHC2 efficiently
transferred acyl-chains 14 carbons and longer, whereas DHHC3 activity was greatly
reduced by acyl-CoAs with chain lengths longer than 16 carbons. The rate and extent of
autoacylation of DHHC3, as well as the rate of acyl-chain transfer to protein substrate,
were reduced with stearoyl-CoA compared to palmitoyl-CoA. This is the first
observation of lipid substrate specificity among DHHC proteins and may account for the
differential S-acylation of proteins observed in cells.
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Introduction
Protein S-acylation is the posttranslational addition of long-chain fatty acids to
cysteine residues via a thioester linkage. Unlike other lipid modifications, S-acylation is
reversible and thus regulated via acylation/deacylation cycles in cells. This regulation is
important for the activity and localization of key signaling proteins including Ras
isoforms (38, 176, 177), G-protein α-subunits (178), huntingtin (111, 121), endothelial
nitric oxide synthase (179), and ion channels (180). Protein acyltransferases (PATs)
catalyze the addition of fatty acids to proteins whereas acyl-protein thioestereases (APTs)
remove them. Despite the importance of protein S-acylation in these signaling pathways
and in human diseases (86), little is known about the kinetic mechanism, regulation, and
substrate specificities of PATs and APTs.
Genetic and biochemical studies in yeast have established that a family of integral
membrane enzymes known as DHHC proteins catalyze protein S-acylation. While S.
cerevisiae have seven DHHC PATs, mammalian genomes encode at least twenty-three.
DHHC proteins are named for a highly conserved Asp-His-His-Cys sequence within a
larger cysteine-rich domain (DHHC-CRD) that is situated on the cytoplasmic face of the
membrane between four transmembrane domains (83). In vitro analyses with
radiolabeled palmitoyl-CoA (palmCoA) have demonstrated that DHHC proteins are
sufficient to catalyze the transfer of fatty acids from CoA to cysteine residues within
target protein substrates. Additionally, DHHC proteins themselves become acylated upon
incubation with palmCoA, a process called enzyme autoacylation. Mutational analysis
has revealed that the cysteine residue within the DHHC motif is indispensable for both
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palmitoyl-transfer and autoacylation activities (81, 82); however the site of autoacylation
remains unknown as well as whether autoacylation occurs in cis or trans. It has been
hypothesized that DHHC autoacylation reflects a transient acyl-enzyme intermediate with
DHHC proteins using a two-step ping-pong mechanism to catalyze transfer (81, 82).
Alternatively, DHHC autoacylation may reflect a modification of the enzyme that is not
transferred to substrate but serves another function.
The fatty acid attached during S-acylation is most often the saturated 16-carbon
fatty acid palmitate; thus, the process is frequently called S-palmitoylation or simply
palmitoylation. However, S-acylation of other chains lengths has been reported.
Incubation of platelets with [3H]-arachidonate acid (C20:4) resulted in the labeling of
endogenous G-protein subunits αi, αq, α13, and αz via a thioester linkage (128). Mass
spectrometry of fatty acids attached to native rhodopsin revealed that approximately 83%
are C16 palmitate while the remaining are a mixture of 14:0, 15:0, 16:1, 18:0, 18:1, 18:2,
20:4, and 22:6 (31). Metabolic radiolabeling with palmitate versus either C20:4
arachidonate (129) or C18:0 stearate (127) demonstrated that some proteins are
preferentially modified with chain lengths other than C16 palmitate. More recently,
using click chemistry techniques and alkyl-fatty acids that mimic myristate, palmitate, or
stearate to enrich for acylated proteins, Hang and coworkers identified proteins from
Jurkat T cells that selectively labeled with different chain lengths (15). The mechanism
responsible for these differences in acyl-chain length attachment remains unclear.
In the present study we characterize the kinetic mechanism and lipid substrate
specificity of DHHC proteins. A high-performance liquid chromatography (HPLC)
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fluorescent peptide-based PAT assay is developed to measure rate constants for a
representative DHHC. Single turnover experiments directly address the question of
whether DHHC autoacylation is a transient acyl-enzyme intermediate in a two-step pingpong mechanism. One corollary of this predicted reaction scheme is that acyl-chain
lengths capable of being transferred to protein substrates should also be capable of
autoacylating the DHHC protein. This prediction is tested as well as the mechanism of
DHHC lipid substrate specificity.

Experimental Procedures
Reagents. The fluorescent peptide myrGCG was synthesized by AnaSpec, Inc
(San Jose, CA) and consists of N-myristoylated glycine, cysteine protected by a disulfide
link tert-butyl group, and glycine linked via ethylenediamine to nitro-benzoxadiazole
(NBD). Aliquots dried under N2 were stored at -80°C. [3H]9,10-palmitate (47.7 Ci/mmol)
was purchased from PerkinElmer Life Science. [3H]9,10-stearic acid was purchased from
Moravek Biochemicals, Brea, CA. The specific activity reported by the manufacturer for
[3H]-stearic acid (75 Ci/mmol) exceeded the theoretical maximum specific activity of
57.6 Ci/mmol. The theoretical value was used for [3H]-stearic acid calculations.
[3H]palmCoA for Figures 3.2 and 3.3 was synthesized and purified as described (181).
For Figure 3.5, [3H]palmCoA and [3H]-stearoyl-CoA were synthesized as described
except that the detergent n-dodecyl-b-D-maltoside (DDM) replaced Triton X-100.
Radiolabeled acyl-CoA was separated from free fatty acid by chloroform/methanol
extraction (28). Acetonitrile was purchased from Honeywell. Internal standard 16-12-

48

NBD-PC (1-palmitoyl-2-{12-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]dodecanoyl}-snglycero-3-phosphocholine) and non-radiolabeled C6- and C10-CoAs were from Avanti
Polar Lipids. CoA and the other unlabeled acyl-CoAs were from Sigma.
HPLC-based fluorescent peptide PAT assay. Peptide was deprotected by
overnight incubation in 77% DMSO, 0.15% DDM, and 7.5 mM TCEP, under argon,
protected from light at 25°C. Greater than 90% deprotection was achieved as assessed by
HPLC before each experiment. Deprotected peptide was diluted with 50 mM MES pH
6.4 to 25% DMSO, 0.05% DDM, and 2.5 mM TCEP. PalmCoA (and later, other acylCoAs) and peptide were mixed in glass test tubes and warmed to 25°C. Partially purified
DHHC protein warmed to 25°C was added to start the reaction. The final reaction was
50 µL at 50 mM MES pH 6.4, 10% DMSO, 1 mM TCEP, and 0.028% DDM. Final
concentrations of DHHC, acyl-CoA, and myrGCG are noted in the figure legends.
Reactions were stopped with 500 µL dichloromethane and held on ice until all reactions
were complete. The reactions were spiked with 250 µL of 0.02 µM 16-12-NBD-PC
dissolved in methanol as an internal standard and 250 µL aqueous buffer (50 mM MES
pH 6.4, 250 mM NaCl) to cause phase separation. This internal standard was chosen
because it was tagged with NBD similar to the peptide, does not overlap with other
peaks, and elutes in the same solvent as the palmitoylated peptide, minimizing NBD’s
high solvatochromic shift (182). The lower organic phase was collected and extracted
twice more with 500 µL dichloromethane. Pooled extracts were clarified with 300 µL
methanol, dried under N2, and stored at -20°C. For directly monitoring transfer of
various acyl-CoA chain lengths, a similar assay was used with 10 µM acyl-CoAs and 5
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µM deprotected myrGCG in a final 50 µL reaction. Addition of DHHC (10 nM) or
buffer was used to start the reaction, which was incubated at 25°C for 10 min. Reactions
were stopped with 500 µL dichloromethane and processed as described above.
Dried acylated peptides were dissolved in 100 µL isopropanol and then, 100 µL
0.5 mM TCEP added to reduce disulfide linked peptides. Samples were analyzed using a
Beckman Coulter Gold HPLC system (508 autosampler, 126NM solvent module, 166NM
detector) inline with a Jasco FP2020 fluorescence detector with buffer A (20%
acetonitrile/80% water/0.1% trifluoroacetic acid) and buffer B (100% acetonitrile). For
each reaction, an aliquot of 50 µL was injected onto a reversed phase Vydac C4 (5 µm,
300 Å, 4.6 x 250 mm) column equilibrated in 35% buffer B at 1 mL/min. After 1 min, a
linear gradient over 5 min increased the mobile phase to 82.5% B, and it was held there
for 10 min. The mobile phase was then returned to 35% B over 1.5 min and allowed to
equilibrate for 3.5 min (Figure 3.1A, dashed line). UV absorbance was recorded at 254
nm and fluorescence excited at 465 nm and emission recorded at 531 nm with the gain set
at 10-100x. This HPLC method was adapted from work by others (183). Version 8, 32
Karat software was used to record data and determine area under the curve for peptide
and internal standard peaks. Areas were converted to pmol acylated myrGCG, fit to the
Michaelis-Menten equation using nonlinear regression, and plotted with Prism 5
(GraphPad Software, Inc.).
Constructs, expression, and protein purification. Plasmids for murine myrLckNT
and human DHHC2 were described previously (181). Mouse DHHC3 was amplified
from the cDNA (Image Clone 3669723, NM_026917.4) and subcloned into pBlueBac4.5
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(Invitrogen; Carlsbad, CA) to encode a protein with a FLAG-His6 sequence
(GSELRYQAYVDYKDDDDKNSAEFHHHHHH(stop)) appended to the C-terminus of
DHHC3. Called pML1117, this plasmid was used to generate catalytically inactive
DHHS3-FLAG-His6 (pML1354) by site-directed mutagenesis (Stratagene) of Cys157.
Recombinant baculoviruses were generated as previously described (181). DHHC-2 and
-3 WT and DHHS mutants were expressed in Sf9 cells and purified by Ni-NTA metal
chelate chromatography as previously described except that TriEx™ Sf9 cells and media
(EMD Chemicals) were used for cell culture. For peptide studies, direct transfer, and
acyl-CoA competitions, Ni-NTA elutions were used, whereas for enzyme autoacylation
studies (Figure 3.5) pooled FLAG affinity-resin elutions were used. N-myristoylated Gprotein αi1 (myrGαi1) and myrLckNT were co-expressed in E. coli with Nmyristoyltransferase and purified as C-terminal His6-tagged proteins using established
protocols (181, 184).
Direct Transfer from DHHC to protein substrate. For single turnover
experiments (Figure 3.2), 350 pmol DHHC protein was incubated with 40 µL FLAG
affinity resin equilibrated in buffer C (50 mM Tris pH 7.4, 100 mM NaCl, 0.06% DDM,
5% glycerol, and 1 mM EDTA) at 4°C with end-over-end rotation for 60 min. Bound
DHHC was washed three times with 500 µL buffer C and twice with 650 µL buffer D (50
mM MES pH 6.4, 20 mM NaCl, 0.06% DDM, 5% glycerol, and 1 mM EDTA). Bound
DHHC was autoacylated by incubation with buffer D containing [3H]palmCoA (1400
pmol) for 7 min on ice. Free [3H]palmCoA was removed by washing with 850 µL buffer
D eleven times until the radioactive acyl-CoA content of the washes was <5nM.
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Radiolabeled DHHC was eluted eight times with 50 mL buffer D containing 0.3 µg/µL
3X FLAG peptide (Sigma). Elutions 2-8 were pooled and the time course initiated by the
addition of 1 µM unlabeled palmCoA and either protein substrate or buffer at 25°C.
Aliquots were removed at the indicated times and stopped with 5× sample buffer with 2
mM tris(2-carboxyethyl)phosphine (TCEP) final. Reactions were divided between two
SDS-PAGE gels with one set being processed for fluorography and the other for
scintillation counting using established methods (181). For single turnover experiments
with stearate (Figure 3.5C and D), an identical procedure was followed except [3H]stearoyl-CoA was used.
Acyl-CoA specificity of autoacylation and transfer. For competition PAT assays,
[3H]palmCoA and unlabeled acyl-CoA were pre-mixed on ice. Likewise, DHHC and
protein substrate were pre-mixed before adding to the lipid substrate mixture and
incubating 6 min at 25°C. Final assay concentrations were 20 nM DHHC, 1 µM
[3H]palmCoA, 10 µM competing acyl-CoA, and either 1 µM myrGαi1 or 0.5 µM
myrLckNT in a total of 25 µL. Assays were stopped with 5× sample buffer with 2 mM
TCEP final and processed for scintillation counting.
Hydrolysis of acyl-CoAs (Table 3.2) was determined by incubating DHHC-2, -3
(45 nM), or buffer with either [3H]palmCoA or [3H]-stearoyl-CoA at 25°C and stopping
with SDS. An aliquot of the reaction, equivalent to 5 pmol of the initial acyl-CoA in the
reaction, was spotted on thin layer chromatography plates (LK6DF silica gel, Whatman)
and resolved with 50% n-butanol/ 20% acetic acid/ 30% water for 5 hrs. The plate was
dried, sprayed twice with EN3HANCE™ autoradiography enhancer spray (PerkinElmer),
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and exposed to film at -70°C for 42 hrs. The regions of the TLC plate containing free
fatty acids were located by comparison with the film, scraped, and quantitated with
scintillation counting. Background free fatty acid was determined from a control reaction
lacking DHHC and subtracted before fitting the data by linear regression. To the
remaining reaction, 5× sample buffer was added and an aliquot representing 1 pmol of
DHHC protein was resolved on SDS-PAGE gels and processed for scintillation counting
to monitor enzyme autoacylation. Analyzing a reaction without DHHC was set as the
zero time point allowing the data to be fit to a single phase exponential by nonlinear
regression.

Results
Determination of DHHC3 kinetic constants with fluorescent peptide, HPLCbased PAT assay. To characterize DHHC proteins mechanistically, we determined
steady state kinetic parameters with a modified high performance liquid chromatographic
(HPLC) method initially described for the characterization of PAT activity in cell lysates
(183). The advantages of the HPLC-based peptide assay were ease of achieving
saturating substrate concentrations and elimination of the need for radioactive acyl-CoA
compounds. For a palmitoylation site mimic, the three-residue peptide glycine-cysteineglycine was synthesized with the N-terminus myristoylated and the C-terminus linked to
the fluorescent group NBD (myrGCG; Figure 3.1A inset). A previous study showed that
myrGCG is taken up by cells and efficiently palmitoylated in a manner that is time-
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dependent and saturable (185), suggesting it is a good substrate for in vitro palmitoylation
assays.
DHHC2, DHHC3, and DHHC9/GCP16 were individually tested for their ability
to palmitoylate myrGCG. DHHC2 and DHHC3 showed similar levels of palmitate
incorporation, approximately 2.5 times that of DHHC9/GCP16 (unpublished results). In
vivo evidence suggests DHHC3 has broad protein substrate specificity (86), and it
expresses well in insect cells infected with recombinant baculovirus. Therefore, it was
chosen for further kinetic analysis. To determine the linear range of the reaction, a time
course was performed. DHHC3, palmCoA, and myrGCG were incubated for various
times, spiked with an internal standard, and separated on a C4 reversed phase HPLC
column monitored with a fluorescence detector. A representative chromatogram is
shown in Figure 3.1A. In addition to peaks of unreacted and palmitoylated peptide, a
peak corresponding to a disulfide-linked myrGCG dimer appears, which results from the
drying of unprotected myrGCG in the absence of reducing agent. The area of the
palmitoylated peptide peak was compared to that of the internal standard and converted
to pmol of palmitoylated peptide. At low concentrations of both substrates, the reaction
was linear for at least the first 6 minutes (Figure 3.1B), however the standard assay was
limited to 4 minutes before depletion of either substrate occurred. To determine Km and
Vmax values, one substrate concentration was held at a constant saturating concentration
while the other varied. Saturation with palmCoA and analysis with non-linear regression
revealed a Vmax of 10.0 pmol/min/pmol of DHHC3 and a Km of 1.5 µM myrGCG (Figure
3.1C, Table 3.1). At saturating myrGCG, a Vmax of 10.7 pmol/min/pmol and a Km of 1.2
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µM palmCoA were observed (Figure 3.1D). For both peptide and palmCoA titration
curves, Vmax values were approximately the same (Table 3.1) as expected under saturating
conditions. Both substrate concentrations were varied around their Km values to generate
data for a double reciprocal, Lineweaver-Burke analysis. Unfortunately, these data were
not adequate to distinguish a ternary complex from a ping-pong mechanism (186).
Direct measurement of acyl-transfer from acyl-DHHC to protein substrate. All
DHHC proteins tested to date autoacylate, a process hypothesized to result from DHHC
proteins using a ping-pong catalytic mechanism for substrate acylation. We directly
tested whether DHHC enzyme autoacylation is a transfer intermediate. Because DHHC3
was identified as a PAT for G-protein α-subunits (187), we first confirmed that DHHC3,
but not the catalytically inactive mutant DHHS3 (DHHC3 C157S), could palmitoylate Nmyristoylated Gαi1 (myrGαi1) above background levels. Also as expected, DHHC3, but
not DHHS3, became autoacylated during the assay (Figure 3.2A).
Using this enzyme/substrate pair, we tracked the transfer of [3H]palmitate from
[3H]palm-DHHC3 to myrGαi1. Palmitoyl-DHHC3 was generated by binding partially
purified DHHC3 to FLAG affinity resin and incubating with [3H]palmCoA to
autoacylate. Unreacted [3H]palmCoA was washed out and [3H]palm-DHHC3 was eluted
with FLAG peptide. Immunoblotting and fluorography indicated that elutions 2 through
7 contained [3H]palm-DHHC3 (Figure 3.2B). The absence of thiol-based reducing agents
from the buffers was critical for purification of the acylated enzyme. Elutions were
pooled and incubated with non-radiolabeled palmCoA and either myrGαi1 or buffer.
Aliquots removed at various times were stopped, separated by SDS-PAGE, and analyzed
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by both fluorography and scintillation counting. Figures 3.2C and 3.2D show that at
early times most of the [3H]palmitate was attached to the DHHC3 but over time was lost
from the enzyme and accumulated on myrGαi1. The rate of transfer of [3H]palmitate from
DHHC3 inversely paralleled the rate of gain of [3H]palmitate on myrGαi1 (Figure 3.2D).
A comparable experiment was performed with DHHC2 and its substrate myrLckNT (181),
and a similar pattern was observed both by fluorography (not shown) and scintillation
counting (Figure 3.2E). A slower loss of [3H]palmitate from both DHHC proteins was
observed when incubated without a protein substrate; this is likely due to hydrolysis of
the thioester-attached lipid. Inclusion of an excess of non-radiolabeled palmCoA (1 µM)
in the reaction was intended to compete with any residual [3H]palmCoA not removed
during purification and to drive the reaction to completion. However, radiolabeled
palmitate remained associated with DHHC2 and DHHC3 even at extended time courses
up to 45 minutes. Spiking the reaction with additional protein substrate after 10 minutes
did not cause the reaction to proceed further (data not shown).
DHHC enzyme autoacylation acyl-CoA chain-length specificity parallels
substrate acylation specificity. If enzyme autoacylation is a transfer intermediate, then
the protein substrate should only acylate with acyl-CoAs that also can acylate the DHHC
protein. To test this prediction a competition assay was set up in which a ten-fold excess
of non-radiolabeled acyl-CoAs of different chain lengths and saturations were used to
compete with [3H]palmCoA (C16:0) for acylation of enzyme and substrate. For both
DHHC2 and DHHC3, the level of enzyme autoacylation paralleled that of substrate
acylation for each competing acyl-CoA tested (Figure 3.3A and B). Together with Figure
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3.2 and work by others (175), these data strongly suggest that DHHC autoacylation
represents a transient transfer intermediate and DHHC proteins use a two-step ping-pong
mechanism for catalysis.
DHHC2 and DHHC3 display different acyl-CoA specificities. In Figure 3.3, a
difference in lipid substrate profiles for DHHC2 and DHHC3 was observed. For
DHHC2, acyl-CoAs of 14 carbons and longer inhibited [3H]palmCoA labeling of both
substrate and enzyme. However, with DHHC3 only myristoyl-, palmitoyl-, and
palmioleoyl-CoA were effective and longer acyl-CoAs competed less well. The
competition assays in Figure 3.3 suggested that DHHC2 transfers fatty acids longer than
16 carbons. However, the reduction in the [3H]palmitate labeling could be caused by
these longer acyl-CoAs acting through a distinct mechanism, for example, by acting as
inhibitors. The difference in acyl-CoA specificities between the DHHCs could also result
from the different protein substrates used. To address both of these issues, DHHC-2 and
-3 were tested in the HPLC-based PAT assay to directly monitor their ability to transfer
various fatty acids to the same substrate, myrGCG. DHHC2 transferred fatty acids from
all acyl-CoAs chain lengths tested (Figure 3.4) consistent with it having a broad
specificity for long chain acyl-CoAs as seen in the competition assay (Figure 3.3B). In
contrast, DHHC3 displayed a narrower lipid substrate profile, transferring only myristate
(C14) and palmitate (C16) at significant levels. Thus, the difference in acyl-CoA
specificity between DHHC2 and DHHC3 was independent of the protein or peptide
substrate used.
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Discussion
In this study we examined the mechanism DHHC proteins use to catalyze acyltransfer and their acyl-CoA specificity. An HPLC, peptide-based PAT assay enabled us
to determine kinetic constants for each substrate. Single turnover assays confirmed the
hypothesis that DHHC autoacylation represents the transient acyl-enzyme transfer
intermediate of a two-step ping-pong mechanism. Acyl-CoA competition assays
provided further evidence for this mechanism and revealed an unexpected difference in
acyl-CoA preferences between DHHC2 and DHHC3. This difference was shown to
result from DHHC3’s reduced ability to autoacylate with and transfer acyl-chains longer
than 16-carbon palmitate.
Kinetic mechanism of DHHC-mediated protein acylation. Others and we had
previously hypothesized that DHHC proteins use a two-step mechanism based on their
ability to autoacylate. Ungermann and coworkers used a “two-step reaction mechanism”
to describe the activity of the yeast DHHC protein Pfa3p (188). However, their two steps
referred to the binding of protein substrate by the DHHC and a second event
encompassing the entire catalytic reaction. More recently, Mitchell et al. proposed a twostep reaction mechanism in the classical kinetic sense to differentiate steps within the
catalytic reaction (175). Using TLC to monitor free palmitate production, they showed
that Erf2p has palmCoA hydrolase activity that occurs with a rapid autoacylation step and
a slower second step involving the transfer of palmitate to water. Addition of Ras2p, a
palmitoylation substrate, increased Erf2p consumption of palmCoA but slowed
production of free palmitate, suggesting the palmitate was now being transferred to
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Ras2p in the second reaction step. Using single turnover assays, we isolated acylatedDHHC protein and confirmed that it can transfer its attached lipid group to a protein
substrate. This confirmed DHHC autoacylation represents a transient transfer
intermediate and thus supports the hypothesis that DHHC proteins use a two-step transfer
mechanism.
To further characterize the mechanism of DHHC-mediated acylation, kinetic
constants were determined for each substrate using an HPLC, peptide-based PAT assay.
These constants were determined by fitting substrate titration data to the MichaelisMenten equation. Michaelis-Menten assumes that enzyme and substrate(s) are freely
diffusible in solution. However, DHHC proteins are integral membrane enzymes and
were bound to detergent micelles in our assays. It is unclear whether DHHC proteins
acquire their substrates from bulk solution or by horizontal diffusion within a lipid
environment. Surface dilution kinetic models account for limited two-dimensional
horizontal diffusion and offer an alternative model for fitting the data (189).
In single turnover assays, it is interesting to note that in no case did all the lipid
transfer off the DHHC, even at later time points. Additionally at these later times, a
similar amount of enzyme remained labeled regardless if the acyl-group was transferred
to protein substrate or was hydrolyzed. It is unknown whether this reflects enzyme that is
inactive with lipid still attached or whether there are secondary acylation sites that are not
transferred and are less susceptible to hydrolysis. The stoichiometry of DHHC3
autoacylation was 0.5 palmitate per DHHC (Figure 3.5A), similar to a value of 0.65
reported for the yeast DHHC protein Erf2p (175). These data suggest that the
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stoichiometry of autoacylation in vitro is one acyl chain per DHHC. The autoacylation
site is predicted to be the conserved cysteine of the DHHC motif. Mutation of this
canonical DHHC cysteine blocks autoacylation and transfer, but there is no direct
evidence that this is the acylated cysteine. Proteomic analysis of DHHC proteins isolated
from cells has revealed that a three-cysteine motif (CCX7-13C(S/T) in the cytoplasmic Cterminal domain of DHHC5, 6, and 8 is palmitoylated (20). This motif is not conserved
among DHHC proteins, and it seems unlikely that palmitoylation of this domain
represents the acyltransfer intermediate. However, it has been proposed that that
intramolecular transfer of the acyl group from the catalytic cysteine to the distal
palmitoylated cysteines could occur (20). Mapping of the sites of in vitro autoacylation
is necessary to resolve this issue.
It is likely that the two-step transfer mechanism described here and elsewhere is
common to all DHHC proteins. For DHHC2 and DHHC3, and for the yeast Ras PAT
Erf2/Erf4 (175), the first step of autoacylation was rapid, suggesting that within cells,
DHHC proteins in the presence of acyl-CoAs may persist in the acylated state poised for
transfer. Regulation of protein acylation may depend on controlling the association
between DHHC proteins and their substrates. Indeed, following activity blockade in
neurons, DHHC2 was shown to translocate to postsynaptic densities, colocalize with one
of its substrates, post-synaptic scaffolding protein PSD-95, and increase PSD-95
acylation (93). Alternatively, the acylation machinery may be constitutively active and
deacylation is a regulated step. To date, no mechanism of post-translational modification
has been described for the regulation of DHHC proteins or deacylating enzymes. While
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we are beginning to develop a mechanistic understanding of DHHC proteins, more work
is needed to understand their structure and regulation.
Fatty Acyl-CoA Substrate Specificity. Investigating the kinetic mechanism of
DHHC proteins lead us to determine their acyl-CoA chain-length specificity.
Surprisingly, a difference in acyl-CoA specificity was observed between DHHC3 and
DHHC2. In the competition assay shown in Figure 3.3, the reduction of [3H]-palmitate
incorporation into substrate by non-radiolabeled acyl-CoAs was presumed to be because
unlabeled acyl-groups were transferred onto the substrate. Indeed, this was likely the
case for DHHC2 and all acyl-CoAs tested in Figure 3.4 as they could be transferred.
However, with DHHC3 and C18- or C20:4-CoA and to a lesser degree with C18:1, very
little acyl-group was transferred to the peptide (Figure 3.4), yet all three caused about
70% reduction of [3H]-palmitate incorporation in the competition assay. Thus, it is likely
acyl-CoAs longer than 16 carbons were interacting with DHHC3 in such a way as to slow
acylation with palmitate. This was confirmed for DHHC3, in which the extent of
autoacylation and the rate of transfer of stearate was slower than with palmCoA. The
differential sensitivity of DHHC PAT activity to different acyl-CoAs suggests a possible
mode of regulation in cells where changes in the availability of different species of acylCoA would impact which DHHC proteins were active and accordingly, which proteins
are modified.
Hydrocarbon rulers for filtering different lipid lengths have been characterized for
other enzymes. Protein N-myristoyltransferase (NMT) shows exquisite specificity for 14
carbon acyl-CoAs. Crystal structures of NMT bound to substrate analogs reveal that
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specificity is achieved by measuring the fatty acid between an oxyanion hole binding the
carbonyl and the floor of the hydrophobic pocket. Furthermore, a hydrophobic groove
induces bends in myristate that further restrict acyl-chain saturation and branching (69).
Fen1p and Sur4p subunits of the very-long chain fatty acid (VLCFA) synthase complex
also display acyl-chain length specificity and, similar to DHHC proteins, are polytopic
integral membrane enzymes (190). The sizing mechanism results from the distance
between a cytoplasmic active site and a lysine residue extending from a transmembrane
helix within the lipid bilayer. By shifting the lysine up and down turns of the helix, acylchain specificity was altered. While DHHC3 does not contain lysine residues within its
predicted TMDs, it does contain charged residues that may behave similarly in restricting
acyl-chain length. The structural basis for DHHC lipid substrate specificity provides a
new area for investigation.
Inhibitors of DHHC proteins will be important tools for studying DHHC biology
within cells, as well as having potential as therapeutic agents. An increasing number of
DHHC proteins have been linked to different human diseases (86). We and others have
attempted to find and characterize DHHC inhibitors with limited success (181). To date,
2-bromopalmitate (2-BP) remains the best DHHC inhibitor available, even though it
lacks specificity among DHHC proteins as well as other cellular enzymes. Given the
two-step mechanism of DHHC catalysis, it might be predicted that inhibitors of the
autoacylation step would block acylation by all DHHC proteins. However, data
presented here indicate that the autoacylation step displays acyl-CoA specificity. Thus it
is likely that inhibitory compounds can be found that are selective for different DHHC
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proteins, possibly through acyl-CoA analogs with different fatty acid chains. The success
with developing potent and highly selective kinase inhibitors that occupy the ATP
binding site encourages efforts to identify small molecules that target DHHC
autoacylation.
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Table 3.1. Kinetic parameters for DHHC3 analyzed with fluorescent peptide,
HPLC-based PAT assay

MyrGCG titration at
10 µM palmitoyl-CoA (n = 4)
Palmitoyl-CoA titration at
10 µM myrGCG (n = 3)

Km
(µm)

Vmax
(pmol/min/pmol)

1.5±0.3

10.0±1.2

1.2±0.2

10.7±1.7

Table 3.2. Hydrolysis rates of different acyl-CoAs with DHHC3 and DHHC2

DHHC3 (n = 2)
DHHC2 (n = 2)

C16:0 palmitoyl-CoA
(pmol/min/pmol)

C18:0 Stearoyl-CoA
(pmol/min/pmol)

0.027

0.008

0.030

0.038
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Figure 3.1. Fluorescent peptide, HPLCbased kinetic characterization of DHHC3.
A, Structure of the tripeptide substrate
N-myristoylated Gly-Cys-Gly tagged via
ethylenediamine with fluorescent NBD
(myrGCG, inset). The elution profile of
myrGCG following reversed-phase chromatography. After in vitro reaction with acylCoA and DHHC3, myrGCG was spiked with
internal standard (16-12-NBD-PC), extracted,
dried, and chromatographed using the gradients (dashed line) shown with Buffer A (20 %
ACN/80% water/0.1% TFA) and Buffer B
(100% ACN). Identity of peaks is indicated.
B, Time course for the enzymatic palmitoylation of myrGCG (0.5 μM) with palmCoA (0.5
μM). Nonlinear regression fit the overall
reaction to a single phase exponential, whereas
values for 0 to 6 min were fit to a straight line
(R2 = 0.99). C, Michaelis-Menton fit to
myrGCG titration with DHHC3 (5 nM) and
saturating palmCoA (10 µM) reacting for 4
min. D, Michaelis-Menton fit to palmCoA
titration with DHHC (5 nM) and saturating
myrGCG (10 µM) reacting for 4 min. A representative of three independent experiments is
shown for each.
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Figure 3.2. Autoacylated DHHC proteins transfer their acyl chain to protein substrate. A, DHHC3
palmitoylates N-myristoylated Gαi1 (myrGαi1). DHHC3-FLAG-His6 (20 nM), the catalytically inactive
mutant DHHC3 C157S (DHHS3, 20 nM), or buffer were incubated with myrGαi1 (1 μM) and
[3H]palmCoA (1 μM) for 6 min at 25°C. The reaction was stopped and [3H]palmitate incorporation was
detected by fluorography (lower panel) or quantitated by scintillation spectrometry as described in Experimental Procedures. B, Partially purified DHHC3 (350 pmol, LOAD) was immobilized on FLAG affinity
resin and the flow through (FT) collected. The column was washed (Wash) and prepped (Prep) for incubation with on-column acylation buffer (OCAB) containing [3H]palmCoA for 7 min on ice. Unbound
[3H]palmCoA was washed out (WOP) with eleven column volumes. Radiolabeled DHHC3 was eluted and
analyzed for DHHC3 by immunoblotting and [3H]palmitate incorporation. C, [3H]palm-DHHC3 was
incubated either alone or with myrGαi1 in the presence of unlabeled palmCoA to monitor a single transfer
event. After incubation at 25°C for the indicated times, reactions were stopped and analyzed as in A by film
(C) or scintillation counting (D). D, Incubation of [3H]palm-DHHC3 () with myrGαi1 () or alone ()
as in C were processed for scintillation counting. Data were fit to single phase exponential using nonlinear
regression. E, Similar to D, [3H]palm-DHHC2 () was incubated with myrLckNT () or alone ().
Exposures were at -70°C. Data are representative of one of three independent experiments.
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Figure 3.3. Acyl-CoA chain-length specificity of DHHC enzyme autoacylation parallels substrate
specificity. A, Non-radiolabeled acyl-CoAs of the indicated chain length and saturation (10 µM),
coenzyme A (CoA), or buffer were added to reactions containing [3H]palmCoA (1 µM), DHHC3 (20 nM)
and myrGαi1 (1 µM). Reactions were incubated at 25°C for 6 min and processed for quantitation by
scintillation spectroscopy. [3H]-palmitate incorporation in the presence of each competitor was normalized
to the average of two reactions lacking competitor. For DHHC3 without competitor, the average 100%
values were 112, 114, and 65 fmol whereas for myrGαi1 they were 646, 630, and 585 fmol. Mean and
standard error of the mean are shown for three independent experiments. B, Similar to A, except with
DHHC2 (20 nM) and myrLckNT (0.5 µM). For DHHC2 without competitor, the average 100% values were
56, 46, and 30 fmol, whereas for myrLckNT they were 1035, 914, and 886 fmol.
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Figure 3.4. DHHC2 displays broader lipid substrate specificity than DHHC3. DHHC2, DHHC3 (10
nM), or enzyme buffer were incubated with myrGCG (5 µM) and acyl-CoAs (10 µM) of the indicated
chain length for 10 min at 25°C. Reactions were stopped, extracted, and processed on an HPLC C4
column. For each reaction, the fluorescence chromatogram of myrGCG elution is shown between 9.5 and
15 min.
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Figure 3.5. Hydrolysis, enzyme autoacylation, and direct transfer of DHHC2 and DHHC3 with C18
stearate and C16 palmitate. A and B, Enzyme autoacylation for DHHC3 (A) or DHHC2 (B) was determined by adding sample buffer to aliquots of the reactions described in Table 3.1 representing 1 pmol of
DHHC and resolving it by SDS-PAGE. The DHHC band was excised and processed for scintillation counting. Analyzing a reaction lacking any DHHC was set as the zero time point allowing the data to be fit to a
one phase exponential by nonlinear regression. Symbols are:  DHHC3 with C16-CoA,  DHHC3 with
C18-CoA,  DHHC2 with C16-CoA, and  DHHC2 with C18-CoA. C and D, Single turnover assays
with [3H]stearoyl-DHHC. C, Incubation of [3H]stearoyl-DHHC3 () with myrGαi1 () or [3H]stearoylDHHC3 alone () for the indicated times and processed for scintillation counting. D, Similar to C,
incubating [3H]stearoyl-DHHC2 () with myrLckNT () or [3H]stearoyl-DHHC2 alone () for the
indicated times. Data were fit to a single exponential.
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Chapter 4

2-Bromopalmitate and 2-(2-Hydroxy-5-nitro-benzylidene)benzo[b]thiophen-3-one Inhibit DHHC-Mediated
Palmitoylation In Vitro

This chapter was published in Jennings, B. C., Nadolski, M. J., Ling, Y., Baker, M. B.,
Harrison, M. L., Deschenes, R. J., and Linder, M. E. 2009. Journal of Lipid Research.
50:233-242. Marissa Nadolski and Yiping Ling provided purified yeast proteins.
Meredith Baker and Marietta Harrison provided plasmids to express wildtype and mutant
LckNT. I generated and purified the other constructs and conducted all of the
experiments.
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Abstract
Pharmacologic approaches to studying palmitoylation are limited by the lack of
specific inhibitors. Recently, screens have revealed five chemical classes of small
molecules that inhibit cellular processes associated with palmitoylation (Ducker et al.
(2006) Mol Cancer Ther 5:1647-1659). Compounds that selectively inhibited
palmitoylation of N-myristoylated vs. farnesylated peptides were identified in assays of
palmitoyltransferase activity using cell membranes. Palmitoylation is catalyzed by a
family of enzymes that share a conserved DHHC cysteine-rich domain. In this study, we
evaluated the ability of these inhibitors to reduce DHHC-mediated palmitoylation using
purified enzymes and protein substrates. Human DHHC2 and yeast Pfa3 were assayed
with their respective N-myristoylated substrates, Lck and Vac8. Human DHHC9/GCP16
and yeast Erf2/Erf4 were tested using farnesylated Ras proteins. Surprisingly, all four
enzymes showed a similar profile of inhibition. Only one of the novel compounds, 2-(2hydroxy-5-nitro-benzylidene)-benzo[b]thiophen-3-one (Compound V), and 2bromopalmitate (2BP) inhibited the palmitoyltransferase activity of all DHHC proteins
tested. Hence, the reported potency and selectivity of these compounds were not
recapitulated with purified enzymes and their cognate lipidated substrates. Further
characterization revealed both compounds blocked DHHC enzyme autoacylation and
displayed slow, time-dependent inhibition but differed with respect to reversibility.
Inhibition of palmitoyltransferase activity by Compound V was reversible, whereas 2BP
inhibition was irreversible.
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Introduction
Protein palmitoylation is the post-translational attachment of palmitate or other
long-chain fatty acids to cysteine residues in proteins via a thioester linkage (reviewed in
(6, 191). The functional consequences of protein palmitoylation are diverse and include
effects on protein localization, trafficking, and stability. In contrast to other lipid
modifications, palmitoylation is reversible. Consequently several cellular processes use
palmitoylation-depalmitoylation cycles to affect the localization and function of key
proteins.
Protein acyltransferases (PATs) catalyze the addition of palmitate (83). Genetic
and biochemical studies in yeast uncovered a family of integral membrane enzymes that
mediate palmitate addition to proteins that are modified on the cytoplasmic face of cell
membranes. The hallmark of this family of proteins is the DHHC (Asp-His-His-Cys)
cysteine-rich domain. A family of seven DHHC proteins is present in S. cerevisiae and
homology searches have identified at least 23 genes that encode DHHC proteins in
mammals. PAT activity is dependent upon the DHHC domain and mutation of the
cysteine of the DHHC motif abolishes catalytic activity of the enzyme.
Palmitoylated proteins are prominent in cell signaling pathways and are
particularly abundant in the nervous system (192). Signal transducers, receptors, ion
channels, and scaffolds are among the targets of palmitoyltransferases. Finding the
enzymes responsible for palmitoylation has accelerated our understanding of the role of
palmitoylation in both native and disease states. An example is HIP14 (DHHC17), a
DHHC protein initially identified as huntingtin-interacting protein 14 (193). HIP14 has
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been linked to palmitoylation of huntingtin, SNAP-25, cysteine string protein, and other
neuronal substrates (121). Palmitoylation of htt by HIP14 influences htt localization and
protects it from aggregation (111). In flies, HIP14 is essential for presynaptic function
and plays a role in neurotransmitter release, likely through palmitoylation of SNAP-25
and cysteine string protein (194, 195).
Oncogenic Ras proteins are associated with numerous human tumors.
Palmitoylation of H- and N-Ras plays a key role in trafficking between the plasma
membrane and Golgi apparatus (83), as well as facilitating the oncogenic potential of
activating Ras mutations (196). Several DHHC proteins have been linked to cancer.
Human HIP14 is oncogenic, promoting colony formation in soft agar and tumor
formation in nude mice (122). HIP14 mRNA is upregulated in numerous tumors (152).
DHHC9, a PAT for H- and N-Ras in vitro, is upregulated in microsatellite stable tumors
(140), whereas DHHC2 is a putative tumor suppressor (92).
The importance of palmitoylation in physiology and pathophysiology suggest that
palmitoylation inhibitors could be beneficial for the treatment of diseases, as well as tools
for probing the role of palmitoylation in cellular processes. Inhibitors of palmitoylation
have been limited to 2-bromopalmitate (2BP), cerulenin, and tunicamycin. The most
commonly used, 2BP inhibits palmitoylation in cells (197) and PAT activity of DHHC
proteins in vitro (123). However, 2BP also inhibits fatty acid CoA ligase (198) and other
enzymes involved in lipid metabolism (199). Similarly, cerulenin and tunicamycin
inhibit palmitoylation within cells but also inhibit other cellular process including fatty
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acid synthesis (200) and N-glycosylation (165, 167), respectively. Consequently, there is
a need to identify specific inhibitors of palmitoylation.
Smith and coworkers have developed high throughput screens for palmitoylation
inhibitors (152). The screens yielded compounds that fell into five chemical classes and
a representative compound from each class was further characterized. Cell membranes
from MCF-7 cells were used as a source of PAT activity to evaluate the representative
compounds’ ability to inhibit palmitoylation in vitro. Fluorescently labeled peptides
mimicking either N-myristoylated, palmitoylated proteins, such as Gα subunits and Srcrelated tyrosine kinases, or mimicking C-terminally farnesylated, palmitoylated proteins,
like N- and H-Ras, were used as substrates. Four of the representative compounds
showed a preference for inhibiting palmitoylation of the Ras-like peptide (average of
76% inhibition) but not the myristoylated peptide (15% inhibited). Conversely, the fifth
compound displayed the reverse, inhibiting palmitoylation of the myristoylated peptide
(74%) but not the Ras-like peptide (17%). Thus, it appears these compounds not only
inhibit palmitoylation but also display substrate specificity. Additionally, IC50 values
were reported in low to sub-micromolar range (11.8 to 0.5 µM) (152).
We sought to further investigate the properties of these compounds. Because cell
membranes were used as a source of PAT activity, it is unclear whether the inhibitors
reduced palmitoylation by directly blocking DHHC proteins. Here we tested if these
compounds inhibit DHHC-mediated palmitoylation of protein substrates. Additionally,
by using DHHC proteins that display different substrate preferences, the ability of these
inhibitor compounds to specifically inhibit palmitoylation of farnesylated substrates vs.
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N-myristoylated substrates was examined. Compounds that inhibited DHHC-mediated
palmitoylation were further characterized.

Experimental Procedures:
Inhibitor Compounds and Reagents. Inhibitor compounds (Figure 4.1) were
purchased from ChemBridge Corporation (San Diego, CA). [3H]palmitoyl-CoA was
synthesized using [3H]palmitate (45 Ci/mmol, PerkinElmer Life Sciences), Coenzyme A
(Sigma), and acyl CoA synthase (Sigma) as described (26) with the following
modification. Following synthesis, [3H]palmitoyl-CoA was separated from palmitate by
chloroform/methanol extraction (28) and subsequently purified on a C8 reversed phase
cartridge (26).
Plasmids. Standard molecular biology techniques were used to manipulate DNA.
All plasmid constructs were verified by DNA sequence analysis. DHHC2 was expressed
using recombinant baculovirus. DHHC2 was prone to proteolysis and several constructs
were made with affinity tags at both ends to generate a virus that would yield intact
DHHC2 protein. Oligonucleotide sequences used to generate plasmids are available
upon request. Human DHHC2 was amplified from Image Clone 4398300 (GenBank ID
BF983682) and subcloned as a KpnI fragment into pBlueBacHis2B (Invitrogen;
Carlsbad, CA). This yielded pML850, encoding His6Express-DHHC2. pML850 was
digested with HindIII and SalI to permit ligation with a double stranded oligonucleotide
linker that encodes a HindIII site, the FLAG epitope, an EcoRI site, a His6 epitope, a stop
codon, and a SalI site. This yielded pML892, encoding His6Express-DHHC2-FLAG-
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His6. pML892 was cut with BglII and AgeI, purified, and ligated with double stranded
oligonucleotides encoding the calmodulin binding peptide (CBP) followed by an XbaI
site to generate His6Express-CBP-DHHC2-FLAG-His6 (pML943). Catalytically inactive
DHHS2 (pML1023) was generated by site directed mutagenesis (Stratagene) of pML943.
Plasmids expressing the N-terminal 226 amino acids of Lck (LckNT) and
LckNT(C3,5S) were constructed as follows. The murine Lck cDNA encoding residues 1226 was amplified as a NdeI-XhoI fragment and subcloned into the bacterial expression
vector pET23a(+) yielding pML1008. This construct was used as template to generate
the C3,5S mutant (pML1175) using a mutagenic primer to amplify the 5’ end of the
coding sequence.
Yeast N-myristoyltransferase (yNMT) was expressed using pBB131 (201). The
plasmid pML1067 was constructed to express human NMT1 by excising the yeast NMT1
gene from pBB131 with BglII and EcoR1 and replacing it with human NMT1 flanked by
pBB131 vector sequences. Human NMT1 was amplified from pBB218 and overlap
extension PCR was used to generate flanking pBB131 vector sequences (202).
Recombinant baculovirus and insect cell culture. Sf9 insect cells were purchased
from ATCC and grown in suspension culture medium (IPL-41 (Gibco) supplemented
with 10% heat inactivated bovine growth serum, yeastolate, Pluronic F68, 50 mg/mL
gentamycin, and 250 ng/mL fungizone) at 27°C with rotation at 110 rpm. Recombinant
baculoviruses were generated using Invitrogen’s Bac-n-Blue™ transfection kit with
pML943 and pML1023 and plaque-purified.
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Purification of DHHC proteins. For DHHC2, Sf9 insect cells were inoculated
with baculovirus expressing human DHHC2 N-terminally tagged with His6-Express-CBP
and C-terminally tagged with FLAG-His6. Infected cells were collected by centrifugation
and washed with cold PBS 61 hr post infection. Cell pellets were stored at -80°C until
purification. All purification steps were performed at 4°C and all buffers contained the
protease inhibitors 1 mM PMSF, 1-5 µg/mL pepstatin A, 1.4 µg/mL aprotinin, 1.6 µg/mL
leupeptin, and 1.6 µg/mL lima bean trypsin inhibitor. A cell pellet of ~5 mL (from 335
mL Sf9 culture) was quickly thawed at 37°C and suspended in 35 mL cavitation buffer
(50 mM Tris pH 7.4, 150 mM NaCl, 10 mM β-ME, 1 mM EDTA). Cells were lysed by
nitrogen cavitation (30 min at 700 psi). The lysate was centrifuged at 700g for 10 min to
remove nuclei and unbroken cells. The postnuclear supernatant was centrifuged at
100,000g for 30 min to generate P100 and S100 fractions. P100 membranes were
suspended in 9 mL extract buffer (50 mM Tris pH 7.4, 200 mM NaCl, 10 mM β-ME, and
10% glycerol) by sequential passage through 14, 18, and 25 gauge needles. Total protein
concentration was determined using Bio-Rad’s Bradford protein assay (Hercules, CA).
Membranes were diluted with extract buffer and 10% n-dodecyl-β-D-maltoside detergent
(DDM; Dojindo Laboratories, Japan) to give a final protein concentration of 2 mg/mL in
1% DDM. The extract was again passed through a 25G needle and incubated 80 min
with end-over-end rotation. The extract was cleared at 100,000g for 30 min, diluted 1:1
with extract buffer (no DDM), and gravity-flowed twice through a column of 3.4 mL
Ni2+-nitrilotriacetic acid-agarose resin (Ni-NTA; Qiagen) equilibrated in wash buffer (50
mM Tris pH 7.4, 100 mM NaCl, 3 mM β-ME, 10% glycerol, 0.1% DDM, and 20 mM
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imidazole). The resin was washed with 60 mL wash buffer and eluted with wash buffer
containing 200 mM imidazole (2 3 mL) and wash buffer containing 500 mM imidazole
(3 3 mL). Ni elutions 1-4 were pooled, diluted 1:1 with buffer A (50 mM Tris pH 7.4,
100 mM NaCl, 10% glycerol, 0.1% DDM, 1 mM EDTA, and 0.2 mM β-ME), and passed
thrice through a column of 300 µL ANTI-FLAG® M2-agarose affinity gel (Sigma)
equilibrated in buffer A. The resin was washed with 14 mL buffer A and eluted with 5 
250 µL buffer A containing 0.23 mg/mL FLAG peptide (Sigma) with a 10 min
incubation for each elution. The concentration of enzyme was determined by
extrapolation from a linear curve with known concentrations of bovine serum albumin
using Sypro Ruby protein gel stain (Molecular Probes) and quantitation with a StormTM
860 (Amersham Biosciences).
DHHS2 purification paralleled that of DHHC2 through nickel affinity
chromatography. The identity of purified DHHC2 or DHHS2 was confirmed by
immunoblots using antibodies at the following dilutions: anti-FLAG 1:3000 (Stratagene),
anti-Express 1:1500 (Invitrogen), and goat anti-mouse IgG secondary conjugated to HRP
at 1:2000 (MP Biomedicals, OH).
For human DHHC9/GCP16, Sf9 cells were co-infected with baculoviruses
expressing DHHC9-myc-His6 and FLAG-GCP16 (114) and cultured for 73 h before
harvesting. DHHC9/GCP16 was purified similarly to DHHC2.
The purification of Erf2/Erf4p was performed as previously described (203).
For partially purified yeast Pfa3, YPH499 was transformed with a Pfa3-His6-Flag
pESC expression construct. Yeast were cultured and cell membranes prepared as
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described (91). Pfa3-His6-Flag was extracted from cell membranes in 1% Triton X-100
at 5 mg/mL total protein in extraction buffer (50 mM Tris pH 8.0, 100 mM NaCl, 10%
glycerol, 5 mM β-ME, and 0.1 mM PMSF) rotating for 1 hr at 4˚C. Insoluble material
was pelleted at 200,000g for 20 min. The detergent extract (7.5 mg total protein) was
diluted 1:1 in extraction buffer and allowed to bind to 2 mL Ni-NTA resin for 1 hr at 4°C.
The resin was reconstituted in a column and washed with 20 mL wash buffer (50 mM
Tris pH 8.0, 100 mM NaCl, 10% glycerol, 5 mM β-ME, 0.1% Triton X-100, 0.1 mg/mL
bovine liver lipids (Avanti Polar Lipids), and 0.1 mM PMSF). Bound proteins were
eluted with elution buffer (50 mM Tris pH 8.0, 100 mM NaCl, 10% glycerol, 200 mM
imidazole, 1 mM β-ME, 0.1 % Triton X-100, and 0.1 mg/ml bovine liver lipids) and four
2 mL fractions were collected. Fractions one and two were pooled, aliquoted, and stored
at -80°C.
Purification of PAT substrates. Mouse N-myristoylated LckNT (myrLckNT) was
purified from ER2566 E.coli (New England Biolabs) harboring pBB131 (201) and
pML1008. Cells were grown in Luria-Bertani broth containing 50 µg/mL kanamycin and
50 µg/mL ampicillin at 37°C with shaking at 250 rpm for 4 hr. IPTG was added to 0.6
mM final concentration and the temperature was reduced to 30°C for 5 hr. Cells were
harvested by centrifugation at 3080g for 20 min at 4°C. Cell pellets were washed with
cold PBS, collected by centrifugation at 3800g for 17 min at 4°C, flash frozen in liquid
N2, and stored at -80°C until needed. Purification steps were performed on ice or in a
4°C cold room. Cell pellets representing 400 mL culture were quickly thawed at 30°C,
suspended in 11 mL lysis buffer (50 mM Tris pH 7.4, 8 mM β-ME, 150 mM NaCl, 1
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µg/mL pepstatin A, 1.6 µg/mL leupeptin, 1.6 µg/mL lima bean trypsin inhibitor, and 1.4
µg/mL aprotinin), and passed thrice through a French Press cell. The soluble fraction
was collected by centrifugation at 76,500g for 30 min. To enrich for myristoylatedLckNT, this soluble fraction was extracted twice with 1.3 mL 10% Triton X-114 detergent
(Sigma) essentially as described (204) except incubations were for 5 min at 37°C. The
detergent phases were pooled, diluted to 0.2% Triton X-114 (135 mL total), and gravity
loaded onto a 3 mL Ni-NTA column equilibrated in wash buffer (50 mM Tris pH 8.0,
300 mM NaCl, 10 mM imidazole, and 8 mM β-ME). The column was washed with 150
mL wash buffer and eluted 5  3 mL with elution buffer (50 mM Tris pH 7.4, 100 mM
NaCl, 300 mM imidazole, 8 mM β-ME, and 10% glycerol). Elution 2 was used for
subsequent PAT assays. The concentration of myrLckNT was determined by
extrapolation from a linear curve with known concentrations of bovine serum albumin
using Coomassie Blue gel stain and quantitation with ImageJ software (NIH). C3,5S
myrLckNT was expressed in BL21(DE3) E.coli transformed with pML1067 and
pML1175 and purified as described for WT. The identity of purified protein was
confirmed by immunoblotting with mouse monoclonal anti-Lck (3A5, sc-433) purchased
from Santa Cruz Biotechnology (Santa Cruz, CA).
Yeast N-myristoylated Vac8 was purified by ion-exchange and hydroxylapatite
chromatography as described (203). Prenylated Ras proteins were expressed in yeast
from the galactose-inducible vector pEG(KG) and purified as described (81, 203). The
GST-Ras2(HV) construct consists of the C-terminal 35 amino acid residues of yeast Ras2
fused to GFP. Full-length mammalian H-Ras was fused to GST.
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In vitro PAT assays. Inhibitors were dissolved and serially diluted to 100X stocks
in 100% DMSO. Stocks were diluted to 5X with TED (20 mM Tris pH 7.4, 1 mM
EDTA, and 1 mM DTT). Equal volumes (5 µL) of DHHC enzyme and 5X inhibitor
solutions were pre-incubated for various times and temperatures as indicated in figure
legends. Protein substrates diluted in TED (5 µL) were pre-mixed with reaction hot mix
(RHM; 10 µL; 250 mM MES pH 6.4, 1 mM DTT, 1.2-3.4 µM [3H]palmCoA) and
incubated at the same temperature as enzyme/inhibitor mix. This substrate mixture (15
µL) was added to the enzyme/inhibitor mix to start the reaction and incubated as indicted
for each figure. The reactions (25 µL) were stopped by addition of 5X gel loading buffer
with final 2 mM DTT (6.25 µL). Except for assays of reversibility, all inhibitor
concentrations shown are for the final 25 µL reaction. Stopped reactions were heated for
60 sec at 95°C before resolution by SDS-PAGE. Gels were stained with Coomassie
Blue, destained, and scanned. Protein substrate bands were excised from the gel, placed
into scintillation vials, solubilized in 500 µL Soluene 350 (PerkinElmer) at 50°C for at
least 3 hr, and quantitated by liquid scintillation spectroscopy.
Enzyme autoacylation assays without inhibitors (Figure 4.2, right panel) were
performed similar to inhibitor profile assays described above. Briefly, 500 fmol of
enzyme was incubated in 0.82 µM [3H]palmCoA for 10 min at 25°C in RHM. Reactions
were stopped with gel loading buffer and resolved by SDS-PAGE. Gels were stained,
destained, soaked in 1 M sodium salicylate/15% methanol for 20 min, dried onto filter
paper, and exposed to film at -80°C for 8 days. Enzyme autoacylation assays with
inhibitors (Figure 4.5) were performed similar to inhibitor profile assay except without
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protein substrate. Briefly, 250 fmol of DHHC2 was pre-incubated with inhibitor for 8
min at 25°C. Pre-warmed RHM was added to give a final concentration of 1.1 µM
[3H]palmCoA in 25 µL and the reaction proceeded for 2 min before stopping with 5X gel
loading buffer. Reactions were processed similar to those in Figure 4.2.
The assay for reversibility was similar to those above, except the initial reaction
volume was 200 µL and 25 µL aliquots were removed at the indicated times. DHHC2
was pre-incubated for 30 min at 25°C with inhibitor at the first concentration indicated.
Equilibrated substrates in RHM with either DMSO or inhibitor were used to dilute the
enzyme/inhibitor 40-fold to the second concentration indicated and to start the reaction,
which was maintained at 25°C. At the indicated times, aliquots (25 µL) were removed
from the reaction, stopped with gel loading buffer, and processed as above. In
experiments to measure time-dependent inhibition, DHHC2 (100 fmol) was preincubated 30 min at 25°C with inhibitor or a DMSO control. Reactions were started by
addition of either both substrates in RHM to enzyme/inhibitor mix (pre-incubation) or
both substrates and inhibitor to enzyme/DMSO mix (no pre-incubation). Reactions (25
µL, 2% DMSO final) were incubated 7 min at 25°C before stopping and processing as
above. Data were graphed and analyzed using Microsoft Excel and GraphPad Prism 5.0.

Results
Purification of active DHHC2. The predicted targets of the palmitoylation
inhibitors identified by Ducker et al. are the DHHC proteins. Furthermore, the pattern of
specificity shown by the inhibitors in assays using cell membranes as a source of
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palmitoyltransferase activity suggests that some of the inhibitors would more potently
inhibit DHHC proteins that modify farnesylated substrates, whereas others would be
more effective inhibitors of PATs for N-myristoylated substrates. To test these
predictions, we purified mammalian and yeast DHHC PATs that display the appropriate
substrate specificity. Yeast Erf2/Erf4 is a PAT for yeast Ras (81), but displays little
activity toward Vac8, an N-myristoylated protein (203). Conversely, yeast Pfa3
palmitoylates Vac8 (91) but not Ras2 (203). Mammalian DHHC9/GCP16 palmitoylates
H-Ras in vitro, but has little or no activity for N-myristoylated Gia1 (114).
We sought to identify a mammalian DHHC protein that has robust activity for an
N-myristoylated substrate. Preliminary experiments revealed that the nonreceptor
tyrosine kinase Lck, a protein palmitoylated at cysteine residues near the myristoylated
N-terminus, was a good substrate for DHHC2 (data not shown). To further characterize
this interaction, we expressed human DHHC2 with epitope tags at both the N- and Ctermini to aid in the purification of full-length enzyme. Detergent extracts from
membranes were passed sequentially over nickel and FLAG affinity resins to generate
purified enzyme (Figure 4.2, left). Immunoblotting revealed full-length protein was
isolated (Figure 4.2, center).
In all DHHC proteins characterized to date, PAT activity has been coupled with
incorporation of palmitate into the DHHC protein itself, a process termed enzyme
autoacylation (83). Although it is uncertain whether this process represents an acylenzyme transfer intermediate, autoacylation serves as a read out for functional enzyme.
Purified DHHC2 incorporated [3H]palmitate derived from [3H]palmitoyl CoA. This
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reaction was specific as neither heat-treated DHHC2 nor DHHS2, a mutant predicted by
homology to be catalytically inactive (83), showed radiolabeling (Figure 4.2, right).
Thus, we have purified DHHC2 and shown it to be functionally active as monitored by
autoacylation.
DHHC2 palmitoylates myrLckNT at cysteines 3 and 5. To test Lck as a substrate
for DHHC2, we used a model substrate consisting of the N-terminal myristoylation,
palmitoylation motif (SH4 domain) and the SH3 and SH2 domains (LckNT). This
fragment is more easily purified than the full-length protein that includes the kinase
domain. To confirm that in vitro palmitoylation of LckNT was occurring at cysteine
residues palmitoylated in vivo, we also expressed and purified C3,5S myrLckNT. Lck is
palmitoylated in vivo at Cys3 and Cys5, which may differentially regulate Lck
localization (205). Lck has two additional cysteines near the amino terminus (Cys20 and
Cys23) that are required for binding coreceptors CD4 and CD8 (206). Because
myristoylation facilitates subsequent palmitoylation both in vivo and in vitro (26, 207),
we purified wild type and mutant LckNT from E. coli coexpressing human Nmyristoyltransferase (NMT) to produce N-myristoylated substrates. Metabolic labeling
with [3H]myristic acid indicated that both proteins were myristoylated in this system and
that mutation of the palmitoylation sites did not affect myristoylation (see Supplemental
Figure 4.S1).
Wildtype and C3,5S myrLckNT were purified and assayed for their ability to be
acylated by DHHC2 in an in vitro PAT assay. Incubation of either form of myrLckNT
with [3H]palmCoA and enzyme buffer did not result in incorporation of radiolabel in

84

myrLckNT as monitored by scintillation counting or fluorography (Figure 4.3, first 3
lanes). When 200 fmol of DHHC2 was included in the reaction, greater than 1500 fmol
of [3H]palmitate was incorporated into wild type myrLckNT, indicating that transfer is
catalytic. Less than 100 fmol of [3H]palmitate was incorporated into C3,5S myrLckNT by
DHHC2. When autoacylation-defective DHHS2 was assayed, no radiolabel was
incorporated into myrLckNT (Figure 4.3, last 3 lanes). The low levels of radiolabel in
C3,5S myrLckNT may indicate that DHHC2 weakly palmitoylates myrLckNT at other
cysteine residues nonspecifically.
Evaluation of potential PAT inhibitors using enzyme-substrate pairs. Using the
three established enzyme-substrate pairs described above along with DHHC2 and
myrLckNT, we sought to determine if the PAT inhibitors identified by Ducker et al.
blocked DHHC-mediated palmitoylation and displayed the predicted substrate
specificity. We obtained and tested four of the five compounds along with 2bromopalmitate (2BP; Figure 4.1). Compound IV (CIV; 2-(2-fluoro-benzyl)-1-phenyl1,2,3,4-tetrahydro-pyrrolo[1,2,-a]pyrazine) was not available from commercial sources
and was not tested here. For inhibitor PAT assays, the inhibitor was pre-incubated with
DHHC protein, followed by the addition of both protein substrate and [3H]palmCoA that
had been pre-mixed and equilibrated at the assay temperature. To remain in the linear
range for each reaction, concentrations, temperature, and lengths of incubations varied for
each pair and are listed in the legend to Figure 4.4.
Overall, less potent and specific inhibition was observed than expected (Figure
4.4). For all pairs tested, 2BP was the best inhibitor displaying an average IC50 of ~10
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µM. This result confirmed that 2BP inhibits DHHC-mediated palmitoylation in vitro as
shown previously for DHHC15 (123). Compound V (CV) was initially described as a
selective inhibitor of N-myristoylated, palmitoylated protein but not farnesylated,
palmitoylated proteins, with an IC50 of 0.5 µM for an N-myristoylated peptide (152). As
shown here, CV inhibited all DHHCs tested but was less potent than 2BP, displaying a
higher IC50 for three of the four enzyme-substrate pair. The remaining compounds (CI,
CII, and CIII) were previously demonstrated to inhibit PAT activity toward a farnesylated
peptide mimicking Ras, with IC50 values of 4 to 12 µM. When tested against the DHHC
Ras PATs, DHHC9/GCP16 and Erf2/Erf4, little or no inhibition was observed for any of
the enzymes, even at the highest concentration tested (100 µM, Figure 4.4). Thus with
the DHHC enzyme-substrate pairs tested, the predicted selectivity of these compounds
was not observed.
2-Bromopalmitate and Compound V inhibit enzyme autoacylation. 2BP and CV
reduced DHHC-mediated palmitoylation. Accordingly, we characterized these
compounds further. Because 2BP and CV affected all four enzyme-substrates pairs
equally, DHHC2 and myrLckNT were chosen as a representative pair for further
experiments. To date all DHHC proteins that display PAT activity also autoacylate.
Thus, we determined the effect of 2BP and CV on enzyme autoacylation. As seen in
Figure 4.5, both compounds inhibited enzyme autoacylation, with 2BP being more potent
at blocking enzyme radiolabeling than CV.
Evaluation of reversibility and time-dependent inhibition. We next wanted to
assess whether the inhibition of PAT activity by 2BP and CV was reversible or
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irreversible. DHHC2 was pre-incubated with either 2BP or CV at the first, pre-dilution
concentration indicated in Figure 4.6A. This preformed enzyme-inhibitor complex was
diluted 40-fold with buffer containing both protein and lipid substrates to give the second
inhibitor concentration indicated. The lack of recovery of PAT activity following
dilution of 2BP compared to the inhibited controls maintained at persistent concentrations
of inhibitor indicates that 2BP is an irreversible inhibitor (Figure 4.6A, left side; square
symbols relative to filled symbols). In contrast, when CV was similarly diluted,
approximately 70 percent of PAT activity was recovered compared to the inhibited
control maintained at the diluted concentration of CV (Figure 4.6A, right side). This
indicates that the inhibitory effect of CV is reversible.
Finally, because inhibitor profiles for each enzyme-substrate pairs were done
following pre-incubation with inhibitor, we wanted to assess whether 2BP and CV
displayed time-dependent inhibition (also called slow-binding inhibition; Figure 4.6B).
During one set of conditions (without inhibitor pre-incubation) substrates and 2BP or CV
were premixed and the assay started by addition of DHHC2 pre-incubated with a DMSO
control. Alternatively, under a second set of conditions (with inhibitor pre-incubation),
DHHC2 and 2BP or CV were pre-incubated 30 minutes before addition of both substrates
to initiate the reaction. For both compounds, an increase in inhibitor potency following
pre-incubation was observed with the curves shifting to the left (Figure 4.6B). This
suggests that both CV and 2BP are time-dependent inhibitors of DHHC2 PAT activity.
Higher concentrations of CV were not tested because of limitations in the solubility of the
compound.
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Discussion
As advances are made in the palmitoylation field it is becoming increasingly clear
that DHHC proteins play an important role in both native and disease states. DHHC
proteins have been identified that are responsible for palmitoylating proteins involved in
cell growth (114, 122), maintaining vascular homeostasis (179), neurotransmitter receptor
trafficking (123), and cell-cell adhesion (208). DHHC proteins have also been linked to
several diseases including cancer (122, 140, 152), Huntington’s disease (111), and mental
retardation (139). Identification of potent and specific palmitoylation inhibitors that
target DHHC proteins could lead to novel therapies, as well as provide tools to
investigate palmitoylation’s roles in cellular processes.
With that in mind, we sought to determine whether DHHC proteins were targets
of the palmitoylation inhibitor compounds described by Ducker et al. (152). We found
that one of the four compounds, CV, behaved similarly to 2BP, in that it inhibited all four
of the DHHC proteins tested. Both 2BP and CV inhibited autoacylation of the enzyme,
which is tightly correlated with the ability to transfer palmitate to substrate. It is
unknown whether autoacylation represents an acyltransfer intermediate. However, the
loss of autoacylation with inhibitors that also block transfer to substrate is consistent with
such a mechanism. Furthermore, the ability of CV to inhibit autoacylation, a property
common to all DHHC proteins, suggests that it will not be selective for different DHHC
proteins.
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Inhibition of DHHC2 PAT activity by 2BP was irreversible. This was not
unexpected as 2BP has been shown to irreversibly inhibit fatty acid metabolism (209,
210), as have other halogenated fatty acid analogs (211). Additionally, others have
previously hypothesized that 2BP forms an irreversible bond with PATs (212). In
contrast the inhibition by CV was mostly reversible. This is perhaps not unexpected in
that CV does not contain any highly reactive centers (Figure 4.1). Both 2BP and CV
displayed time-dependent inhibition, albeit to different degrees. Time-dependent
inhibition is considered an advantage in a pharmacological setting because the enzyme is
inhibited for longer periods of time (213). This, plus the fact that 2BP inhibits other
enzyme families (198, 199), suggest that CV may be a good candidate for future
structure-activity relationship studies with substituent side-chain replacement focused on
enhancing potency and specificity.
We were unable to detect significant inhibition of DHHC proteins by three of the
compounds tested, nor did CV display selective inhibition of DHHC PAT activity for Nmyristoylated substrates. Several possible explanations could account for the differences
between the original report describing these compounds and those documented here.
Ducker et al. (152) used MCF-7 cell membranes as a source of PAT activity. DHHC
proteins have not been studied in these cells, but given the large family size, it is likely
that multiple DHHC proteins are expressed. Reverse transcriptase-PCR has detected
mRNA for both DHHC2 and DHHC9 in MCF-7 cells (unpublished observations).
However, it is possible that DHHC proteins other than DHHC2 and DHHC9/GCP16 are
possibly more sensitive to these compounds. Phylogenetic analysis of DHHC sequences
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from humans and yeast place DHHC9 and Erf2 within a larger subfamily (DHHC5, 8, 9,
14, 18, 19, and Erf2). Similarly, DHHC2 and Pfa3 cluster with a different group of
DHHC proteins (DHHC2, 3, 7, 15, 20, and Pfa3) (123). DHHC proteins less closely
related to these two groups were not tested.
An important difference between the two studies is the substrates that were tested.
Ducker et al. assayed short fluorescent, lipidated peptides (myristoyl-Gly-Cys and CysLeu-Cys-farnesyl,O-methyl). We assayed full-length (myristoyl-Vac8 and farnesyl-HRas) or larger protein fragments (HVRas2, the farnesylated hypervariable domain of Ras,
and myristoyl-LckNT). It remains to be determined whether Lck and H-Ras are in vivo
substrates, as well as in vitro substrates of DHHC2 and DHHC9/GCP16. However, the
yeast enzymes and their substrates have been validated both genetically and
biochemically (81, 91, 214), and display strong preferences for their respective substrates
relative to the other lipidated substrates (203). Accordingly, these yeast enzymes and
their substrates represented an excellent system to test the inhibitors for substrate
specificity.
Inhibition of PAT activity in MCF-7 membranes by the compounds may be
dependent on a membrane environment. DHHC proteins are integral membrane proteins
and the surrounding lipid environment can affect both rate and specificity of such
enzymes (160). The hydrophobic compounds tested here may act indirectly, disrupting
the membrane surrounding DHHC proteins rather than directly interacting with them.
Alternatively, DHHC proteins within a lipid bilayer may adapt a conformation that makes
them more susceptible to these compounds. Because the DHHC proteins tested here
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were purified and assayed in detergent micelles, effects of the compounds on DHHC
proteins that require a lipid membrane would have been missed. Initial attempts at
reconstituting DHHC proteins into liposome were unsuccessful and more work is needed
in this area.
Finally, it is possible that proteins other than DHHC proteins are targets of these
compounds. A study of the palmitoylproteome in yeast suggests that DHHC PATs
account for most cellular palmitoylation events (16). In mammals, secreted proteins such
as the morphogens Hedgehog and Wnt, as well as the peptide hormone ghrelin, are
posttranslationally modified with fatty acids through the action of membrane-bound Oacyltransferases (MBOAT) (6, 215). Modification of these secreted proteins occurs in
the lumen of the secretory pathway. To date only one MBOAT protein has been
characterized biochemically (8). It is unknown if these activities could account for
palmitoylation of the peptides in the MCF-7 cell membranes.
The finding that CV is an inhibitor of DHHC PATs and the antitumor activity
reported for all of the compounds makes them interesting reagents for further study.
Future investigations into DHHC enzymology and mechanism will likely aid the search
for specific and potent PAT inhibitors.
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Figure 4.1. Structure and names of inhibitor compounds used in this study.
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Figure 4.2. Purification of human DHHC2 and catalytically inactive DHHS2. DHHC2 was expressed
in Sf9 cells and purified sequentially by nickel chelate and FLAG affinity chromatography. Catalytically
inactive DHHS2 was purified by nickel affinity chromatography; the fifth elution is shown. Purified
DHHC2 and DHHS2 were detected by Sypro staining (left) and immunoblotting with anti-Express
antibody (center). DHHC2, but not DHHS2, autoacylates (right). DHHC2, DHHS2, or heat inactivated
DHHC2 (500 fmol each) were incubated in 0.8 μM [3H]palmCoA at pH 6.4 for 10 min. The reactions were
stopped with SDS sample buffer and processed for fluorography. The film was exposed for 8 days.
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Figure 4.3. DHHC2 palmitoylates myrLckNT at cysteines 3 and 5. Purified DHHC2, DHHS2 (200
fmol), or enzyme buffer was mixed with purified myrLckNT (25 pmol) on ice. Reaction buffer was added
to give a final concentration of 0.8 μM [3H]palmCoA in 50 μL and incubated at 25°C for 7 min. The
reaction was stopped with SDS sample buffer and divided between two SDS-PAGE gels, which were
stained and destained. A, The region containing myrLckNT was excised from one gel, solubilized with
Soluene, and the amount of [3H]palmitate present determined by scintillation counting. B, The second gel
was processed for fluorography and exposed to film at -80°C for 90 hr. MyrLckNT was detected by immunoblotting reactions run without radioactive palmCoA.
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Figure 4.4. Inhibitor profiles for DHHC proteins. Inhibitor profiles for each enzyme-substrate pair were
carried out as described in the text. A, Partially purified yeast Pfa3 (5 μL) was pre-incubated with inhibitor
for 8 min at 30°C. MyrVac8 and [3H]palmCoA were mixed, warmed to 30°C, and added to the reaction at
final concentrations of 0.5 μM and 0.8 μM, respectively. The reaction proceeded for 10 min at 30°C before
stopping with SDS sample buffer. B, Purified human DHHC2 (100 fmol) was pre-incubated 8 min at 25°C
with inhibitors. MyrLckNT and [3H]palmCoA were added to give final concentrations of 0.5 μM and 0.8
μM, respectively, and the reaction proceeded for 7 min at 25°C before stopping. C, Purified yeast Erf2/Erf4
(100 fmol) was pre-incubated 8 min at 25°C with inhibitors. [3H]palmCoA and the farnesylated hypervariable region of Ras2 fused to GST were added to give final concentrations of 0.9 μM and 1.0 μM, respectively, and the reaction proceeded for 10 min at 25°C before stopping. D, Purified human DHHC9/GCP16
(150 fmol) was pre-incubated 5 min on ice with inhibitors. [3H]palmCoA and the farnesylated H-Ras fused
to GST were added to give final concentrations of 0.9 μM and 1.2 μM, respectively, and the reaction
proceeded for 7 min at 25°C before stopping. Values represent the means ± the standard error of the mean
determined from three independent experiments.
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Figure 4.5. Inhibitor effect on enzyme autoacylation. DHHC2 (250 fmol) was pre-incubated with
inhibitor and assayed as described in Experimental Procedures. The film was exposed for 8 days.
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Figure 4.6. Reversibility and time-dependent inhibition. Experiments were performed as described in
Experimental Procedures. A, Reversibility of 2BP and CV was tested by incubating DHHC2 (100 fmol)
with the first concentration indicated for 30 min at 25°C. This mix was diluted 40-fold with both substrates
to the post-dilution concentration indicated, incubated at 25°C, and aliquots removed at the indicated time
points. B, Time-dependent inhibition was evaluated by pre-incubating enzyme with inhibitors at the
indicated concentrations or DMSO for 30 min at 25°C. Both substrates without or with inhibitor were
added to start the reaction, which was incubated at 25°C for 7 min before stopping. Values represent the
means ± the standard error of the mean determined from three independent experiments.
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Supplemental Figure 4.S1. Recombinant WT and C3,5S LckNT are myristoylated. E. coli
BL21(DE3) were transformed with pML1008 (WT LckNT-His6), pML1175 (C3,5S LckNT-His6), or empty
pET21 vector with or without pML1067 (human NMT1). Cultures were grown at 37°C to OD600 = 0.7-0.8
and induced with 0.3 mM IPTG for 100 min at 30°C. A portion of the culture (1 mL) was incubated with
1.7 nmol [3H]myristic acid (50 μCi, PerkinElmer Life Sciences) for 4 hr at 30°C. Cells were collected by
centrifugation and washed in cold PBS. Whole cell lysates were made by addition of 200 μL 1.5X sample
buffer with 30 mM DTT and heating to 95°C for 4 min with vortexing. Samples were frozen overnight at
-20°C. The next day thawed samples were spun at 10,000g for 2 min and 3 μL of each were separated by
SDS-PAGE and processed for fluorography or immunoblotting with α-Lck (1:5000). The dried gel was
exposed to film at -80°C for 16 hr. The dark bands present in lanes 2 and 3 indicate that both WT and C3,5S
LckNT are being myristoylated in E. coli.
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Chapter 5

Implications and Future Directions

Findings of the thesis
In this thesis, I have described the development and utilization of protein Sacyltransferase (PAT) assays to examine the mechanism of DHHC proteins. When this
work began, the DHHC protein family had recently been identified as the group of
enzymes responsible for catalyzing protein S-acylation. Of the DHHC proteins that had
previously been isolated, all incorporated palmitate when incubated with radiolabeled
palmCoA. Although this was hypothesized to reflect an acyl-enzyme intermediate (81,
82), it was possible that DHHC acylation represented a non-transferable modification
consistent with other integral membrane proteins being stably acylated on cysteine
residues adjacent to transmembrane domains. Thus, the hypothesis that DHHC
autoacylation reflected a transfer intermediated needed to be tested. Assays initially used
for the characterization of PAT activity in tissues and cell lines were optimized for
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DHHC proteins. The detrimental effects of thiol-based reducing agents on DHHC
activity were reported and assay conditions altered.
Using these new assay conditions, the predicted catalytic mechanism of DHHC
proteins was determined. Single turnover assays provided evidence to support the
hypothesis that autoacylated DHHC proteins represent a transient acyl-enzyme transfer
intermediate. These results supporting a two-step ping-pong mechanism of transfer that
agree well with results by others published recently (175). During this investigation it
was discovered that DHHC proteins display different acyl-CoA specificities and the
mechanism of this specificity was investigated. For DHHC3 the reduced ability to
transfer longer chain fatty acids was not due to increased hydrolysis of the acylintermediate but rather reduced formation of acyl-enzyme and a significantly reduced rate
of transfer to protein substrate. These differences in DHHC acyl-CoA specificity provide
a mechanism to explain the differences in acyl-chain lengths observed on native Sacylated proteins isolated from cells and tissues.
Assays of PAT activity were also used to evaluate the specificity and potency of
potential protein S-acylation inhibitors with DHHC proteins. At the initiation of these
studies, previously described inhibitors of protein acylation were limited to 2bromopalmitate (2BP), cerulenin, and tunicamycin. While capable of reducing Sacylation within cells, these compounds were also known to inhibit other enzymes and
thus, lacked specificity. Nevertheless, tunicamycin and cerulenin were assayed for their
ability to block DHHC-mediated acylation and found to have no effect on PAT activity
(Table 2.2). This lack of specific S-acylation inhibitors motivated others to develop
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screens for finding new inhibitors. Ducker et al published five representative compounds
they found using cell-based screening methods and follow-up studies with assays of PAT
activity in crude cell membranes (152). I directly tested whether these compounds and
2BP were capable of inhibiting DHHC-mediated protein acylation. My studies revealed
that two compounds, 2BP and Compound V, were capable of inhibiting DHHC-mediated
protein acylation, and their mechanism of inhibition was characterized. Given the
importance of DHHC proteins in human diseases, my results stress the importance of
testing lead compounds directly on intended targets and outline a methodology to do so.

Future Directions
The following model is proposed for the catalytic mechanism of DHHC proteins
based on my investigation and the published work of others. A DHHC protein initially
binds a long-chain acyl-CoA and, in a reaction that is dependent on the cysteine residue
of the DHHC motif, forms a thioester bond with the acyl group. This enzyme
autoacylation step of the reaction is rapid and may display burst kinetics. A free thiol
group on a protein substrate, which can bind before (188) or after autoacylation (Figure
3.2 and 3.5), then enters the active site. In the acyltransfer step, the acyl chain attached to
the DHHC is transferred to the free thiol and a new thioester bond is formed in a reaction
that is dependent on the first histidine of the DHHC motif (81, 175). Release of the
newly S-acylated protein generates free enzyme that then becomes available for another
round of catalysis. Given the hydrophobic character of the protein substrate, I speculate
that the acylated protein product dissociates from the enzyme and diffuses within the
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plane of the membrane. The mechanistic insight into DHHC catalysis provided by this
thesis work represents a significant advance from knowledge available when these
investigations began. However, the details of the DHHC catalytic mechanism remain to
be determined.
Acyl-CoA source. How DHHC proteins acquire their acyl-CoAs in cells is
unknown. Cytosolic free long-chain acyl-CoA (LCA) concentrations are calculated to be
in the 2-10 nM range even though total cellular concentrations may be as high as 160 µM
(36). The difference reflects that fact that most LCAs are compartmentalized in the
mitochondria or other organelles, membrane-bound, cleaved by hydrolases, or bound by
acyl-CoA binding protein (ACBP) or fatty acid bind protein (FABP). Given that other
enzymes utilize LCAs and the rapid kinetics observed for cellular acylation-deacylation
cycles (38, 216), it is predicted that if DHHC proteins used free LCAs, the low cytosolic
pool would rapidly become depleted. One possibility is that DHHC protein acquire their
LCAs through lateral diffusion in the membrane. This could require the LCA to slide
into a binding pocket, capable of determining chain-length preference, and may suggest
membrane fluidity surrounding the DHHC could regulate substrate accessibility. An
alternative is that DHHC proteins could use ACBP-bound LCAs. Supporting this
substrate source, the integral membrane enzyme acyl-CoA:lysophospholipid
acyltransferase (LAT) prefers ACBP-bound LCAs over free acyl-CoAs (217).
Furthermore, previous work in our lab has shown that an unidentified PAT activity is
capable of utilizing ACBP-bound acyl-CoAs (39). If DHHC proteins acquire LCAs from
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ACBP in cells, then inclusion of ACBP in PAT assays may better represent physiological
conditions.
Kinetic rate constants. Little quantitative information is available on the rates of
individual steps within the reaction pathway. Based on the work here, it is known that
the enzyme autoacylation step occurs rapidly reaching maximum incorporation of
radiolabeled acyl group in less than ten seconds, relative to a slower transfer step.
Measurements less than this time scale are not possible with the discontinuous radiolabelbased PAT assay. Combining the CoA production coupled-assay (175) and stop-flow
spectroscopy could allow more accurate determination of autoacylation rates. Rates for
different enzymes as well as with different acyl-CoAs could be used to quantify acylCoA and protein substrate preferences. Rates could also be used to quantitatively
determine the contribution of other membrane anchoring signals such as N-myristoylation
or prenylation to the reaction. Although the acyltransfer step is slower than
autoacylation, it is unknown whether acyl group transfer or release of acyl-substrate is
the rate-limiting step. Measuring rate constants could address this. Measuring reaction
rates for DHHC proteins with mutations within the conserved DHHC cysteine rich
domain (CRD) could help determine the role of individual residues within the reaction
mechanism and provide insight into structure-function relationships.
Mapping the acyl-DHHC attachment site. The cysteine of the DHHC motif is
required for enzyme autoacylation and is likely the site of acyl attachment, although this
has not been shown. DHHC proteins have seven conserved cysteine residues within the
DHHC cysteine rich domain (DHHC-CRD) and an additional 1 to 15 non-conserved

104

cysteine residues; the average DHHC has a total of 16 cysteine residues. It is likely that
S-acylation occurs outside the DHHC motif. Indeed for DHHC-5, -6, and -8, a tricysteine
motif in the C-terminal tail has been shown to be acylated (20). Mapping the modified
residue(s) of the acyl-enzyme intermediate would provide a target residue for inhibitor
design and would aid in determining the stoichiometry of autoacylation. Knowing the
stiochiometry would allow enzyme concentrations to be based on functional enzyme
concentrations rather than total enzyme, which is skewed by misfolded, aggregated, and
inactivated protein. Our early attempts to identify the acylated peptide by mass
spectrometry of trypsin-digested acyl-DHHC have been unsuccessful. Two
improvements are suggested: enrichment of the acyl-peptide and removal or replacement
of the fatty acid prior to mass spectrometry. Acyl resin-assisted capture (acyl-RAC) (18)
or acyl-biotin exchange (ABE) (218) are newer, nonradiolabel-based methods of
analyzing protein S-acylation and accomplish both improvements.
Oligomerization of DHHC proteins. It is unknown whether DHHC proteins
function as multimers. Co-immunoprecipitation of epitope-tagged DHHC3 and DHHC7
expressed in cells suggests that these DHHC proteins can form homo- and
heteromultimers (219). Further suggesting DHHC proteins may interact directly, ectopic
expression of DHHS-15 or AAHC-15 in cells resulted in a dominant negative phenotype
with reduced activity observed for cotransfected wildtype DHHC15 and DHHC2 (123).
For DHHC9 and the yeast ortholog, Erf2, heterodimers are formed with cognate binding
partners GCP16 and Erf4, respectively. Although the function of these binding partners
is unknown, multimerization of other DHHC proteins may serve a similar function. If
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DHHC proteins form oligomers, then cooperativity between subunits is possible and this
would affect interpretation of kinetic data.
Oligomerization of DHHC proteins also allows a type of behavior called half-ofsites reactivity. This is a behavior in oligomeric enzymes in which the number of active
subunits is less, typically one-half, than the total number of subunits. This can be caused,
for example, by substrate binding to one subunit of a dimer and inducing a
conformational change in the other subunit that blocks substrate binding, and thus is a
type of negative cooperativity (220). The integral membrane protein phospholipase A
(OMPLA) is an example of an enzyme displaying this behavior (221). In kinetic studies
this mode of reactivity presents itself as the maximal stoichiometric yields of either an
enzyme intermediate or the product of a single turnover assay as being only half the
number of enzyme active sites. The maximal stoichiometries of DHHC autoacylation
observed were 0.5 palmitate per DHHC3 (Figure 3.5A) and 0.65 palmitate per Erf2/Erf4
(175), consistent with a half-of-sites mechanism. However, other explanations, such as
inactive enzyme, could also explain DHHC stoichiometries less than one. In single
turnover assays we observed approximately half the acyl-enzyme transferring its acyl
group to protein substrate. Again, this could be explained by either a half-of-sites model
or by enzyme inactivated after autoacylating. Knowing if DHHC proteins form
oligomers would be the first step in testing this mechanism.
Structural basis for acyl-CoA specificity. The structural basis for the observed
differences in acyl-CoA specificity for DHHC proteins remains unclear. When tested by
an in vitro competition PAT assay, DHHC15-mediated incorporation of radiolabeled
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palmitate was reduced 90% by non-labeled palmCoA but only 57% by non-labeled C18
stearoyl-CoA (123). This may suggest that DHHC15, similar to DHHC3, is less able to
transfer acyl chains longer than 16-carbon palmitate. A structural basis for these
observed specificities may reside in the DHHC transmembrane domains (TMDs). It has
been shown for the multienzyme complex fatty acid synthase (FAS) that a lysine residue
regulates final acyl-CoA chain length by protruding from TMDs in Fen1 or alternative
subunit Sur4 at different distances from the catalytic core. Examining their predicted
membrane topology, three TMDs of DHHC3 contain charged residues at the midpoint of
the bilayer that are not present in DHHC2, which has broader acyl-CoA specificity.
Swapping TMDs between these DHHCs and site-directed mutagenesis could reveal
whether this region controls acyl-CoA specificity. If this is found not to be the case,
mutations at these sites may still be informative as these charged residues buried within
DHHC3’s TMDs likely serve some function, perhaps forming a salt bridge that stabilizes
dimers.
Zinc binding capability and other cofactors. DHHC proteins were originally
classified as zinc-finger proteins (87) and have been implicated in the transport of Mg2+
and Ca2+ ions (99, 100), however their ability to bind these metal ions has not been
tested. Inductively coupled plasma mass spectrometry (ICP-MS) could be used to
determine the number and species of metal ions bound to DHHC protein. It is probable
that DHHC proteins contain at least one metal ion, likely binding residues with the
DHHC-CRD domain, based on predictions and sequence conservation of residues known
to bind metal-ions in other proteins. Given that mammalian DHHC22 and yeast Ark1,
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Ark2, and Pfa5 lack a number of residues within the DHHC-CRD, it is possible they do
not share this feature or bind a different metal species. Reports describing the Mg2+ and
Ca2+ transport capabilities of DHHC proteins were based on indirect assays and these
alternative functions should be tested directly. Reconstitution of DHHC proteins into
liposomes and monitoring ion uptake by fluorescent chlelators or radiolabeled ions is one
method of testing ion transport.
Discovering new inhibitors of DHHC-mediated protein S-acylation. Inhibitors of
protein S-acylation would be beneficial both as tools for studying DHHC proteins within
cells and as potential pharmaceutical agents. Having inhibitors with characterized
methods of inhibition can aid in determining the order of substrate binding and product
release. For example, although the acyl chain is transferred from CoA to DHHC forming
the acyl-intermediate, it is unknown whether the CoA leaves before protein substrate
binding or after release of acylated protein. Given the role of protein S-acylation and
DHHC proteins in human diseases (Table 1.3), inhibitors may be clinically useful.
Additional screens are needed to find inhibitors of DHHC proteins. The
compounds tested in chapter 4 were representative of 4 chemical classes from the results
of three inhibitor screens. An additional 87 compounds were identified that belonged to
these classes as well as 65 unique compounds not belonging to any of the chemoclasses
(152). Given that these compounds inhibited S-acylation in both a live cell-based screen
and in PAT assays with crude cell membranes, they should be directly screened with
purified proteins and in vitro PAT assays to determine their ability to inhibit DHHC
proteins.
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High-content screening (HCS) is one strategy to find DHHC inhibitors. A DHHC
protein and/or one of its substrates fused to a monomeric fluorescent protein are
expressed in cells. The assay is based on a substrate displaying a different localization in
the acylated and non-acylated states. Following growth in a multi-well imaging plate,
cells are treated with compounds and monitored for changes in fluorescence localization.
Because of the complexities of cells and protein trafficking, compounds that altered
localization would need to be validated with secondary screens. A more detailed
explanation of this approach is available (222).
Cell-free screens for the direct inhibition of DHHC proteins are also possible.
Using purified DHHC proteins and either a protein or peptide substrate, the production of
the reaction by-product CoA can be monitored. One such assay has already been
described and used to monitor the rates of palmCoA hydrolysis by Erf2 (175). This
approach involves coupling the production CoA to the reduction of NAD+ with αketoglutarate dehydrogenase (α-KDH) and monitoring the reaction by NADH
fluorescence emission. Lead compounds would need to be validated by secondary screen
for a number of reasons, including the possibility of inhibiting α-KDH. Another cell-free
screen possible with purified DHHC protein could be based on the ultra-high throughput
screen (uHTS) developed to find inhibitors of fatty acid synthase and acetyl-CoA
carboxylase (223). The free thiol of CoA would react with 7-diethylamino-3-(4′maleimidylphenyl)-4-methylcoumarin (CPM), a compound that becomes fluorescent
upon reaction with thiols. It is unknown if CPM would react with thiols on the DHHC
and protein substrate, however this was not the case for two enzymes previously tested.
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Unlike the coupled-assay, this latter approach involves only one enzyme and may present
fewer challenges. Compounds found through any screening assay will need further
validation with secondary assays and subsequent characterization. Additionally,
structure-activity relationship (SAR) studies and the synthesis of analogous compounds
will likely be needed to develop potent and specific inhibitors. One feature of DHHC
proteins to exploit to achieve inhibitor specificity is the acyl-chain length specificities
demonstrated in this work.

Concluding Remarks
With this work, I have shown that the currently available inhibitors for DHHC
proteins are limited in potency and specificity and have further characterized the two
most potent inhibitors available. Uncovering the mechanism of DHHC proteins will aid
in our ability to find better inhibitors as well as improve our understanding of this
biologically important family of enzymes. With that goal in mind, I have determined that
DHHC proteins use a two-step ping-pong catalytic mechanism and display acyl-CoA
specificity. I hope that I have highlighted the contributions this work has made to a
mechanistic understanding of DHHC proteins and the future work that is needed to
further advance the protein S-acylation field.
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Appendix

Characterization of DHHC9 in Ras Signaling
and
X-linked Mental Retardation

The portion of this appendix related in FKBP12 and H-ras S-acylation was published in
Ahearn, I. M., Tsai, F. D., Court, H., Zhou, M., Jennings, B. C., Ahmed, M.,
Fehrenbacher, N., Linder, M. E., and Philips, M. R. 2011. FKBP12 binds to acylated Hras and promotes depalmitoylation. Molecular Cell. 41:173-185. My contributions
appear in Figure 2.
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Introduction
The yeast protein Erf2 and its mammalian ortholog DHHC9 are protein Sacyltransferases (PATs) for ras proteins. Effector of ras function 2 (Erf2) as well as Erf4
were identified in a genetic screen that required S-acylation of yeast Ras2 for survival
(79). These proteins were later shown to form a complex localized in the endoplasmic
reticulum (80) and catalyze the acylation of Ras2 in vitro (81). DHHC9 is the
mammalian ortholog of Erf2, and along with its binding partner Golgi complex protein
16 (GCP16), can catalyze the acylation of N- and H-ras (114). Although the most likely
candidate, to date no one has shown that DHHC9/GCP16 is responsible for acylating Ras
in cells. The role of Erf4 and GCP16 is unknown, as no other DHHC proteins tested have
required binding partners for activity. DHHC9 has been associated with a number of
human diseases (Table 1.3) including colorectal cancer (140, 142) and X-linked mental
retardation (139). This appendix highlights two projects related to DHHC9 mediated
protein S-acylation.

FKBP12 binds to acylated H-ras and promotes depalmitoylation.
Proline isomerization of H-ras affects its palmitoylation status. Workers within
the laboratory of Mark Philips noted that green fluorescent protein (GFP) tagged with last
19 amino acids of H-ras recapitulated the full-length protein localization to both the
Golgi and PM, but GFP tagged with the last 10 amino acids of H-ras localized only to the
PM. The last ten amino acids of H-ras (-GCMSCKCVLS.) has two cysteine residues
known to be acylated and a CaaX box cysteine residue known to be prenylated.
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Acylation of these constructs was evaluated and the shorter GFP-10aa tail was shown to
contain 2.5 times more radiolabeled palmitate than the GFP-19aa tail. The additional
nine residues (-LNPPDESGP-) in the longer GFP tail was rich in proline residues and led
researchers to hypothesize that proline isomerization may regulate H-ras acylation and
thereby trafficking.
Inhibiting prolyl isomerization was used to test this hypothesis. Indeed, chemical
inhibition of prolyl isomerization increased H-ras incorporation of radiolabeled palmitate
up to 4-fold. FK506-binding proteins (FKBPs) are one family of prolyl isomerases with
FKBP12 being the best characterized, and it is inhibited by FK506. Cells expressing the
GFP-19aa tail of H-ras, when treated with FK506 or FKBP12 siRNA showed an increase
in palmitate incorporation into GFP-19aa tail. This was not observed when constructs
lacking the proline residues or the GFP-10aa tail were expressed. This increase in H-ras
acylation when FKBP12 activity is suppressed could result from increased H-ras
acylation, decreased H-ras deacylation, or both.
Directly testing whether FKBP12 altered H-ras acylation with purified
components was my contribution to this work. In a radiolabel-based in vitro PAT assay,
DHHC9/GCP16 was used to palmitoylate the last 30aa of H-ras fused to GST, and the
effects of FKBP12 and FK506 on this reaction were monitored. The last 30aa rather than
the last 19aa were used because purified preparations of farnesylated protein were
available. As shown in Figure A.1, inclusion of FKBP and/or FK506 into the reaction
did not significantly alter the palmitoylation of GST-H-ras 30aa tail [PAT ID#617].
Three similar experiments were performed to confirm the result: one with full-length N-
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terminally tagged H-ras, His6-H-ras [PAT ID#621], and the remaining two with fulllength N-terminally tagged N-ras, His6-N-ras, including a titration of FKBP12 [PAT
ID#621 and 625]. In no case was FKBP12 or FK506 able to alter DHHC9-mediated
acylation of H-ras or N-ras. While their effect could be through another DHHC protein
in cells, it seemed more likely that FKBP12-mediated prolyl isomerization was
decreasing deacylation of H-ras in cells.
Indeed, further experiments showed that FKBP12 affected the acylation level and
localization of H-ras by increasing the deacylation of H-ras. Co-immunoprecipitation
experiments showed that FKBP12 bound to H-ras and N-ras, but not K-ras. These
interactions were blocked by FK506, 2-bromopalmitate, or mutation of the H-ras
acylation sites (C181,184S), suggesting that acylation of H-ras was required for FKBP12
binding. Interestingly, FKBP12 did not require the C-terminal proline residues to co-IP
with H-ras. Additional functional studies showed that FBKP12 affected H-ras
localization and retrograde trafficking from the PM to the Golgi. Inhibition of FKBP12
also resulted in greater GTP-loading of endogenous H-ras following EGF stimulation,
consistent with inhibition of FKBP12 preventing depalmitoylation of H-ras and confining
it to the PM adjacent upstream activators.
The role of FKBP12 in modulating Ras deacylation adds a new level to
complexity to the regulation of Ras signaling. It also raises several questions. For
example, how does soluble FKBP12 bind the membrane anchored acylated tail of H-ras
and does the deacylation involve recruitment of acyl-protein thioesterases (APTs)?
Another issued raised in the Preview for this article (224) is that FK506 is currently in
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use as an immunosuppressant and the work here may suggest FK506 has tumor
promoting properties. Given the challenges in monitoring prolyl isomerization, it
remains to be determined whether the interplay between these two modifications is
unique to Ras signaling or if prolyl cis-trans isomerization is a broader regulator of
protein S-acylation.

DHHC9 X-linked mental retardation mutant R148W displays reduced association
with binding partner GCP16 and protein S-acyltransferase activity.
Genetic studies in humans have linked DHHC9 to X-linked mental retardation
(XLMR) (139). In order to find genes that cause XLMR, researchers characterized a
cohort of 250 families in which at least two males have clinically diagnosed mental
retardation with no known molecular cause. Two truncations arising from a 4 bp
insertion and a mutation causing alternative exon splicing, and two missense mutations
were found in the ZDHHC9 gene. The ZDHHC9 missense mutations resulted in proteins
in which arginine 148 was changed to tryptophan (R148W) and proline 150 to serine
(P150S). These residues (R148 and P150) are conserved in DHHC9 orthologs from yeast
to humans whereas overall sequence conservation is only 30%. Both mutations are
upstream of the canonical DHHC motif but still within the 51aa cysteine-rich domain.
Our laboratory has begun to investigate the protein product of these mutations for
differences in localization, PAT activity, and protein stability.
Given my expertise in analyzing DHHC PAT activity, I set out to determine if
either of these point mutants affects the ability of DHHC9 to palmitoylate H-ras.
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Coworkers generated Baculoviruses to express R148W and P150S DHHC9-myc-His6
proteins in Sf9 insect cells. The P150S virus had poor expression levels and was not
analyzed further. The R148W DHHC9 was co-expressed with FLAG-GCP16 and
purified over nickel resin (Figure A.2A). Interestingly, unlike similar purifications with
WT DHHC9, the binding partner GCP16 did not co-purify with R148W DHHC9.
Another purification was attempted and compared to identical purifications of WT
DHHC9 and both with and without GCP16. As shown with nickel elutions in Figure
A.2B, the R148W mutant displayed markedly reduced ability to co-purify GCP16
relative to WT DHHC9. Because the nickel elutions contained a number of
contaminating proteins (not shown), we attempted to use myc-affinity resin to further
purify all four samples. The yield from such purifications was insufficient to use in
activity assay, however immunoblotting of elutions did confirm again that WT DHHC9
binds GCP16 whereas the R148W mutant does not (Figure A.2C). Collectively, these
results demonstrate that R148W DHHC9 displays reduced affinity for GCP16.
Using samples normalized for equal amounts of DHHC9 protein (Figure A.3B), I
determined the ability of WT and R148W to palmitoylate H-ras using the standard
radiolabel-based PAT assay (Figure A.3A). WT DHHC9 with GCP16 robustly
palmitoylated H-ras and autoacylated as previously described by our group (114).
DHHC9 alone also autoacylated and palmitoylated H-ras but only at 30% of the levels
observed when GCP16 was present. This is unlike the original characterization of
DHHC9 that showed no activity in the absence of GCP16 (114). R148W alone and with
GCP16 displayed a similar pattern to WT DHHC9 but with activities reduced by 50%.
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These results suggest that R148W DHHC9 has reduced PAT activity because of its
reduced association with GCP16.
While these results do not provide a clear connection to XLMR, they do raise
several new questions. One difference between the original characterization of DHHC9
PAT activity and those here is that in the earlier studies PAT assay buffers contained
thiol-based reducing agents. These reagents may have cleaved the acyl-enzyme thioester
bonds present in the DHHC9 alone reactions here. This would point to a role for GCP16
in protecting the acyl-enzyme intermediate from hydrolysis. Measuring acyl-CoA
hydrolysis by WT and R148W could test this hypothesis. R148W may display reduced
PAT activity exclusively due to reduced GCP16 interaction or R148W may also be
detrimental to catalysis. Titration of GCP16 into the PAT reaction may differentiate
these possibilities. Interestingly, in the genetic screen in yeast that identified Erf2 as a
Ras PAT, mutation of the R148 equivalent residue, R182, to alanine was not lethal. This
may suggest that in cells R148W retains enough PAT activity to acylate Ras and that
defects in the acylation of other substrates are responsible for the XLMR phenotype.
Techniques have been described to find protein substrates of individual DHHC proteins
in mammalian cells (225); such methods may be needed to draw a connection between
DHHC9 and XLMR. Further, cell-based work examining protein localization and
stability will also be important for characterizing these disease-associated mutations.
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Figure A.1. Palmitoylation of GST-H-ras 30aa tail in vitro using purified DHHC9/GCP16 and [3H]palmitoyl-CoA in the presence or absence of FK506 or recombinant FKBP12. The indicated concentrations of reaction components were incubated at 25°C for 7 min. Reactions were stopped with sample
buffer and resolved by SDS-PAGE. GST-H-ras 30aa tail bands were excised from one set of gels and
processed for scintillation counting, while the other set of gels was processed for fluorography and exposed
to film at -80°C [PAT ID#617].
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Figure A.2. DHHC9 R148W displays reduced interaction with GCP16. A, Purification of DHHC9myc-His6 R148W (pML1311) co-expressed with FLAG-GCP16 (pML756) over Ni-NTA resin. Sf9 cells
were co-infected with viruses expressing both constructs, harvested, and lysed by nitrogen cavitation. The
soluble (S100) and membrane (P100) fractions were separated by centrifugation. Detergent (DDM) was
added to the membranes to extract DHHC9. This detergent extract (S100.2) was diluted and loaded onto
Ni-NTA resin. The flow through (FT) was collected, the column was washed, and proteins were eluted with
imidazole. Immunoblotting was used to detect proteins within each sample [PAT ID#725]. B, WT and
R148W DHHC9-myc-His6 were expressed with or without FLAG-GCP16 in Sf9 cells. Purification with
Ni-NTA resin was performed as in A. Two volumes of a nickel elution were loaded for each sample [PAT
ID#775]. C, Partially purified nickel elutions containing WT or R148W DHHC9-myc-His6 co-expressed
with FLAG-GCP16 were bound to myc-affinity resin. The flow through (FT) was collected, the column
was washed, and proteins were eluted with myc peptide. A sample of myc-affinity resin after elution was
also run on the gel [PAT ID#737]. Purification and immunoblotting procedures were similar to those
described in Chapters 3 and 4.
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Figure A.3. DHHC9 R148W displays reduced protein S-acyltransferase activity for H-ras. A,
Normalized amounts of partially purified DHHC9-myc-His6 WT or R148W co-expressed with or without
FLAG-GCP16 were incubated with His6-H-ras and radiolabeled palmCoA. Fluorography exposures were
at -80°C for the indicated time. The longer exposure shows that WT DHHC9 alone and R148W DHHC9
with GCP16 incorporated palmitate, albeit at low levels. B, Immunoblot of the reactions in A to show that
equal amounts of DHHC9 were assayed [PAT ID#785].

120

References
1.
Nadolski, M. J., and Linder, M. E. 2007. Protein lipidation. FEBS J. 274:52025210.
2.
Fujita, M., and Kinoshita, T. 2010. Structural remodeling of GPI anchors during
biosynthesis and after attachment to proteins. FEBS Letters. 584:1670-1677.
3.
Chatterjee, S., and Mayor, S. 2001. The GPI-anchor and protein sorting. Cell.
Mol. Life Sci. 58:1969-1987.
4.
Takeda, J., and Kinoshita, T. 1995. GPI-anchor biosynthesis. Trends Biochem.
Sci. 20:367-371.
5.
Chang, S.-C., and Magee, A. I. 2009. Acyltransferases for secreted signalling
proteins (Review). Mol. Membr. Biol. 26:104-113.
6.
Resh, M. D. 2006. Palmitoylation of ligands, receptors, and intracellular
signaling molecules. Sci. STKE. 2006:re14.
7.
Miura, G. I., and Treisman, J. E. 2006. Lipid modification of secreted signaling
proteins. Cell Cycle. 5:1184-1188.
8.
Buglino, J. A., and Resh, M. D. 2008. Hhat is a palmitoylacyltransferase with
specificity for N-palmitoylation of Sonic Hedgehog. J. Biol. Chem. 283:22076-22088.
9.
Kleuss, C., and Krause, E. 2003. Galpha(s) is palmitoylated at the N-terminal
glycine. EMBO J. 22:826-832.
10.
Linder, M. E. 2001. Reversible modification of proteins with thioester-linked
fatty acids, in Protein Lipidation, pp 215-240. Academic Press.
11.
Stoffyn, P., and Folch-Pi, J. 1971. On the type of linkage binding fatty acids
present in brain white matter proteolipid apoprotein. Biochemical and Biophysical
Research Communications. 44:157-161.
12.
Gagnon, J., Finch, P. R., Wood, D. D., and Moscarello, M. A. 1971. Isolation of
a highly purified myelin protein. Biochemistry. 10:4756-4763.
13.
Schmidt, M. F., Bracha, M., and Schlesinger, M. J. 1979. Evidence for covalent
attachment of fatty acids to Sindbis virus glycoproteins. Proc. Natl. Acad. Sci. U.S.A.
76:1687-1691.
14.
Schlesinger, M. J., Magee, A. I., and Schmidt, M. F. 1980. Fatty acid acylation
of proteins in cultured cells. J. Biol. Chem. 255:10021-10024.
15.
Wilson, J. P., Raghavan, A. S., Yang, Y.-Y., Charron, G., and Hang, H. C. 2011.
Proteomic Analysis of Fatty-acylated Proteins in Mammalian Cells with Chemical
Reporters Reveals S-Acylation of Histone H3 Variants. Molecular & Cellular
Proteomics. 10.
16.
Roth, A. F., Wan, J., Bailey, A. O., Sun, B., Kuchar, J. A., Green, W. N., Phinney,
B. S., Yates, J. R., 3rd, and Davis, N. G. 2006. Global analysis of protein palmitoylation
in yeast. Cell. 125:1003-1013.
17.
Kang, R., Wan, J., Arstikaitis, P., Takahashi, H., Huang, K., Bailey, A. O.,
Thompson, J. X., Roth, A. F., Drisdel, R. C., Mastro, R., Green, W. N., Yates, J. R., 3rd,
Davis, N. G., and El-Husseini, A. 2008. Neural palmitoyl-proteomics reveals dynamic
synaptic palmitoylation. Nature. 456:904-909.
121

18.
Forrester, M. T., Hess, D. T., Thompson, J. W., Hultman, R., Moseley, M. A.,
Stamler, J. S., and Casey, P. J. 2011. Site-specific analysis of protein S-acylation by
resin-assisted capture. J. Lipid Res. 52:393-398.
19.
Emmer, B. T., Nakayasu, E. S., Souther, C., Choi, H., Sobreira, T. J. P., Epting,
C. L., Nesvizhskii, A. I., Almeida, I. C., and Engman, D. M. 2011. Global analysis of
protein palmitoylation in African trypanosomes. Eukaryotic Cell. 10:455-463.
20.
Yang, W., Di Vizio, D., Kirchner, M., Steen, H., and Freeman, M. R. 2010.
Proteome scale characterization of human S-acylated proteins in lipid raft-enriched and
non-raft membranes. Mol. Cell Proteomics. 9:54-70.
21.
Gutierrez, L., and Magee, A. I. 1991. Characterization of an acyltransferase
acting on p21N-ras protein in a cell-free system. Biochimica et Biophysica Acta (BBA) Protein Structure and Molecular Enzymology. 1078:147-154.
22.
Berthiaume, L., and Resh, M. D. 1995. Biochemical characterization of a
palmitoyl acyltransferase activity that palmitoylates myristoylated proteins. J. Biol.
Chem. 270:22399-22405.
23.
Liu, L., Dudler, T., and Gelb, M. H. 1996. Purification of a Protein
Palmitoyltransferase that Acts on H-Ras Protein and on a C-terminal N-Ras Peptide.
Journal of Biological Chemistry. 271:23269 -23276.
24.
Liu, L., Dudler, T., and Gelb, M. H. 1999. Purification of a protein
palmitoyltransferase that acts on H-Ras protein and on a C-terminal N-Ras peptide.
Journal of Biological Chemistry. 274:3252.
25.
Hiol, A., Caron, J. M., Smith, C. D., and Jones, T. L. Z. 2003. Characterization
and partial purification of protein fatty acyltransferase activity from rat liver. Biochimica
et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1635:10-19.
26.
Dunphy, J. T., Greentree, W. K., Manahan, C. L., and Linder, M. E. 1996. Gprotein palmitoyltransferase activity is enriched in plasma membranes. J. Biol. Chem.
271:7154-7159.
27.
Ohno, Y., Kihara, A., Sano, T., and Igarashi, Y. 2006. Intracellular localization
and tissue-specific distribution of human and yeast DHHC cysteine-rich domaincontaining proteins. Biochim. Biophys. Acta. 1761:474-483.
28.
Duncan, J. A., and Gilman, A. G. 1996. Autoacylation of G protein alpha
subunits. J. Biol. Chem. 271:23594-23600.
29.
Bizzozero, O. A., McGarry, J. F., and Lees, M. B. 1987. Autoacylation of
myelin proteolipid protein with acyl coenzyme A. J. Biol. Chem. 262:13550-13557.
30.
Bharadwaj, M., and Bizzozero, O. A. 1995. Myelin P0 glycoprotein and a
synthetic peptide containing the palmitoylation site are both autoacylated. J. Neurochem.
65:1805-1815.
31.
O’Brien, P. J., St Jules, R. S., Reddy, T. S., Bazan, N. G., and Zatz, M. 1987.
Acylation of disc membrane rhodopsin may be nonenzymatic. J. Biol. Chem. 262:52105215.
32.
Kümmel, D., Walter, J., Heck, M., Heinemann, U., and Veit, M. 2010.
Characterization of the self-palmitoylation activity of the transport protein particle
component Bet3. Cell. Mol. Life Sci. 67:2653-2664.

122

33.
Mollner, S., Ferreira, P., Beck, K., and Pfeuffer, T. 1998. Nonenzymatic
palmitoylation at Cys 3 causes extra-activation of the alpha-subunit of the stimulatory
GTP-binding protein Gs. Eur. J. Biochem. 257:236-241.
34.
Scholich, K., Yigzaw, Y., and Patel, T. B. 2000. Cysteine 3 is not the site of in
vitro palmitoylation on G(salpha). Biochem. Biophys. Res. Commun. 270:131-136.
35.
Zahler, W. L., Barden, R. E., and Cleland, W. W. 1968. Some physical
properties of palmityl-coenzyme A micelles. Biochim. Biophys. Acta. 164:1-11.
36.
Knudsen, J., Neergaard, T. B., Gaigg, B., Jensen, M. V., and Hansen, J. K. 2000.
Role of acyl-CoA binding protein in acyl-CoA metabolism and acyl-CoA-mediated cell
signaling. J. Nutr. 130:294S-298S.
37.
Leventis, R., Juel, G., Knudsen, J. K., and Silvius, J. R. 1997. Acyl-CoA binding
proteins inhibit the nonenzymic S-acylation of cysteinyl-containing peptide sequences by
long-chain acyl-CoAs. Biochemistry. 36:5546-5553.
38.
Rocks, O., Peyker, A., Kahms, M., Verveer, P. J., Koerner, C., Lumbierres, M.,
Kuhlmann, J., Waldmann, H., Wittinghofer, A., and Bastiaens, P. I. H. 2005. An
acylation cycle regulates localization and activity of palmitoylated Ras isoforms.
Science. 307:1746-1752.
39.
Dunphy, J. T., Schroeder, H., Leventis, R., Greentree, W. K., Knudsen, J. K.,
Silvius, J. R., and Linder, M. E. 2000. Differential effects of acyl-CoA binding protein
on enzymatic and non-enzymatic thioacylation of protein and peptide substrates.
Biochim. Biophys. Acta. 1485:185-198.
40.
Bañó, M. C., Jackson, C. S., and Magee, A. I. 1998. Pseudo-enzymatic Sacylation of a myristoylated yes protein tyrosine kinase peptide in vitro may reflect nonenzymatic S-acylation in vivo. Biochem. J. 330 ( Pt 2):723-731.
41.
Quesnel, S., and Silvius, J. R. 1994. Cysteine-containing peptide sequences
exhibit facile uncatalyzed transacylation and acyl-CoA-dependent acylation at the lipid
bilayer interface. Biochemistry. 33:13340-13348.
42.
Xue, Y., Chen, H., Jin, C., Sun, Z., and Yao, X. 2006. NBA-Palm: prediction of
palmitoylation site implemented in Naïve Bayes algorithm. BMC Bioinformatics. 7:458.
43.
Zhou, F., Xue, Y., Yao, X., and Xu, Y. 2006. CSS-Palm: palmitoylation site
prediction with a clustering and scoring strategy (CSS). Bioinformatics. 22:894-896.
44.
Ren, J., Wen, L., Gao, X., Jin, C., Xue, Y., and Yao, X. 2008. CSS-Palm 2.0: an
updated software for palmitoylation sites prediction. Protein Eng. Des. Sel. 21:639-644.
45.
Wang, X.-B., Wu, L.-Y., Wang, Y.-C., and Deng, N.-Y. 2009. Prediction of
palmitoylation sites using the composition of k-spaced amino acid pairs. Protein Eng.
Des. Sel. 22:707-712.
46.
Li, Y.-X., Shao, Y.-H., and Deng, N.-Y. 2011. Improved prediction of
palmitoylation sites using PWMs and SVM. Protein Pept. Lett. 18:186-193.
47.
Hu, L.-L., Wan, S.-B., Niu, S., Shi, X.-H., Li, H.-P., Cai, Y.-D., and Chou, K.-C.
2011. Prediction and analysis of protein palmitoylation sites. Biochimie. 93:489-496.
48.
Peitzsch, R. M., and McLaughlin, S. 1993. Binding of acylated peptides and
fatty acids to phospholipid vesicles: pertinence to myristoylated proteins. Biochemistry.
32:10436-10443.

123

49.
Shahinian, S., and Silvius, J. R. 1995. Doubly-lipid-modified protein sequence
motifs exhibit long-lived anchorage to lipid bilayer membranes. Biochemistry. 34:38133822.
50.
Silvius, J. R., and l’ Heureux, F. 1994. Fluorimetric evaluation of the affinities of
isoprenylated peptides for lipid bilayers. Biochemistry. 33:3014-3022.
51.
Resh, M. D. 2006. Trafficking and signaling by fatty-acylated and prenylated
proteins. Nat. Chem. Biol. 2:584-590.
52.
Aitken, A., Cohen, P., Santikarn, S., Williams, D. H., Calder, A. G., Smith, A.,
and Klee, C. B. 1982. Identification of the NH2-terminal blocking group of calcineurin
B as myristic acid. FEBS Letters. 150:314-318.
53.
Carr, S. A., Biemann, K., Shoji, S., Parmelee, D. C., and Titani, K. 1982. nTetradecanoyl is the NH2-terminal blocking group of the catalytic subunit of cyclic
AMP-dependent protein kinase from bovine cardiac muscle. Proceedings of the National
Academy of Sciences. 79:6128 -6131.
54.
Duronio, R. J., Towler, D. A., Heuckeroth, R. O., and Gordon, J. I. 1989.
Disruption of the yeast N-myristoyl transferase gene causes recessive lethality. Science.
243:796-800.
55.
Ntwasa, M., Aapies, S., Schiffmann, D. A., and Gay, N. J. 2001. Drosophila
Embryos Lacking N-Myristoyltransferase Have Multiple Developmental Defects.
Experimental Cell Research. 262:134-144.
56.
Resh, M. D. 1999. Fatty acylation of proteins: new insights into membrane
targeting of myristoylated and palmitoylated proteins. Biochimica et Biophysica Acta
(BBA) - Molecular Cell Research. 1451:1-16.
57.
Martin, D. D. O., Beauchamp, E., and Berthiaume, L. G. 2011. Post-translational
myristoylation: Fat matters in cellular life and death. Biochimie. 93:18-31.
58.
Zha, J., Weiler, S., Oh, K. J., Wei, M. C., and Korsmeyer, S. J. 2000.
Posttranslational N-myristoylation of BID as a molecular switch for targeting
mitochondria and apoptosis. Science. 290:1761-1765.
59.
Utsumi, T., Sakurai, N., Nakano, K., and Ishisaka, R. 2003. C-terminal 15 kDa
fragment of cytoskeletal actin is posttranslationally N-myristoylated upon caspasemediated cleavage and targeted to mitochondria. FEBS Lett. 539:37-44.
60.
Sakurai, N., and Utsumi, T. 2006. Posttranslational N-myristoylation is required
for the anti-apoptotic activity of human tGelsolin, the C-terminal caspase cleavage
product of human gelsolin. J. Biol. Chem. 281:14288-14295.
61.
Vilas, G. L., Corvi, M. M., Plummer, G. J., Seime, A. M., Lambkin, G. R., and
Berthiaume, L. G. 2006. Posttranslational myristoylation of caspase-activated p21activated protein kinase 2 (PAK2) potentiates late apoptotic events. Proc. Natl. Acad.
Sci. U.S.A. 103:6542-6547.
62.
Rudnick, D. A., McWherter, C. A., Adams, S. P., Ropson, I. J., Duronio, R. J.,
and Gordon, J. I. 1990. Structural and functional studies of Saccharomyces cerevisiae
myristoyl-CoA:protein N-myristoyltransferase produced in Escherichia coli. Evidence
for an acyl-enzyme intermediate. J. Biol. Chem. 265:13370-13378.

124

63.
Peseckis, S. M., and Resh, M. D. 1994. Fatty acyl transfer by human N-myristyl
transferase is dependent upon conserved cysteine and histidine residues. J. Biol. Chem.
269:30888-30892.
64.
Rudnick, D. A., McWherter, C. A., Rocque, W. J., Lennon, P. J., Getman, D. P.,
and Gordon, J. I. 1991. Kinetic and structural evidence for a sequential ordered Bi Bi
mechanism of catalysis by Saccharomyces cerevisiae myristoyl-CoA:protein Nmyristoyltransferase. J. Biol. Chem. 266:9732-9739.
65.
Rocque, W. J., McWherter, C. A., Wood, D. C., and Gordon, J. I. 1993. A
comparative analysis of the kinetic mechanism and peptide substrate specificity of human
and Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase. Journal
of Biological Chemistry. 268:9964 -9971.
66.
Weston, S. A., Camble, R., Colls, J., Rosenbrock, G., Taylor, I., Egerton, M.,
Tucker, A. D., Tunnicliffe, A., Mistry, A., Mancia, F., de la Fortelle, E., Irwin, J.,
Bricogne, G., and Pauptit, R. A. 1998. Crystal structure of the anti-fungal target Nmyristoyl transferase. Nat. Struct. Biol. 5:213-221.
67.
Bhatnagar, R. S., Fütterer, K., Farazi, T. A., Korolev, S., Murray, C. L., JacksonMachelski, E., Gokel, G. W., Gordon, J. I., and Waksman, G. 1998. Structure of Nmyristoyltransferase with bound myristoylCoA and peptide substrate analogs. Nat.
Struct. Biol. 5:1091-1097.
68.
Farazi, T. A., Waksman, G., and Gordon, J. I. 2001. Structures of
Saccharomyces cerevisiae N-myristoyltransferase with bound myristoylCoA and peptide
provide insights about substrate recognition and catalysis. Biochemistry. 40:6335-6343.
69.
Farazi, T. A., Waksman, G., and Gordon, J. I. 2001. The biology and
enzymology of protein N-myristoylation. J. Biol. Chem. 276:39501-39504.
70.
Kamiya, Y., Sakurai, A., Tamura, S., Takahashi, N., Abe, K., Tsuchiya, E., Fukui,
S., Kitada, C., and Fujino, M. 1978. Structure of rhodotorucine , a novel lipopeptide,
inducing mating tube formation in. Biochemical and Biophysical Research
Communications. 83:1077-1083.
71.
Casey, P. J., Solski, P. A., Der, C. J., and Buss, J. E. 1989. p21ras is modified by
a farnesyl isoprenoid. Proceedings of the National Academy of Sciences. 86:8323 -8327.
72.
Reiss, Y., Goldstein, J. L., Seabra, M. C., Casey, P. J., and Brown, M. S. 1990.
Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides.
Cell. 62:81-88.
73.
Goodman, L. E., Judd, S. R., Farnsworth, C. C., Powers, S., Gelb, M. H.,
Glomset, J. A., and Tamanoi, F. 1990. Mutants of Saccharomyces cerevisiae defective
in the farnesylation of Ras proteins. Proc. Natl. Acad. Sci. U.S.A. 87:9665-9669.
74.
He, B., Chen, P., Chen, S. Y., Vancura, K. L., Michaelis, S., and Powers, S.
1991. RAM2, an essential gene of yeast, and RAM1 encode the two polypeptide
components of the farnesyltransferase that prenylates a-factor and Ras proteins. Proc.
Natl. Acad. Sci. U.S.A. 88:11373-11377.
75.
Kohl, N. E., Diehl, R. E., Schaber, M. D., Rands, E., Soderman, D. D., He, B.,
Moores, S. L., Pompliano, D. L., Ferro-Novick, S., and Powers, S. 1991. Structural
homology among mammalian and Saccharomyces cerevisiae isoprenyl-protein
transferases. J. Biol. Chem. 266:18884-18888.
125

76.
Lane, K. T., and Beese, L. S. 2006. Thematic review series: lipid
posttranslational modifications. Structural biology of protein farnesyltransferase and
geranylgeranyltransferase type I. J. Lipid Res. 47:681-699.
77.
Furfine, E. S., Leban, J. J., Landavazo, A., Moomaw, J. F., and Casey, P. J. 1995.
Protein farnesyltransferase: kinetics of farnesyl pyrophosphate binding and product
release. Biochemistry. 34:6857-6862.
78.
Tschantz, W. R., Furfine, E. S., and Casey, P. J. 1997. Substrate binding is
required for release of product from mammalian protein farnesyltransferase. J. Biol.
Chem. 272:9989-9993.
79.
Bartels, D. J., Mitchell, D. A., Dong, X., and Deschenes, R. J. 1999. Erf2, a
novel gene product that affects the localization and palmitoylation of Ras2 in
Saccharomyces cerevisiae. Mol. Cell. Biol. 19:6775-6787.
80.
Zhao, L., Lobo, S., Dong, X., Ault, A. D., and Deschenes, R. J. 2002. Erf4p and
Erf2p form an endoplasmic reticulum-associated complex involved in the plasma
membrane localization of yeast Ras proteins. J. Biol. Chem. 277:49352-49359.
81.
Lobo, S., Greentree, W. K., Linder, M. E., and Deschenes, R. J. 2002.
Identification of a Ras palmitoyltransferase in Saccharomyces cerevisiae. J. Biol. Chem.
277:41268-41273.
82.
Roth, A. F., Feng, Y., Chen, L., and Davis, N. G. 2002. The yeast DHHC
cysteine-rich domain protein Akr1p is a palmitoyl transferase. J. Cell Biol. 159:23-28.
83.
Mitchell, D. A., Vasudevan, A., Linder, M. E., and Deschenes, R. J. 2006.
Protein palmitoylation by a family of DHHC protein S-acyltransferases. J. Lipid Res.
47:1118-1127.
84.
Bannan, B. A., Van Etten, J., Kohler, J. A., Tsoi, Y., Hansen, N. M., Sigmon, S.,
Fowler, E., Buff, H., Williams, T. S., Ault, J. G., Glaser, R. L., and Korey, C. A. 2008.
The Drosophila protein palmitoylome: characterizing palmitoyl-thioesterases and DHHC
palmitoyl-transferases. Fly (Austin). 2:198-214.
85.
Hemsley, P. A., and Grierson, C. S. 2008. Multiple roles for protein
palmitoylation in plants. Trends Plant Sci. 13:295-302.
86.
Greaves, J., and Chamberlain, L. H. 2011. DHHC palmitoyl transferases:
substrate interactions and (patho)physiology. Trends Biochem. Sci. 36:245-253.
87.
Putilina, T., Wong, P., and Gentleman, S. 1999. The DHHC domain: a new
highly conserved cysteine-rich motif. Mol. Cell. Biochem. 195:219-226.
88.
Politis, E. G., Roth, A. F., and Davis, N. G. 2005. Transmembrane topology of
the protein palmitoyl transferase Akr1. J. Biol. Chem. 280:10156-10163.
89.
González Montoro, A., Quiroga, R., Maccioni, H. J. F., and Valdez Taubas, J.
2009. A novel motif at the C-terminus of palmitoyltransferases is essential for Swf1 and
Pfa3 function in vivo. Biochem. J. 419:301-308.
90.
Faergeman, N. J., and Knudsen, J. 1997. Role of long-chain fatty acyl-CoA
esters in the regulation of metabolism and in cell signalling. Biochem. J. 323 ( Pt 1):112.
91.
Smotrys, J. E., Schoenfish, M. J., Stutz, M. A., and Linder, M. E. 2005. The
vacuolar DHHC-CRD protein Pfa3p is a protein acyltransferase for Vac8p. J. Cell Biol.
170:1091-1099.
126

92.
Oyama, T., Miyoshi, Y., Koyama, K., Nakagawa, H., Yamori, T., Ito, T.,
Matsuda, H., Arakawa, H., and Nakamura, Y. 2000. Isolation of a novel gene on
8p21.3-22 whose expression is reduced significantly in human colorectal cancers with
liver metastasis. Genes Chromosomes Cancer. 29:9-15.
93.
Noritake, J., Fukata, Y., Iwanaga, T., Hosomi, N., Tsutsumi, R., Matsuda, N.,
Tani, H., Iwanari, H., Mochizuki, Y., Kodama, T., Matsuura, Y., Bredt, D. S.,
Hamakubo, T., and Fukata, M. 2009. Mobile DHHC palmitoylating enzyme mediates
activity-sensitive synaptic targeting of PSD-95. J. Cell Biol. 186:147-160.
94.
Greaves, J., Carmichael, J. A., and Chamberlain, L. H. 2011. The palmitoyl
transferase DHHC2 targets a dynamic membrane cycling pathway: regulation by a Cterminal domain. Mol. Biol. Cell. 22:1887-1895.
95.
Greaves, J., Gorleku, O. A., Salaun, C., and Chamberlain, L. H. 2010.
Palmitoylation of the SNAP25 protein family: specificity and regulation by DHHC
palmitoyl transferases. J. Biol. Chem. 285:24629-24638.
96.
Jia, L., Linder, M. E., and Blumer, K. J. 2011. Gi/o signaling and the
palmitoyltransferase DHHC2 regulate palmitate cycling and shuttling of RGS7 familybinding protein. J. Biol. Chem. 286:13695-13703.
97.
Dighe, S. A., and Kozminski, K. G. 2008. Swf1p, a member of the DHHC-CRD
family of palmitoyltransferases, regulates the actin cytoskeleton and polarized secretion
independently of its DHHC motif. Mol. Biol. Cell. 19:4454-4468.
98.
Kraft, B., Johswich, A., Kauczor, G., Scharenberg, M., Gerardy-Schahn, R., and
Bakker, H. 2011. “Add-on” domains of Drosophila β1,4-Nacetylgalactosaminyltransferase B in the stem region and its pilot protein. Cell Mol Life
Sci.
99.
Goytain, A., Hines, R. M., and Quamme, G. A. 2008. Huntingtin-interacting
proteins, HIP14 and HIP14L, mediate dual functions, palmitoyl acyltransferase and
Mg2+ transport. J. Biol. Chem. 283:33365-33374.
100. Hines, R. M., Kang, R., Goytain, A., and Quamme, G. A. 2010. Golgi-specific
DHHC zinc finger protein GODZ mediates membrane Ca2+ transport. J. Biol. Chem.
285:4621-4628.
101. Roy, S., Plowman, S., Rotblat, B., Prior, I. A., Muncke, C., Grainger, S., Parton,
R. G., Henis, Y. I., Kloog, Y., and Hancock, J. F. 2005. Individual palmitoyl residues
serve distinct roles in H-ras trafficking, microlocalization, and signaling. Mol. Cell. Biol.
25:6722-6733.
102. Henis, Y. I., Rotblat, B., and Kloog, Y. 2006. FRAP beam-size analysis to
measure palmitoylation-dependent membrane association dynamics and microdomain
partitioning of Ras proteins. Methods. 40:183-190.
103. Singaraja, R. R., Kang, M. H., Vaid, K., Sanders, S. S., Vilas, G. L., Arstikaitis,
P., Coutinho, J., Drisdel, R. C., El-Husseini, A. E. D., Green, W. N., Berthiaume, L., and
Hayden, M. R. 2009. Palmitoylation of ATP-binding cassette transporter A1 is essential
for its trafficking and function. Circ. Res. 105:138-147.
104. Delint-Martinez, I., Willoughby, D., Hammond, G. V. R., Ayling, L. J., and
Cooper, D. M. F. 2011. Palmitoylation targets AKAP79 to lipid rafts and promotes its
regulation of the calcium sensitive adenylyl cyclase type 8. J Biol Chem.
127

105. Chakrabandhu, K., Hérincs, Z., Huault, S., Dost, B., Peng, L., Conchonaud, F.,
Marguet, D., He, H.-T., and Hueber, A.-O. 2007. Palmitoylation is required for efficient
Fas cell death signaling. EMBO J. 26:209-220.
106. Guardiola-Serrano, F., Rossin, A., Cahuzac, N., Luckerath, K., Melzer, I.,
Mailfert, S., Marguet, D., Zornig, M., and Hueber, A.-O. 2010. Palmitoylation of human
FasL modulates its cell death-inducing function. Cell Death and Dis. 1:e88.
107. Levental, I., Lingwood, D., Grzybek, M., Coskun, U., and Simons, K. 2010.
Palmitoylation regulates raft affinity for the majority of integral raft proteins. Proc. Natl.
Acad. Sci. U.S.A. 107:22050-22054.
108. Harder, T., Scheiffele, P., Verkade, P., and Simons, K. 1998. Lipid domain
structure of the plasma membrane revealed by patching of membrane components. J.
Cell Biol. 141:929-942.
109. Abrami, L., Leppla, S. H., and van der Goot, F. G. 2006. Receptor
palmitoylation and ubiquitination regulate anthrax toxin endocytosis. J. Cell Biol.
172:309-320.
110. Yang, H., Qu, L., Ni, J., Wang, M., and Huang, Y. 2008. Palmitoylation
participates in G protein coupled signal transduction by affecting its oligomerization.
Mol. Membr. Biol. 25:58-71.
111. Yanai, A., Huang, K., Kang, R., Singaraja, R. R., Arstikaitis, P., Gan, L., Orban,
P. C., Mullard, A., Cowan, C. M., Raymond, L. A., Drisdel, R. C., Green, W. N.,
Ravikumar, B., Rubinsztein, D. C., El-Husseini, A., and Hayden, M. R. 2006.
Palmitoylation of huntingtin by HIP14 is essential for its trafficking and function. Nat.
Neurosci. 9:824-831.
112. Stoffel, R. H., Inglese, J., Macrae, A. D., Lefkowitz, R. J., and Premont, R. T.
1998. Palmitoylation increases the kinase activity of the G protein-coupled receptor
kinase, GRK6. Biochemistry. 37:16053-16059.
113. Mueller, G. M., Maarouf, A. B., Kinlough, C. L., Sheng, N., Kashlan, O. B.,
Okumura, S., Luthy, S., Kleyman, T. R., and Hughey, R. P. 2010. Cys palmitoylation of
the beta subunit modulates gating of the epithelial sodium channel. J. Biol. Chem.
285:30453-30462.
114. Swarthout, J. T., Lobo, S., Farh, L., Croke, M. R., Greentree, W. K., Deschenes,
R. J., and Linder, M. E. 2005. DHHC9 and GCP16 constitute a human protein fatty
acyltransferase with specificity for H- and N-Ras. J. Biol. Chem. 280:31141-31148.
115. Huang, K., Sanders, S. S., Kang, R., Carroll, J. B., Sutton, L., Wan, J., Singaraja,
R., Young, F. B., Liu, L., El-Husseini, A., Davis, N. G., and Hayden, M. R. 2011. Wildtype HTT modulates the enzymatic activity of the neuronal palmitoyl transferase HIP14.
Hum Mol Genet.
116. Charych, E. I., Jiang, L.-X., Lo, F., Sullivan, K., and Brandon, N. J. 2010.
Interplay of palmitoylation and phosphorylation in the trafficking and localization of
phosphodiesterase 10A: implications for the treatment of schizophrenia. J. Neurosci.
30:9027-9037.
117. Ho, G. P. H., Selvakumar, B., Mukai, J., Hester, L. D., Wang, Y., Gogos, J. A.,
and Snyder, S. H. 2011. S-Nitrosylation and S-Palmitoylation Reciprocally Regulate
Synaptic Targeting of PSD-95. Neuron. 71:131-141.
128

118. Veit, M., and Schmidt, M. F. G. 2006. Palmitoylation of influenza virus proteins.
Berl. Munch. Tierarztl. Wochenschr. 119:112-122.
119. Corvi, M. M., Berthiaume, L. G., and De Napoli, M. G. 2011. Protein
palmitoylation in protozoan parasites. Front Biosci (Schol Ed). 3:1067-1079.
120. Majeau, N., Fromentin, R., Savard, C., Duval, M., Tremblay, M. J., and Leclerc,
D. 2009. Palmitoylation of hepatitis C virus core protein is important for virion
production. J. Biol. Chem. 284:33915-33925.
121. Huang, K., Yanai, A., Kang, R., Arstikaitis, P., Singaraja, R. R., Metzler, M.,
Mullard, A., Haigh, B., Gauthier-Campbell, C., Gutekunst, C.-A., Hayden, M. R., and ElHusseini, A. 2004. Huntingtin-interacting protein HIP14 is a palmitoyl transferase
involved in palmitoylation and trafficking of multiple neuronal proteins. Neuron.
44:977-986.
122. Ducker, C. E., Stettler, E. M., French, K. J., Upson, J. J., and Smith, C. D. 2004.
Huntingtin interacting protein 14 is an oncogenic human protein: palmitoyl
acyltransferase. Oncogene. 23:9230-9237.
123. Fukata, M., Fukata, Y., Adesnik, H., Nicoll, R. A., and Bredt, D. S. 2004.
Identification of PSD-95 palmitoylating enzymes. Neuron. 44:987-996.
124. Okubo, K., Hamasaki, N., Hara, K., and Kageura, M. 1991. Palmitoylation of
cysteine 69 from the COOH-terminal of band 3 protein in the human erythrocyte
membrane. Acylation occurs in the middle of the consensus sequence of F--I-IICLAVL
found in band 3 protein and G2 protein of Rift Valley fever virus. J. Biol. Chem.
266:16420-16424.
125. Casey, W. M., Gibson, K. J., and Parks, L. W. 1994. Covalent attachment of
palmitoleic acid (C16:1 delta 9) to proteins in Saccharomyces cerevisiae. Evidence for a
third class of acylated proteins. J. Biol. Chem. 269:2082-2085.
126. Fujimoto, T., Stroud, E., Whatley, R. E., Prescott, S. M., Muszbek, L., Laposata,
M., and McEver, R. P. 1993. P-selectin is acylated with palmitic acid and stearic acid at
cysteine 766 through a thioester linkage. J. Biol. Chem. 268:11394-11400.
127. Veit, M., Reverey, H., and Schmidt, M. F. 1996. Cytoplasmic tail length
influences fatty acid selection for acylation of viral glycoproteins. Biochem. J. 318 ( Pt
1):163-172.
128. Hallak, H., Muszbek, L., Laposata, M., Belmonte, E., Brass, L. F., and Manning,
D. R. 1994. Covalent binding of arachidonate to G protein alpha subunits of human
platelets. J. Biol. Chem. 269:4713-4716.
129. Muszbek, L., and Laposata, M. 1993. Covalent modification of proteins by
arachidonate and eicosapentaenoate in platelets. J. Biol. Chem. 268:18243-18248.
130. Choi, Y.-W., Bae, S. M., Kim, Y.-W., Lee, H. N., Kim, Y. W., Park, T. C., Ro, D.
Y., Shin, J. C., Shin, S. J., Seo, J.-S., and Ahn, W. S. 2007. Gene expression profiles in
squamous cell cervical carcinoma using array-based comparative genomic hybridization
analysis. Int. J. Gynecol. Cancer. 17:687-696.
131. Brunner, R. M., Srikanchai, T., Murani, E., Wimmers, K., and Ponsuksili, S.
2011. Genes with expression levels correlating to drip loss prove association of their
polymorphism with water holding capacity of pork. Mol Biol Rep.

129

132. Hungermann, D., Schmidt, H., Natrajan, R., Tidow, N., Poos, K., Reis-Filho, J.
S., Brandt, B., Buerger, H., and Korsching, E. 2011. Influence of whole arm loss of
chromosome 16q on gene expression patterns in oestrogen receptor-positive, invasive
breast cancer. J. Pathol. 224:517-528.
133. Sudo, H., Tsuji, A. B., Sugyo, A., Imai, T., Saga, T., and Harada, Y.-nobu. 2007.
A loss of function screen identifies nine new radiation susceptibility genes. Biochem.
Biophys. Res. Commun. 364:695-701.
134. Mukai, J., Liu, H., Burt, R. A., Swor, D. E., Lai, W.-S., Karayiorgou, M., and
Gogos, J. A. 2004. Evidence that the gene encoding ZDHHC8 contributes to the risk of
schizophrenia. Nat. Genet. 36:725-731.
135. Chen, W.-Y., Shi, Y.-Y., Zheng, Y.-L., Zhao, X.-Z., Zhang, G.-J., Chen, S.-Q.,
Yang, P.-D., and He, L. 2004. Case-control study and transmission disequilibrium test
provide consistent evidence for association between schizophrenia and genetic variation
in the 22q11 gene ZDHHC8. Hum. Mol. Genet. 13:2991-2995.
136. Shin, H. D., Park, B. L., Bae, J. S., Park, T. J., Chun, J. Y., Park, C. S., Sohn, J.W., Kim, B.-J., Kang, Y.-H., Kim, J. W., Kim, K.-H., Shin, T.-M., and Woo, S.-I. 2010.
Association of ZDHHC8 polymorphisms with smooth pursuit eye movement
abnormality. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B:1167-1172.
137. Mukai, J., Dhilla, A., Drew, L. J., Stark, K. L., Cao, L., MacDermott, A. B.,
Karayiorgou, M., and Gogos, J. A. 2008. Palmitoylation-dependent neurodevelopmental
deficits in a mouse model of 22q11 microdeletion. Nat. Neurosci. 11:1302-1310.
138. Maynard, T. M., Meechan, D. W., Dudevoir, M. L., Gopalakrishna, D., Peters, A.
Z., Heindel, C. C., Sugimoto, T. J., Wu, Y., Lieberman, J. A., and Lamantia, A.-S. 2008.
Mitochondrial localization and function of a subset of 22q11 deletion syndrome
candidate genes. Mol. Cell. Neurosci. 39:439-451.
139. Raymond, F. L., Tarpey, P. S., Edkins, S., Tofts, C., O’Meara, S., Teague, J.,
Butler, A., Stevens, C., Barthorpe, S., Buck, G., Cole, J., Dicks, E., Gray, K., Halliday,
K., Hills, K., Hinton, J., Jones, D., Menzies, A., Perry, J., Raine, K., Shepherd, R., Small,
A., Varian, J., Widaa, S., Mallya, U., Moon, J., Luo, Y., Shaw, M., Boyle, J., Kerr, B.,
Turner, G., Quarrell, O., Cole, T., Easton, D. F., Wooster, R., Bobrow, M., Schwartz, C.
E., Gecz, J., Stratton, M. R., and Futreal, P. A. 2007. Mutations in ZDHHC9, which
encodes a palmitoyltransferase of NRAS and HRAS, cause X-linked mental retardation
associated with a Marfanoid habitus. Am. J. Hum. Genet. 80:982-987.
140. Mansilla, F., Birkenkamp-Demtroder, K., Kruhøffer, M., Sørensen, F. B.,
Andersen, C. L., Laiho, P., Aaltonen, L. A., Verspaget, H. W., and Orntoft, T. F. 2007.
Differential expression of DHHC9 in microsatellite stable and instable human colorectal
cancer subgroups. Br. J. Cancer. 96:1896-1903.
141. Maak, S., Boettcher, D., Tetens, J., Swalve, H. H., Wimmers, K., and Thaller, G.
2010. Expression of microRNAs is not related to increased expression of ZDHHC9 in
hind leg muscles of splay leg piglets. Mol. Cell. Probes. 24:32-37.
142. Birkenkamp-Demtroder, K., Christensen, L. L., Olesen, S. H., Frederiksen, C. M.,
Laiho, P., Aaltonen, L. A., Laurberg, S., Sørensen, F. B., Hagemann, R., and ØRntoft, T.
F. 2002. Gene expression in colorectal cancer. Cancer Res. 62:4352-4363.

130

143. Yamamoto, Y., Chochi, Y., Matsuyama, H., Eguchi, S., Kawauchi, S., Furuya, T.,
Oga, A., Kang, J. J., Naito, K., and Sasaki, K. 2007. Gain of 5p15.33 is associated with
progression of bladder cancer. Oncology. 72:132-138.
144. Kang, J. U., Koo, S. H., Kwon, K. C., Park, J. W., and Kim, J. M. 2008. Gain at
chromosomal region 5p15.33, containing TERT, is the most frequent genetic event in
early stages of non-small cell lung cancer. Cancer Genet. Cytogenet. 182:1-11.
145. Saleem, A. N., Chen, Y.-H., Baek, H. J., Hsiao, Y.-W., Huang, H.-W., Kao, H.-J.,
Liu, K.-M., Shen, L.-F., Song, I.-W., Tu, C.-P. D., Wu, J.-Y., Kikuchi, T., Justice, M. J.,
Yen, J. J. Y., and Chen, Y.-T. 2010. Mice with alopecia, osteoporosis, and systemic
amyloidosis due to mutation in Zdhhc13, a gene coding for palmitoyl acyltransferase.
PLoS Genet. 6:e1000985.
146. Rinaldi, A., Kwee, I., Poretti, G., Mensah, A., Pruneri, G., Capello, D., Rossi, D.,
Zucca, E., Ponzoni, M., Catapano, C., Tibiletti, M. G., Paulli, M., Gaidano, G., and
Bertoni, F. 2006. Comparative genome-wide profiling of post-transplant
lymphoproliferative disorders and diffuse large B-cell lymphomas. Br. J. Haematol.
134:27-36.
147. Anami, K., Oue, N., Noguchi, T., Sakamoto, N., Sentani, K., Hayashi, T., Hinoi,
T., Okajima, M., Graff, J. M., and Yasui, W. 2010. Search for transmembrane protein in
gastric cancer by the Escherichia coli ampicillin secretion trap: expression of DSC2 in
gastric cancer with intestinal phenotype. J. Pathol. 221:275-284.
148. Yu, L., Reader, J. C., Chen, C., Zhao, X. F., Ha, J. S., Lee, C., York, T., Gojo, I.,
Baer, M. R., and Ning, Y. 2011. Activation of a novel palmitoyltransferase ZDHHC14
in acute biphenotypic leukemia and subsets of acute myeloid leukemia. Leukemia.
25:367-371.
149. Mansouri, M. R., Marklund, L., Gustavsson, P., Davey, E., Carlsson, B., Larsson,
C., White, I., Gustavson, K.-H., and Dahl, N. 2005. Loss of ZDHHC15 expression in a
woman with a balanced translocation t(X;15)(q13.3;cen) and severe mental retardation.
Eur. J. Hum. Genet. 13:970-977.
150. Metzger, S., Bauer, P., Tomiuk, J., Laccone, F., Didonato, S., Gellera, C.,
Mariotti, C., Lange, H. W., Weirich-Schwaiger, H., Wenning, G. K., Seppi, K., Melegh,
B., Havasi, V., Balikó, L., Wieczorek, S., Zaremba, J., Hoffman-Zacharska, D., Sulek,
A., Basak, A. N., Soydan, E., Zidovska, J., Kebrdlova, V., Pandolfo, M., Ribaï, P.,
Kadasi, L., Kvasnicova, M., Weber, B. H. F., Kreuz, F., Dose, M., Stuhrmann, M., and
Riess, O. 2006. Genetic analysis of candidate genes modifying the age-at-onset in
Huntington’s disease. Hum. Genet. 120:285-292.
151. Berchtold, L. A., Størling, Z. M., Ortis, F., Lage, K., Bang-Berthelsen, C.,
Bergholdt, R., Hald, J., Brorsson, C. A., Eizirik, D. L., Pociot, F., Brunak, S., and
Størling, J. 2011. Huntingtin-interacting protein 14 is a type 1 diabetes candidate protein
regulating insulin secretion and {beta}-cell apoptosis. Proc Natl Acad Sci U S A.
152. Ducker, C. E., Griffel, L. K., Smith, R. A., Keller, S. N., Zhuang, Y., Xia, Z.,
Diller, J. D., and Smith, C. D. 2006. Discovery and characterization of inhibitors of
human palmitoyl acyltransferases. Mol. Cancer Ther. 5:1647-1659.
153. Jacobsen, M., Kracht, S. S., Esteso, G., Cirera, S., Edfors, I., Archibald, A. L.,
Bendixen, C., Andersson, L., Fredholm, M., and Jørgensen, C. B. 2010. Refined
131

candidate region specified by haplotype sharing for Escherichia coli F4ab/F4ac
susceptibility alleles in pigs. Anim. Genet. 41:21-25.
154. Draper, J. M., and Smith, C. D. 2010. DHHC20: a human palmitoyl
acyltransferase that causes cellular transformation. Mol. Membr. Biol. 27:123-136.
155. Mill, P., Lee, A. W. S., Fukata, Y., Tsutsumi, R., Fukata, M., Keighren, M.,
Porter, R. M., McKie, L., Smyth, I., and Jackson, I. J. 2009. Palmitoylation regulates
epidermal homeostasis and hair follicle differentiation. PLoS Genet. 5:e1000748.
156. Honey, S., Schneider, B. L., Schieltz, D. M., Yates, J. R., and Futcher, B. 2001.
A novel multiple affinity purification tag and its use in identification of proteins
associated with a cyclin–CDK complex. Nucleic Acids Research. 29:e24.
157. Li, Y. 2010. Commonly used tag combinations for tandem affinity purification.
Biotechnology and Applied Biochemistry. 55:73-83.
158. Infed, N., Hanekop, N., Driessen, A. J. M., Smits, S. H. J., and Schmitt, L. 2011.
Influence of detergents on the activity of the ABC transporter LmrA. Biochimica et
Biophysica Acta (BBA) - Biomembranes. 1808:2313-2321.
159. Vergis, J. M., Purdy, M. D., and Wiener, M. C. 2010. A high-throughput
differential filtration assay to screen and select detergents for membrane proteins. Anal.
Biochem. 407:1-11.
160. Anderson, J. L., Frase, H., Michaelis, S., and Hrycyna, C. A. 2005. Purification,
functional reconstitution, and characterization of the Saccharomyces cerevisiae
isoprenylcysteine carboxylmethyltransferase Ste14p. J. Biol. Chem. 280:7336-7345.
161. Romir, J., Lilie, H., Egerer-Sieber, C., Bauer, F., Sticht, H., and Muller, Y. A.
2007. Crystal structure analysis and solution studies of human Lck-SH3; zinc-induced
homodimerization competes with the binding of proline-rich motifs. J. Mol. Biol.
365:1417-1428.
162. Getz, E. B., Xiao, M., Chakrabarty, T., Cooke, R., and Selvin, P. R. 1999. A
comparison between the sulfhydryl reductants tris(2-carboxyethyl)phosphine and
dithiothreitol for use in protein biochemistry. Anal. Biochem. 273:73-80.
163. Hallak, H., and Rubin, R. 2004. Ethanol inhibits palmitoylation of G protein G
alpha(s). J. Neurochem. 89:919-927.
164. De Vos, M. L., Lawrence, D. S., and Smith, C. D. 2001. Cellular pharmacology
of cerulenin analogs that inhibit protein palmitoylation. Biochem. Pharmacol. 62:985995.
165. DeJesus, G., and Bizzozero, O. A. 2002. Effect of 2-fluoropalmitate, cerulenin
and tunicamycin on the palmitoylation and intracellular translocation of myelin
proteolipid protein. Neurochem. Res. 27:1669-1675.
166. Lawrence, D. S., Zilfou, J. T., and Smith, C. D. 1999. Structure-activity studies
of cerulenin analogues as protein palmitoylation inhibitors. J. Med. Chem. 42:49324941.
167. Patterson, S. I., and Skene, J. H. 1995. Inhibition of dynamic protein
palmitoylation in intact cells with tunicamycin. Meth. Enzymol. 250:284-300.
168. Grosenbach, D. W., Hansen, S. G., and Hruby, D. E. 2000. Identification and
analysis of vaccinia virus palmitylproteins. Virology. 275:193-206.

132

169. Duraffour, S., Vigne, S., Vermeire, K., Garcel, A., Vanstreels, E., Daelemans, D.,
Yang, G., Jordan, R., Hruby, D. E., Crance, J.-M., Garin, D., Andrei, G., and Snoeck, R.
2008. Specific targeting of the F13L protein by ST-246 affects orthopoxvirus production
differently. Antivir. Ther. (Lond.). 13:977-990.
170. Marciano, D., Ben-Baruch, G., Marom, M., Egozi, Y., Haklai, R., and Kloog, Y.
1995. Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell
growth. J. Med. Chem. 38:1267-1272.
171. Marom, M., Haklai, R., Ben-Baruch, G., Marciano, D., Egozi, Y., and Kloog, Y.
1995. Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid. J.
Biol. Chem. 270:22263-22270.
172. Bhat, B. G., Wang, P., and Coleman, R. A. 1994. Hepatic monoacylglycerol
acyltransferase is regulated by sn-1,2-diacylglycerol and by specific lipids in Triton X100/phospholipid-mixed micelles. J. Biol. Chem. 269:13172-13178.
173. Bayburt, T. H., and Sligar, S. G. 2010. Membrane protein assembly into
Nanodiscs. FEBS Letters. 584:1721-1727.
174. Sando, J. J., Maurer, M. C., Bolen, E. J., and Grisham, C. M. 1992. Role of
cofactors in protein kinase C activation. Cell. Signal. 4:595-609.
175. Mitchell, D. A., Mitchell, G., Ling, Y., Budde, C., and Deschenes, R. J. 2010.
Mutational analysis of Saccharomyces cerevisiae Erf2 reveals a two-step reaction
mechanism for protein palmitoylation by DHHC enzymes. J. Biol. Chem. 285:3810438114.
176. Goodwin, J. S., Drake, K. R., Rogers, C., Wright, L., Lippincott-Schwartz, J.,
Philips, M. R., and Kenworthy, A. K. 2005. Depalmitoylated Ras traffics to and from
the Golgi complex via a nonvesicular pathway. J. Cell Biol. 170:261-272.
177. Lorentzen, A., Kinkhabwala, A., Rocks, O., Vartak, N., and Bastiaens, P. I. H.
2010. Regulation of Ras localization by acylation enables a mode of intracellular signal
propagation. Sci Signal. 3:ra68.
178. Marrari, Y., Crouthamel, M., Irannejad, R., and Wedegaertner, P. B. 2007.
Assembly and trafficking of heterotrimeric G proteins. Biochemistry. 46:7665-7677.
179. Fernández-Hernando, C., Fukata, M., Bernatchez, P. N., Fukata, Y., Lin, M. I.,
Bredt, D. S., and Sessa, W. C. 2006. Identification of Golgi-localized acyl transferases
that palmitoylate and regulate endothelial nitric oxide synthase. J. Cell Biol. 174:369377.
180. Shipston, M. J. 2011. Ion channel regulation by protein palmitoylation. J. Biol.
Chem. 286:8709-8716.
181. Jennings, B. C., Nadolski, M. J., Ling, Y., Baker, M. B., Harrison, M. L.,
Deschenes, R. J., and Linder, M. E. 2009. 2-Bromopalmitate and 2-(2-hydroxy-5-nitrobenzylidene)-benzo[b]thiophen-3-one inhibit DHHC-mediated palmitoylation in vitro. J.
Lipid Res. 50:233-242.
182. Fery-Forgues, S., Fayet, J.-P., and Lopez, A. 1993. Drastic changes in the
fluorescence properties of NBD probes with the polarity of the medium: involvement of a
TICT state? Journal of Photochemistry and Photobiology A: Chemistry. 70:229-243.

133

183. Varner, A. S., De Vos, M. L., Creaser, S. P., Peterson, B. R., and Smith, C. D.
2002. A fluorescence-based high performance liquid chromatographic method for the
characterization of palmitoyl acyl transferase activity. Anal. Biochem. 308:160-167.
184. Mumby, S. M., and Linder, M. E. 1994. Myristoylation of G-protein alpha
subunits. Meth. Enzymol. 237:254-268.
185. Schroeder, H., Leventis, R., Shahinian, S., Walton, P. A., and Silvius, J. R. 1996.
Lipid-modified, cysteinyl-containing peptides of diverse structures are efficiently Sacylated at the plasma membrane of mammalian cells. J. Cell Biol. 134:647-660.
186. Cook, P. F., and Cleland, W. W. 2007. Enzyme Kinetics and Mechanism 1st ed.
Garland Science.
187. Tsutsumi, R., Fukata, Y., Noritake, J., Iwanaga, T., Perez, F., and Fukata, M.
2009. Identification of G protein alpha subunit-palmitoylating enzyme. Mol. Cell. Biol.
29:435-447.
188. Hou, H., John Peter, A. T., Meiringer, C., Subramanian, K., and Ungermann, C.
2009. Analysis of DHHC acyltransferases implies overlapping substrate specificity and a
two-step reaction mechanism. Traffic. 10:1061-1073.
189. Carman, G. M., Deems, R. A., and Dennis, E. A. 1995. Lipid signaling enzymes
and surface dilution kinetics. J. Biol. Chem. 270:18711-18714.
190. Denic, V., and Weissman, J. S. 2007. A molecular caliper mechanism for
determining very long-chain fatty acid length. Cell. 130:663-677.
191. Linder, M. E., and Deschenes, R. J. 2007. Palmitoylation: policing protein
stability and traffic. Nat. Rev. Mol. Cell Biol. 8:74-84.
192. el-Husseini, A. el-D., and Bredt, D. S. 2002. Protein palmitoylation: a regulator
of neuronal development and function. Nat. Rev. Neurosci. 3:791-802.
193. Singaraja, R. R., Hadano, S., Metzler, M., Givan, S., Wellington, C. L., Warby,
S., Yanai, A., Gutekunst, C.-A., Leavitt, B. R., Yi, H., Fichter, K., Gan, L., McCutcheon,
K., Chopra, V., Michel, J., Hersch, S. M., Ikeda, J.-E., and Hayden, M. R. 2002. HIP14,
a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking
and endocytosis. Hum. Mol. Genet. 11:2815-2828.
194. Stowers, R. S., and Isacoff, E. Y. 2007. Drosophila huntingtin-interacting protein
14 is a presynaptic protein required for photoreceptor synaptic transmission and
expression of the palmitoylated proteins synaptosome-associated protein 25 and cysteine
string protein. J. Neurosci. 27:12874-12883.
195. Ohyama, T., Verstreken, P., Ly, C. V., Rosenmund, T., Rajan, A., Tien, A.-C.,
Haueter, C., Schulze, K. L., and Bellen, H. J. 2007. Huntingtin-interacting protein 14, a
palmitoyl transferase required for exocytosis and targeting of CSP to synaptic vesicles.
J. Cell Biol. 179:1481-1496.
196. Willumsen, B. M., Cox, A. D., Solski, P. A., Der, C. J., and Buss, J. E. 1996.
Novel determinants of H-Ras plasma membrane localization and transformation.
Oncogene. 13:1901-1909.
197. Webb, Y., Hermida-Matsumoto, L., and Resh, M. D. 2000. Inhibition of protein
palmitoylation, raft localization, and T cell signaling by 2-bromopalmitate and
polyunsaturated fatty acids. J. Biol. Chem. 275:261-270.

134

198. Chase, J. F., and Tubbs, P. K. 1972. Specific inhibition of mitochondrial fatty
acid oxidation by 2-bromopalmitate and its coenzyme A and carnitine esters. Biochem.
J. 129:55-65.
199. Coleman, R. A., Rao, P., Fogelsong, R. J., and Bardes, E. S. 1992. 2Bromopalmitoyl-CoA and 2-bromopalmitate: promiscuous inhibitors of membranebound enzymes. Biochim. Biophys. Acta. 1125:203-209.
200. Omura, S. 1976. The antibiotic cerulenin, a novel tool for biochemistry as an
inhibitor of fatty acid synthesis. Bacteriol Rev. 40:681-697.
201. Duronio, R. J., Jackson-Machelski, E., Heuckeroth, R. O., Olins, P. O., Devine, C.
S., Yonemoto, W., Slice, L. W., Taylor, S. S., and Gordon, J. I. 1990. Protein Nmyristoylation in Escherichia coli: reconstitution of a eukaryotic protein modification in
bacteria. Proc. Natl. Acad. Sci. U.S.A. 87:1506-1510.
202. Duronio, R. J., Reed, S. I., and Gordon, J. I. 1992. Mutations of human
myristoyl-CoA:protein N-myristoyltransferase cause temperature-sensitive myristic acid
auxotrophy in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. U.S.A. 89:4129-4133.
203. Budde, C., Schoenfish, M. J., Linder, M. E., and Deschenes, R. J. 2006.
Purification and characterization of recombinant protein acyltransferases. Methods.
40:143-150.
204. Osanai, K., Takahashi, K., Nakamura, K., Takahashi, M., Ishigaki, M., Sakuma,
T., Toga, H., Suzuki, T., and Voelker, D. R. 2005. Expression and characterization of
Rab38, a new member of the Rab small G protein family. Biol. Chem. 386:143-153.
205. Bijlmakers, M. J., Isobe-Nakamura, M., Ruddock, L. J., and Marsh, M. 1997.
Intrinsic signals in the unique domain target p56(lck) to the plasma membrane
independently of CD4. J. Cell Biol. 137:1029-1040.
206. Turner, J. M., Brodsky, M. H., Irving, B. A., Levin, S. D., Perlmutter, R. M., and
Littman, D. R. 1990. Interaction of the unique N-terminal region of tyrosine kinase
p56lck with cytoplasmic domains of CD4 and CD8 is mediated by cysteine motifs. Cell.
60:755-765.
207. Resh, M. D. 1994. Myristylation and palmitylation of Src family members: the
fats of the matter. Cell. 76:411-413.
208. Sharma, C., Yang, X. H., and Hemler, M. E. 2008. DHHC2 affects
palmitoylation, stability, and functions of tetraspanins CD9 and CD151. Mol. Biol. Cell.
19:3415-3425.
209. el-Aleem, S. A., and Schulz, H. 1987. Evaluation of inhibitors of fatty acid
oxidation in rat myocytes. Biochem. Pharmacol. 36:4307-4312.
210. Fong, J. C., Leu, S. J., and Chai, S. P. 1997. Differential inhibition of lipolysis
by 2-bromopalmitic acid and 4-bromocrotonic acid in 3T3-L1 adipocytes. Biochim.
Biophys. Acta. 1344:65-73.
211. Raaka, B. M., and Lowenstein, J. M. 1979. Inhibition of fatty acid oxidation by
2-bromooctanoate. Evidence for the enzymatic formation of 2-bromo-3-ketooctanoyl
coenzyme A and the inhibition of 3-ketothiolase. J. Biol. Chem. 254:6755-6762.
212. Mikic, I., Planey, S., Zhang, J., Ceballos, C., Seron, T., von Massenbach, B.,
Watson, R., Callaway, S., McDonough, P. M., Price, J. H., Hunter, E., and Zacharias, D.

135

2006. A live cell, image-based approach to understanding the enzymology and
pharmacology of 2-bromopalmitate and palmitoylation. Meth. Enzymol. 414:150-187.
213. Baron, R. A., Peterson, Y. K., Otto, J. C., Rudolph, J., and Casey, P. J. 2007.
Time-dependent inhibition of isoprenylcysteine carboxyl methyltransferase by indolebased small molecules. Biochemistry. 46:554-560.
214. Hou, H., Subramanian, K., LaGrassa, T. J., Markgraf, D., Dietrich, L. E. P.,
Urban, J., Decker, N., and Ungermann, C. 2005. The DHHC protein Pfa3 affects
vacuole-associated palmitoylation of the fusion factor Vac8. Proc. Natl. Acad. Sci.
U.S.A. 102:17366-17371.
215. Yang, J., Brown, M. S., Liang, G., Grishin, N. V., and Goldstein, J. L. 2008.
Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating
peptide hormone. Cell. 132:387-396.
216. Chisari, M., Saini, D. K., Kalyanaraman, V., and Gautam, N. 2007. Shuttling of
G protein subunits between the plasma membrane and intracellular membranes. J. Biol.
Chem. 282:24092-24098.
217. Fyrst, H., Knudsen, J., Schott, M. A., Lubin, B. H., and Kuypers, F. A. 1995.
Detection of acyl-CoA-binding protein in human red blood cells and investigation of its
role in membrane phospholipid renewal. Biochem. J. 306 ( Pt 3):793-799.
218. Wan, J., Roth, A. F., Bailey, A. O., and Davis, N. G. 2007. Palmitoylated
proteins: purification and identification. Nat Protoc. 2:1573-1584.
219. Fang, C., Deng, L., Keller, C. A., Fukata, M., Fukata, Y., Chen, G., and Lüscher,
B. 2006. GODZ-mediated palmitoylation of GABA(A) receptors is required for normal
assembly and function of GABAergic inhibitory synapses. J. Neurosci. 26:1275812768.
220. Yuan, C., Rieke, C. J., Rimon, G., Wingerd, B. A., and Smith, W. L. 2006.
Partnering between monomers of cyclooxygenase-2 homodimers. Proc. Natl. Acad. Sci.
U.S.A. 103:6142-6147.
221. Ubarretxena-Belandia, I., Cox, R. C., Dijkman, R., Egmond, M. R., Verheij, H.
M., and Dekker, N. 1999. Half-of-the-sites reactivity of outer-membrane phospholipase
A against an active-site-directed inhibitor. Eur. J. Biochem. 260:794-800.
222. Planey, S. L., and Zacharias, D. A. 2010. Identification of targets and inhibitors
of protein palmitoylation. Expert Opin. Drug Discov. 5:155-164.
223. Chung, C. C., Ohwaki, K., Schneeweis, J. E., Stec, E., Varnerin, J. P., Goudreau,
P. N., Chang, A., Cassaday, J., Yang, L., Yamakawa, T., Kornienko, O., Hodder, P.,
Inglese, J., Ferrer, M., Strulovici, B., Kusunoki, J., Tota, M. R., and Takagi, T. 2008. A
fluorescence-based thiol quantification assay for ultra-high-throughput screening for
inhibitors of coenzyme A production. Assay Drug Dev Technol. 6:361-374.
224. Liu, J. O., Titov, D. V., Dang, Y., and He, Q. 2011. Regulator of Ras
depalmitoylation and retrograde trafficking: a new hat for FKBP. Mol. Cell. 41:131133.
225. Zhang, J., Planey, S. L., Ceballos, C., Stevens, S. M., Jr, Keay, S. K., and
Zacharias, D. A. 2008. Identification of CKAP4/p63 as a major substrate of the
palmitoyl acyltransferase DHHC2, a putative tumor suppressor, using a novel proteomics
method. Mol. Cell Proteomics. 7:1378-1388.
136

Benjamin C Jennings
Department of Molecular Medicine
C3-177 Veterinary Medical Center
College of Veterinary Medicine
Cornell University
Ithaca, New York 14853 USA

Lab Phone: 607-253-3252
Mobile Phone: 314-853-575
E-mail: bcj29@cornell.edu

PERSONAL INFORMATION
Date of Birth:
November 28, 1981
Place of Birth: Green Bay, Wisconsin, USA

Citizenship:

U.S. Citizen

EDUCATION
Washington University in St. Louis
St. Louis, Missouri
Graduate Program in Biochemistry

August 2004 – August 2011

University of Wisconsin-Madison
Madison, Wisconsin
Degree: B.S. in Biochemistry with Honors & Distinction
GPA: 3.83/4.00
AWARDS and HONORS
American Society for Biochemistry and Molecular Biology – Member
ASBMB Travel Grant Award
American Heart Association Predoctoral Fellowship
David F. Silbert Outstanding Teaching Assistant Award
UW-Madison Graduate with Honors and Distinction in Biochemistry
University of Wisconsin-Madison Dean’s List
and Honors Program
Wisconsin Agriculture and Life Science Alumni Association
Senior Activity and Leadership Award
Mary Shine Peterson Scholarship for Biochemistry Research,
UW-Madison
Gamma Sigma Delta, Honorary Life Science Society

August 2000 - August 2004

Jan 2010 - present
April 2010
Jan 2008 - Dec 2009
Oct 2006
Aug 2004
Aug 2000-Aug 2004
May 2004
Fall 2003, Spring 2004
April 2003

RESEARCH EXPERIENCE
Doctoral Thesis:
Enzymology of DHHC-mediated protein S-acylation
Dr. Maurine Linder, Ph.D.
June 2005 - Present
Department of Cell Biology and Physiology, Washington University in St. Louis
Department of Molecular Medicine, Cornell University
Doctoral Rotations at Washington University in St. Louis:
Detection and purification of human von Willebrand factor fragments
Dr. J. Evan Sadler, M.D., Ph.D.
April 2005 - June 2005
Howard Hughes Medical Institute
Internal Medicine: Division of Hematology and Oncology

137

Characterizing the pH-dependency of substrate specificity of the Plasmodium falciparum
metalloprotease falcilysin.
Dr. Daniel E. Goldberg, M.D., Ph.D.
January 2005 - April 2005
Howard Hughes Medical Institute
Departments of Medicine and Molecular Microbiology
Transcriptional control of connexin43 expression: insights from Naxos Disease
Dr. Jeffrey E. Saffitz, M.D., Ph.D.
August 2004 - December 2004
Departments of Pathology and Cardiology
Undergraduate Research at University of Wisconsin-Madison:
Monitoring phosphorylation of mutant cardiac troponin I with MALDI-TOF mass
spectrometry
Dr. Jeffery W. Walker, Ph.D.
May 2003- August 2004
Department of Physiology
Development of a strategy for mitochondrially transforming cucumber pollen
Dr. Michael J. Havey, Ph.D.
August 2001- December 2001
Department of Horticulture and USDA-Agriculture Research Station
TEACHING EXPERIENCE
Teaching Assistant
August 2005- December 2005
Molecular Foundations of Medicine, course master Dr. Linda J. Pike
Washington University in St. Louis, MO
Peer Mentor Tutor
Introductory and Intermediate Biochemistry Courses
Chemistry Learning Center
University of Wisconsin-Madison

August 2003-May 2004

LEADERSHIP AND ACTIVITIES
More Than Carpentry, Project Leader and Advisory Committee,
April 2006-August 2009
Wellston, MO
Firm Foundations Tutoring (Reading, Math, Science)
October 2005-August 2009
Division of Restore St. Louis, MO
Mentor for BiomedRAP: Biomedical Research Apprenticeship Program June 2006-August 2006
Washington University in St. Louis, MO
Mentor for MARC (Minority Access to Research Careers) Program
May 2003-August 2003
University of Wisconsin-Madison
PUBLICATIONS
Primary Research:
Jennings BC and Linder ME. DHHC protein S-acyltransferases use a similar ping-pong kinetic
mechanism but display different acyl-CoA specificities. J Biol. Chem. Accepted pending
revisions.

138

Ahearn IM, Tsai FD, Court H, Zhou M, Jennings BC, Ahmed M, Fehrenbacher N, Linder ME, Philips
MR. FKBP12 binds to acylated H-ras and promotes depalmitoylation. Mol. Cell. 41(2):173-85.
2011.
Jennings BC, Nadolski MJ, Ling Y, Baker MB, Harrison ME, Deschenes RJ, Linder ME. 2Bromopalmitate and 2-(2-hydroxy-5-nitro-benzylidene)-benzo[b]thiophen-3-one inhibit DHHCmediated palmitoylation in vitro. J. Lipid Res. 50(2):233-42. 2009.
Reviews:
Jennings BC and Linder ME. Regulation of G-proteins by covalent modification. Chapter 200 in
Handbook of Cellular Signaling. 2nd Edition. Bradshaw and Dennis. 2009.
Jennings BC and Linder ME. DHHC2. UCSD-Nature Molecule Pages published online: 13 Mar 2008.
doi:10.1038/mp.a003731.01
Jennings BC and Linder ME. DHHC7. UCSD-Nature Molecule Pages published online: 28 Feb 2008.
doi:10.1038/mp.a003724.01
Jennings BC and Linder ME. DHHC8. UCSD-Nature Molecule Pages published online: 13 Mar 2008.
doi:10.1038/mp.a003723.01
Jennings BC and Linder ME. DHHC21. UCSD-Nature Molecule Pages published online: 13 Mar 2008.
doi:10.1038/mp.a003729.01
ABSTRACTS AND PRESENTATIONS
Jennings BC and Linder ME. Enzymology of DHHC-mediated protein palmitoylation. Poster
presented at Experimental Biology 2010 conference and ASBMB annual meeting in Anaheim,
CA. April 2010.
Jennings BC and Linder ME. Enzymatic characterization of DHHC-mediated protein
palmitoylation. Poster presented at FASEB Protein Lipidation, Signaling, and Membrane
Domains conference in Saxtons River, VT. July 2009.
Jennings BC, He Y, and Linder ME. Characterization of human palmitoyltransferase DHHC2.
Poster presented at FASEB Protein Lipidation, Signaling, and Membrane Domains conference in
Palm Springs, CA. July 2006.
Jennings BC, Jacobson RM, and Walker JW. Alteration of phosphorylation in mutated cardiac
troponin I. 9th Annual Scientific Poster Fair held by the UW Cardiovascular Research Center,
Madison, WI. December 2003.
Rivera-Santiago VJ, Jennings BC, and Walker JW. Interaction of FHC mutations and
phosphorylation of troponin I. Poster presented at the Annual Biomedical Research Conference
for Minority Students in San Diego, CA. October 2003.

139

